Annual Report 2019
CONTINUING THE CLIMB
5
50
5
5 years ago a transformation of CONMED was initiated as the company faced investor concern,
market changes and slowed innovation leading to decreased demand. A broad revamp of the board,
management team and company strategy followed. With a new emphasis on people, products and
profits, CONMED began the process of regaining customer trust. New people brought fresh ideas
and novel perspectives. CONMED invested in innovation through internal R&D and acquisitions to
deliver quality products that make a difference to the healthcare providers and the patients they
treat. The results of these efforts have led to the above-market revenue and profitability growth
illustrated in this report.
50 years ago, on February 10th, 1970, the CONMED story began when Eugene Corasanti started
manufacturing disposable ECG electrodes in Utica, New York. Through commercial channel evolution
and acquisitions, CONMED grew in both revenue and profitability resulting in a public listing in
1987. In addition to electrodes, CONMED developed a diversified portfolio with a broad offering of
products in the attractive orthopedic, general surgery and gastrointestinal markets. Today, there are
over 3,300 CONMED employees spanning 6 continents with a global sales presence in over 100
countries. In 2020, CONMED is proud to celebrate our 50-year anniversary punctuated by our move
to the New York Stock Exchange on February 10th, 2020 exactly 50 years after our founding. We think
Mr. Corasanti would be proud of CONMED today!
5 years from now, we see CONMED continuing to Make a Difference in the lives of our customers
and the patients they treat. Times will change, but our mission to enable healthcare providers around
the world to deliver exceptional outcomes for patients through accessible CONMED solutions will
not. We will continue to be focused on people, products and profits. Though the future is impossible
to predict, we know that when we listen to our customers, understand the challenges they face,
solve their problems with new innovations and make it easier for them to care for their patients –
success and growth will follow.
Dear Shareholder,
2019 was a year of continued progress for CONMED Corporation. Our focus on driving innovation through
internal development and strategic acquisitions resulted in a steady cadence of new product introductions
that drove strong revenue and earnings growth.
I would like to extend my sincere gratitude to the Board of Directors and to the entire CONMED team, whose
dedication and ingenuity continued to position the Company as a leading innovator in the markets we serve.
I am excited to be celebrating CONMED’s 50th anniversary in 2020, and it is a great time to reflect on
our achievements. Most notably, our commitment to management’s key initiatives over the last five years
has transformed the Company, and, looking ahead, we remain confident that our strategy will put even
more innovative new products in the hands of clinicians and drive continued momentum in our financial
performance.
I am also proud of the enhancements to support our Environmental, Social, and Governance (ESG) program in
2019. While this is a new topic in my letter, it is not a new topic across CONMED. For example, our Chihuahua,
Mexico plant received its 6th consecutive Clean Industry Certification, and our recently acquired portfolio of
Buffalo Filter products is improving air quality in operating rooms worldwide. In 2020, we will formalize our
global programs by hiring an ESG-focused resource and establishing a CONMED Foundation for charitable
contributions.
In the second half of 2019, we welcomed two new board members, LaVerne Council and Barbara
Schwarzentraub, and both of these women bring a wealth of global executive leadership experience that will
be invaluable in contributing to CONMED’s continued growth.
On behalf of CONMED’s Board of Directors and management team, I would like to thank you for your
continued support and trust in us as stewards of your Company.
Sincerely,
Mark Tryniski
Chair
Dear Shareholder,
When I arrived at CONMED five years ago, we outlined a transformation strategy centered on two core
components: hire the right people and strategically invest in developing a more innovative product portfolio.
As we made progress on these first two components, we introduced a third component in 2018 focused on
greatly improving our profitability. Our commitment to – and focus on – these three strategic mandates has
resulted in above-market revenue and profitability growth, as well as an average annual shareholder return of
22.6% over the 5 years ending on December 31, 2019.
In 2019, we continued to drive innovation within our existing markets, delivered a strong cadence of new
products, and also entered the smoke evacuation market through the exciting acquisition of Buffalo Filter.
Our sales in 2019 were $955.1 million, an increase over the prior year of 11.1% as reported and 11.7% in
constant currency. We also delivered adjusted net income of $77.9 million, an increase of 24.0% over the prior
year, and adjusted diluted net earnings per share of $2.64, an increase of 21.1% over the prior year.
We achieved this solid top- and bottom-line growth for the year while continuing to invest in our future
success. We accelerated investments in our sales infrastructure during the fourth quarter to further solidify
our foundation for sustainable near- and long-term, above-market revenue and profitability growth and to
ensure that we build on the momentum generated throughout 2019.
Now, in 2020, as we celebrate the 50th anniversary of the founding of CONMED by Eugene Corasanti, we
are poised to cross the $1 billion annual revenue mark for the first time in the Company’s history. Further, on
February 10th, 2020 the exact day of the 50th anniversary of the founding of the Company, we transitioned
the listing of our common stock to the New York Stock Exchange and joined an impressive group of high-
performing medical device companies. These are exciting milestones in our continued progress, and all are
made possible by having the right people in the right places to put the innovative products in the hands of
our customers.
As we turn our attention to the next five years, we remain squarely focused on driving revenue growth in the
mid-single-digits or higher, as well as at least double-digit earnings growth on an annual basis. In the last five
years, we have nearly doubled our annual R&D spend, which has played a key role in revenue and profitability
growth of almost 30% and 45%, respectively, as shown in the following chart. We are committed to continuing
to build on this momentum over the next five years.
100%
80%
60%
40%
20%
0
Annual
Revenue
Annual R&D
Spend
Annual
EBITDA
After 45 Years
Added in 5 Years
A balanced product portfolio remains a key driver of our long-term growth outlook. When I joined the company
in 2014, our overall performance was heavily weighted to the performance of our orthopedics portfolio.
Through both internal development and meaningful M&A, including the acquisitions of SurgiQuest in 2016
and Buffalo Filter in 2019, we have achieved more consistent company performance given the good balance
between General Surgery and Orthopedics.
Within this portfolio, we are applying more focus and resources on the faster growing areas of these very
large and attractive markets. As we do this, we are shifting the mix of the portfolio to faster growth, which we
believe will allow us to continue to grow faster than our markets in total.
I would also like to welcome CONMED’s two newest board members, LaVerne Council and Barbara Schwarzentraub.
Both of these women are very distinguished in their previous endeavors, with success at every level of their
careers. I have enjoyed getting to know each of them on a personal and professional level, and I look forward
to their contributions as we continue to drive CONMED forward.
We are very pleased with continued strength of the business demonstrated in 2019, and with the operational
strides we have made, as well as the shareholder value we have created. On behalf of our management team
and the Board of Directors, I thank you for your confidence in CONMED, and I look forward to updating you on
our progress throughout 2020. I truly feel the best is yet to come!
Respectfully,
Curt Hartman
President & CEO
*Constant currency net sales growth, adjusted net income and adjusted diluted net earnings per share are Non-GAAP financial measures.
Refer to the Additional Information page for the “GAAP to Non-GAAP Reconciliations” section for reconciliations to the most directly
comparable GAAP financial measures, reported net sales, net income and diluted net earnings per share.
A Culture of Success Reflected in 2019Became the Leader in Smoke ManagementCONMED completed the acquisition of Buffalo Filter and its comprehensive product portfolio that includes smoke evacuation pencils, smoke evacuators, and laparoscopic solutions. CONMED is now the Leader in Surgical Smoke Evacuation – focused on helping improve air quality and safety in operating rooms.A Paradigm Shift in Hip Arthroscopy In March of 2019, CONMED Orthopedics announced the Paradigm™ Hip System. Designed by some of the world’s leading hip surgeons, this system is a complete portfolio of products designed with safety in mind to provide surgeons with simple and reproducible solutions for arthroscopic hip repairs. ACL and PCL Made EasyIn August of 2019, CONMED’s design team comprised of R&D and world-renowned surgeons, announced the new Infinity™ Knee System. Infinity™ is a modular platform for ACL & PCL reconstructions that is designed to give surgeons one system with multiple possibilities.JANUARYMAYAPRILFEBRUARYJUNEMARCH Increasing Diversity on CONMED’s BoardBringing a wealth of global executive leadership experience and proven track records of success in developing and implementing strategies across global organizations while driving shareholder value, CONMED welcomed LaVerne Council and Barbara Schwarzentraub to our Board of Directors. Winning with Medical Education The number of surgeons trained by CONMED’s Medical Education Team increased by 36% in 2019 – setting a new all-time record and helping ensure that more surgeons received valuable firsthand experience with CONMED’s newest innovations. SEPTEMBERAUGUSTDECEMBEROCTOBERJULYNOVEMBER 2019 Company Snapshot
$955M / FY2019 Revenue
Geographic Revenue
Product Revenue
All Other
17%
Americas
Ex-US 10%
46%
Int’l Rev.
US
54%
Europe
19%
Orthopedics
Endoscopic Technologies
Patient Care
Legacy Advanced Surgical
AirSeal®
Buffalo Filter®
Orthopedics
Surgical devices including capital, single-use, and implants
used in the repair of soft tissue and joint injuries.
79%
Recurring, single-use revenue
General Surgery
Low Impact™ Laparoscopy, enabled by the AirSeal® System
GI therapeutic and diagnostic products
ECG, MFE (Multi-Function Electrodes), and other
Patient Care devices
OR Smoke Management, Buffalo Filter® product line
3,300
Employees globally
1970
Founded and Headquartered in
Utica, New York
Board Members
Top row (Left to Right):
Jerome J. Lande
Director
Charles M. Farkas
Director
David Bronson
Director
Dr. John L. Workman
Director
Brian P. Concannon
Director
Barbara J. Schwarzentraub
Director
Bottom row (Left to Right):
Martha Goldberg Aronson
Director
LaVerne Council
Director
Mark E. Tryniski
Chair of the Board of Directors
Curt R. Hartman
President, Chief Executive
Officer & Director
Executive Officers
Top row (Left to Right):
Peter K. Shagory
Executive Vice President, Strategy
& Corporate Development
Nathan Folkert
Vice President & General
Manager, U.S. Orthopedics
Wilfredo Ruiz-Caban
Executive Vice President, Quality
Assurance, Regulatory Affairs &
Operations
John E. (Jed) Kennedy
Group Executive Vice President,
Patient Care and Endoscopic
Technologies
Patrick J. Beyer
President, CONMED International
Stanley W. (Bill) Peters
Vice President & General Manager,
U.S. Advanced Surgical
Bottom row (Left to Right):
Daniel S. Jonas, Esq.
Executive Vice President, Legal
Affairs & General Counsel &
Secretary
Curt R. Hartman
President, Chief Executive
Officer & Director
Heather L. Cohen
Executive Vice President,
Human Resources
Todd W. Garner
Executive Vice President
& Chief Financial Officer
Not Pictured:
Terence M. Bergé
Vice President, Corporate Controller
Sarah M. Oliker, Esq.
Assistant General Counsel &
Assistant Secretary
Johonna Pelletier
Treasurer & Vice President, Tax
Additional Information
CORPORATE OFFICE
CONMED Corporation
525 French Road
Utica, NY 13502
Phone: 1-315-797-8375
Fax: 1-315-797-0321
Customer Service
1-866-4CONMED
customerexperience@CONMED.com
Website: www.CONMED.com
Ethics policy available at
www.CONMED.com
SHAREHOLDER
INFORMATION
Interested shareholders may
obtain a copy of the Company’s
Annual Report without charge
upon written request to:
Transfer Agent/Registrar
Computershare Investor Services
P.O. Box 505000
Louisville, KY 40233-5000
1-800-368-5948
www.computershare.com/investor
Investor Relations Department
CONMED Corporation
Independent Registered
Public Accounting Firm
Attn: Todd Garner
525 French Road
Utica, NY 13502
1-315-624-3317
PricewaterhouseCoopers LLP
1200 Bausch & Lomb Place
Rochester, NY 14604
STOCK
CONMED Corporation’s stock is
traded on the New York Stock
Exchange with the symbol: CNMD
GAAP to Non-GAAP Reconciliations
Reconciliation of Reported Net Income to Adjusted Net Income*
(in thousands, except per share amounts, unaudited)
Reconciliation of Reported Net Income to Adjusted Net Income*
(in thousands, except per share amounts, unaudited)
Reconciliation of Reported Net Income to Adjusted Net Income*
Reconciliation of Reported Net Income to Adjusted Net Income*
(in thousands, except per share amounts, unaudited)
(in thousands, except per share amounts, unaudited)
Reconciliation of Reported Net Income to Adjusted Net Income*
(in thousands, except per share amounts, unaudited)
Reconciliation of Reported Net Income to Adjusted Net Income*
(in thousands, except per share amounts, unaudited)
Year Ended December 31, 2019
Reconciliation of Reported Net Income to Adjusted Net Income*
(in thousands, except per share amounts, unaudited)
Gross Profit
Gross Profit
Gross Profit
$
$
Gross Profit
As reported
% of sales
Business acquisition costs
Manufacturing consolidation costs
Debt refinancing costs
As reported
% of sales
As reported
As reported
As reported
$
As reported
524,715
As reported
$
Business acquisition costs
% of sales
% of sales
% of sales
% of sales
54.9%
% of sales
Manufacturing consolidation costs
Business acquisition costs
Business acquisition costs
Business acquisition costs
Business acquisition costs
1,335
Business acquisition costs
Debt refinancing costs
Manufacturing consolidation costs
Manufacturing consolidation costs
Manufacturing consolidation costs
Manufacturing consolidation costs
2,858
Manufacturing consolidation costs
$
Debt refinancing costs
Debt refinancing costs
Debt refinancing costs
Debt refinancing costs
-
Debt refinancing costs
Adjusted gross profit %
$
528,908
$
Amortization
$
Adjusted gross profit %
Adjusted gross profit %
Adjusted gross profit %
Adjusted gross profit %
Adjusted gross profit %
55.4%
Adjusted gross profit %
Adjusted net income
Amortization
Amortization
Amortization
Amortization
Amortization
6,000
Amortization
% of sales
Adjusted net income
Adjusted net income
Adjusted net income
Adjusted net income
Adjusted net income
Adjusted net income
% of sales
% of sales
% of sales
% of sales
% of sales
% of sales
$
$
$
$
Year Ended December 31, 2019
Year Ended December 31, 2019
Year Ended December 31, 2019
Year Ended December 31, 2019
Research &
Selling &
Year Ended December 31, 2019
Year Ended December 31, 2019
Effective
Other
Tax
Operating
Development
Administrative
Interest
Research &
Selling &
Research &
Selling &
Research &
Selling &
Research &
Research &
Selling &
Selling &
Research &
Selling &
Tax Rate
Expense
Expense
Income
Expense
Expense
Expense
Tax
Other
Interest
Operating
Effective
Effective
Tax
Other
Tax
Other
Interest
Operating
Operating
Interest
Development
Administrative
Development
Administrative
Development
Administrative
Tax
Effective
Other
Interest
Tax
Interest
Operating
Operating
Other
Development
Administrative
Development
Administrative
Effective
Tax
Other
Operating
Interest
Development
Administrative
$
$
$
8.3%
2,605
5,188
45,460
400,141
524,715
$
$
79,114
42,701
$
Gross Profit
Gross Profit
Expense
Expense
Expense
Expense
Income
Tax Rate
Tax Rate
Expense
Expense
Expense
Expense
Income
Income
Expense
Expense
Expense
Expense
Expense
Expense
Expense
Net Income
Gross Profit
Income
Expense
Tax Rate
Expense
Expense
Expense
Expense
Income
Expense
Expense
Expense
Expense
Expense
Expense
Expense
Income
Tax Rate
Expense
Expense
Expense
4.8%
41.9%
54.9%
8.3%
$
2,605
$
5,188
$
42,701
$
79,114
$
45,460
$
400,141
$
524,715
2,605
$
8.3%
$
5,188
42,701
$
2,605
$
5,188
79,114
$
$
$
$
45,460
$
400,141
$
524,715
$
79,114
$
45,460
400,141
42,701
524,715
$
$
$
8.3%
5,188
$
42,701
45,460
400,141
79,114
28,620
$
$
2,605
2,605
$
5,188
$
42,701
$
$
$
400,141
524,715
$
45,460
$
$
79,114
$
8.3%
$
$
2,605
5,188
$
$
79,114
$
45,460
400,141
42,701
524,715
$
3,609
-
-
14,401
-
(13,066)
1,335
8.3%
4.8%
41.9%
54.9%
8.3%
4.8%
41.9%
54.9%
8.3%
4.8%
41.9%
54.9%
4.8%
41.9%
8.3%
41.9%
54.9%
4.8%
8.3%
8.3%
4.8%
41.9%
54.9%
354
-
2,858
-
-
-
2,858
-
-
14,401
-
(13,066)
1,335
-
-
3,609
-
14,401
-
(13,066)
1,335
14,401
-
(13,066)
-
1,335
3,609
-
-
-
(13,066)
-
-
(13,066)
1,335
14,401
14,401
-
3,609
-
14,401
-
(13,066)
-
1,335
(3,904)
1,149
-
-
-
-
-
-
-
2,858
-
-
2,858
-
-
354
-
2,858
-
-
2,858
2,858
-
-
-
2,858
354
-
-
-
-
2,858
2,858
-
2,858
-
-
-
354
-
2,858
-
-
-
2,858
1,284
$
$
$
$
$
$
7,717
42,701
96,373
45,460
387,075
528,908
-
-
(3,904)
-
-
-
-
-
(3,904)
-
1,149
(3,904)
-
-
-
-
-
-
-
-
(3,904)
-
-
-
-
(3,904)
1,149
-
-
-
-
1,149
(3,904)
-
-
-
-
-
55.4%
$
1,284
$
42,701
$
96,373
$
45,460
$
387,075
$
528,908
$
$
1,284
$
42,701
$
96,373
$
45,460
$
387,075
$
528,908
$
$
7,717
1,284
$
96,373
$
45,460
387,075
$
42,701
528,908
$
$
$
42,701
96,373
$
$
$
1,284
$
42,701
7,717
45,460
528,908
$
96,373
$
45,460
387,075
$
$
$
1,284
$
387,075
$
$
7,717
1,284
$
96,373
$
45,460
387,075
$
42,701
528,908
$
(26,075)
-
(11,756)
32,075
10,590
-
6,000
55.4%
55.4%
55.4%
55.4%
55.4%
18,307
1,284
128,448
$
$
$
$
30,945
45,460
361,000
-
-
-
(11,756)
32,075
-
$
6,000
(11,756)
32,075
$
6,000
10,590
-
32,075
-
(26,075)
(11,756)
6,000
-
-
(11,756)
10,590
(11,756)
32,075
(26,075)
32,075
-
$
6,000
(26,075)
-
10,590
32,075
-
(26,075)
(11,756)
6,000
4.8%
37.8%
13.4%
128,448
$
$
1,284
$
30,945
$
$
45,460
$
$
$
1,284
$
30,945
$
128,448
$
45,460
$
$
18,307
1,284
$
128,448
45,460
361,000
$
30,945
$
$
$
$
$
$
1,284
19.0%
30,945
18,307
361,000
$
128,448
$
45,460
128,448
$
$
$
1,284
361,000
30,945
$
$
$
$
$
1,284
18,307
30,945
128,448
45,460
361,000
$
13.4%
4.8%
13.4%
4.8%
13.4%
4.8%
37.8%
13.4%
4.8%
37.8%
13.4%
37.8%
13.4%
4.8%
37.8%
Sales Summary*
(in millions, unaudited)
Sales Summary*
Sales Summary*
Sales Summary*
Sales Summary*
Sales Summary*
% Change from 2019 to 2018
(in millions, unaudited)
(in millions, unaudited)
(in millions, unaudited)
(in millions, unaudited)
(in millions, unaudited)
% Change from 2019 to 2018
% Change from 2019 to 2018
% Change from 2019 to 2018
% Change from 2019 to 2018
% Change from 2019 to 2018
Impact of
Foreign
Impact of
Impact of
Impact of
Impact of
Currency
Foreign
Foreign
Constant
Foreign
Foreign
0.6%
11.1%
As Reported
Currency
As Reported
Currency
As Reported
Currency
Currency
Currency
11.1%
11.1%
0.6%
11.1%
0.6%
11.1%
11.7%
0.6%
11.1%
859.6
$
2019
2018
2019
2018
2018
2018
2019
2018
$
859.6
$
955.1
$
859.6
$
955.1
$
955.1
859.6
859.6
$
$
$
955.1
859.6
955.1
$
Sales Summary*
(in millions, unaudited)
% Change from 2019 to 2018
Constant
Impact of
Impact of
Currency
Constant
Foreign
Foreign
Constant
11.7%
Currency
Currency
Currency
Currency
0.6%
0.6%
11.7%
11.7%
$
(26,075)
(26,075)
-
361,000
361,000
$
$
45,460
$
37.8%
37.8%
4.8%
3,609
354
1,149
$
7,717
3,609
354
1,149
7,717
$
$
3,609
10,792
354
2,504
1,149
2,755
7,717
44,671
Constant
Currency
0.6%
Constant
Currency
11.7%
Constant
Currency
11.7%
10,590
18,307
$
$
As Reported
As Reported
10,590
18,307
10,590
18,307
33,241
77,912
As Reported
As Reported
19.0%
19.0%
$
19.0%
955.1
2018
2018
Net Income
Diluted EPS
Effective
Effective
$
$
28,620
0.97
Diluted EPS
Diluted EPS
Net Income
Net Income
Net Income
Diluted EPS
Tax Rate
Diluted EPS
Diluted EPS
Net Income
Tax Rate
Diluted EPS
Net Income
$
0.97
$
28,620
8.3%
0.97
$
$
28,620
8.3%
$
28,620
$
0.97
$
28,620
0.97
8.3%
$
$
0.97
$
28,620
$
0.97
10,792
0.37
2,504
0.08
10,792
0.37
10,792
10,792
0.37
2,755
0.09
2,504
0.08
2,504
2,504
0.08
44,671
1.51
2,755
0.09
2,755
2,755
0.09
$
$
44,671
1.51
$
44,671
44,671
1.51
33,241
1.13
77,912
2.64
33,241
1.13
33,241
33,241
1.13
$
$
77,912
2.64
$
19.0%
77,912
77,912
2.64
10,792
10,792
0.37
2,504
2,504
0.08
$
2,755
2,755
0.09
$
44,671
44,671
$
$
1.51
$
0.37
0.08
0.09
$
1.51
$
1.13
$
2.64
$
$
33,241
77,912
$
$
$
33,241
1.13
$
77,912
2.64
0.37
0.08
0.09
1.51
0.37
0.08
0.09
1.51
$
$
19.0%
$
$
1.13
2.64
1.13
2.64
$
$
19.0%
Net Sales
2019
$
2019
2019
$
$
955.1
2019
$
Net Sales
Net Sales
Net Sales
Net Sales
*
Net Sales
Net Sales
Refer to our 2019 Annual Report on Form 10-K, available both within this document and at www.conmed.com, as well as our Form 8-K filed with the SEC on January 29, 2020, for additional information
regarding our non-GAAP measures.
Refer to our 2019 Annual Report on Form 10-K, available both within this document and at www.conmed.com, as well as our Form 8-K filed with the SEC on January 29, 2020, for additional information
Refer to our 2019 Annual Report on Form 10-K, available both within this document and at www.conmed.com, as well as our Form 8-K filed with the SEC on January 29, 2020, for additional information
regarding our non-GAAP measures.
regarding our non-GAAP measures.
*
Refer to our 2019 Annual Report on Form 10-K, available both within this document and at www.conmed.com, as well as our Form 8-K filed with the SEC on January 29, 2020, for additional information
regarding our non-GAAP measures.
*
Refer to our 2019 Annual Report on Form 10-K, available both within this document and at www.conmed.com, as well as our Form 8-K filed with the SEC on January 29, 2020, for additional information
regarding our non-GAAP measures.
Refer to our 2019 Annual Report on Form 10-K, available both within this document and at www.conmed.com, as well as our Form 8-K filed with the SEC on January 29, 2020, for additional information
regarding our non-GAAP measures.
Refer to our 2019 Annual Report on Form 10-K, available both within this document and at www.conmed.com, as well as our Form 8-K filed with the SEC on January 29, 2020, for additional information
regarding our non-GAAP measures.
11.1%
11.7%
859.6
*
*
*
*
United States
Securities and Exchange Commission
Washington, D.C. 20549
Form 10-K
Annual Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
or
Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
For the fiscal year ended: December 31, 2019 Commission file number: 0-16093
CONMED CORPORATION
(Exact name of registrant as specified in its charter)
New York
(State or other jurisdiction of
incorporation or organization)
525 French Road
Utica, New York
(Address of principal executive
offices)
16-0977505
(I.R.S. Employer Identification
No.)
13502
(Zip Code)
(315) 797-8375
(Registrant's telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on
which registered
Common Stock, $0.01 par value
CNMD
NYSE
Yes
Yes
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.
No
Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.
No
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject
to such filing requirements for the past 90 days.
Yes
No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant
to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required
to submit such files). Yes
No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of “large accelerated filer", "accelerated filer", "smaller reporting company", and
"emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
Accelerated filer
Non-accelerated filer
Smaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Yes
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).
No
As of June 28, 2019, the last business day of the registrant’s most recently completed second fiscal quarter, the aggregate market value of
the shares of voting common stock held by non-affiliates of the registrant was approximately $2,420,684,853 based upon the closing price of the
Company’s common stock on the NASDAQ Stock Market.
The number of shares of the registrant's $0.01 par value common stock outstanding as of February 19, 2020 was 28,492,005.
DOCUMENTS INCORPORATED BY REFERENCE:
Portions of the Definitive Proxy Statement and any other informational filings for the 2020 Annual Meeting of Shareholders are incorporated
by reference into Part III of this report.
CONMED CORPORATION
ANNUAL REPORT ON FORM 10-K
FOR YEAR ENDED DECEMBER 31, 2019
TABLE OF CONTENTS
Item 1.
Item 1A.
Item 1B.
Item 2.
Item 3.
Item 4.
Business
Risk Factors
Unresolved Staff Comments
Properties
Legal Proceedings
Mine Safety Disclosures
Part I
Part II
Item 5.
Market for Registrant's Common Equity, Related Stockholder
Item 6.
Item 7.
Item 7A.
Item 8.
Item 9.
Item 9A.
Item 9B.
Item 10.
Item 11.
Item 12.
Item 13.
Item 14.
Matters and Issuer Purchases of Equity Securities
Selected Financial Data
Management's Discussion and Analysis of Financial
Condition and Results of Operations
Quantitative and Qualitative Disclosures About Market Risk
Financial Statements and Supplementary Data
Changes In and Disagreements with Accountants on
Accounting and Financial Disclosure
Controls and Procedures
Other Information
Part III
Directors, Executive Officers and Corporate Governance
Executive Compensation
Security Ownership of Certain Beneficial Owners and
Management and Related Stockholder Matters
Certain Relationships and Related Transactions, and Director Independence
Principal Accounting Fees and Services
Item 15.
Exhibits, Financial Statement Schedules
Signatures
Item 16.
Form 10-K Summary
Part IV
1
Page
2
7
16
17
17
17
18
20
21
28
28
28
28
29
30
30
30
31
31
32
33
77
CONMED CORPORATION
Item 1. Business
Forward Looking Statements
This Annual Report on Form 10-K for the Fiscal Year Ended December 31, 2019 (“Form 10-K”) contains certain forward-
looking statements (as such term is defined in the Private Securities Litigation Reform Act of 1995) and information relating to
CONMED Corporation (“CONMED”, the “Company”, “we” or “us” — references to “CONMED”, the “Company”, “we” or
“us” shall be deemed to include our direct and indirect subsidiaries unless the context otherwise requires) which are based on
the beliefs of our management, as well as assumptions made by and information currently available to our management.
When used in this Form 10-K, the words “estimate”, “project”, “believe”, “anticipate”, “intend”, “expect” and similar
expressions are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties
and other factors, including those identified under the caption “Item 1A-Risk Factors” and elsewhere in this Form 10-K which
may cause our actual results, performance or achievements, or industry results, to be materially different from any future results,
performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the
following:
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
general economic and business conditions;
compliance with and changes in regulatory requirements;
environmental compliance risks, including lack of availability of sterilization with Ethylene Oxide (“EtO”);
the possibility that United States or foreign regulatory and/or administrative agencies may initiate enforcement actions
against us or our distributors;
competition;
changes in customer preferences;
changes in technology;
the introduction and acceptance of new products;
the availability and cost of materials;
cyclical customer purchasing patterns due to budgetary and other constraints;
quality of our management and business abilities and the judgment of our personnel;
the availability, terms and deployment of capital;
future levels of indebtedness and capital spending;
changes in foreign exchange and interest rates;
the ability to evaluate, finance and integrate acquired businesses, products and companies;
changes in business strategy;
the risk of an information security breach, including a cybersecurity breach;
the risk of a lack of allograft tissues due to reduced donations of such tissues or due to tissues not meeting the appropriate
high standards for screening and/or processing of such tissues;
the ability to defend and enforce intellectual property, including the risks related to theft or compromise of intellectual
property in connection with our international operations;
the risk of patent, product and other litigation as well as the cost associated with such litigation;
trade protection measures, tariffs and other border taxes, and import or export licensing requirements; and
various other factors referenced in this Form 10-K.
See “Item 7-Management’s Discussion and Analysis of Financial Condition and Results of Operations”, “Item 1-Business”
and “Item 1A-Risk Factors” for a further discussion of these factors. You are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. We do not undertake any obligation to publicly release any
revisions to these forward-looking statements to reflect events or circumstances after the date of this Form 10-K or to reflect the
occurrence of unanticipated events.
General
CONMED Corporation was incorporated under the laws of the State of New York in 1970. CONMED is a medical
technology company that provides surgical devices and equipment for minimally invasive procedures. The Company’s products
are used by surgeons and physicians in a variety of specialties including orthopedics, general surgery, gynecology, neurosurgery,
thoracic surgery and gastroenterology. Headquartered in Utica, New York, the Company’s 3,300 employees distribute its products
worldwide from three primary manufacturing locations.
2
We have historically used strategic business acquisitions, internal product development and distribution relationships to
diversify our product offerings, increase our market share in certain product lines, realize economies of scale and take advantage
of growth opportunities in the healthcare field.
We are committed to offering products with the highest standards of quality, technological excellence and customer
service. Substantially all of our facilities have attained certification under the ISO international quality standards and other domestic
and international quality accreditations.
Our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those
reports are accessible free of charge through the Investor Relations section of our website (http://www.conmed.com) as soon as
practicable after such materials have been electronically filed with, or furnished to, the United States Securities and Exchange
Commission (the "SEC"). In addition, the SEC maintains an Internet site (http:/www.sec.gov) containing reports, proxy and
information statements and other information regarding issuers that file with the SEC.
Business Strategy
CONMED's vision is to empower healthcare providers worldwide to deliver exceptional outcomes for patients through
the following initiatives:
•
Introduction of New Products and Product Enhancements. We pursue organic growth through developing new
products and enhancing existing products. We seek to develop new technologies which improve the durability,
performance and usability of existing products. In addition to our internal research and development efforts, we receive
new ideas for products and technologies, particularly in procedure-specific areas, from surgeons, inventors and other
healthcare professionals.
• Pursue Strategic Acquisitions. We pursue strategic acquisitions, distribution and similar arrangements in existing and
new growth markets
increased operating efficiencies, geographic diversification and market
penetration. Targeted companies have historically included those with proven technologies and established brand names
which provide potential sales, marketing and manufacturing synergies. This includes the February 11, 2019 acquisition
of Buffalo Filter.
to achieve
• Realize Manufacturing and Operating Efficiencies. We continually review our production systems for opportunities
to reduce operating costs, consolidate product lines or process flows, reduce inventory and optimize existing processes.
• Geographic Diversification. We believe that significant growth opportunities exist for our surgical products outside
the United States. Principal international markets for our products include Europe, Latin America, Canada and Asia/
Pacific Rim.
• Active Participation in the Medical Community. We believe that excellent working relationships with physicians and
others in the medical industry enable us to gain an understanding of trends and emerging opportunities. Active
participation allows us to quickly respond to the changing needs of physicians and patients. In addition, we are an active
sponsor of medical education both in the United States and internationally, offering training on new and innovative
surgical techniques as well as other medical education materials for use with our products.
Products
The following table sets forth the percentage of net sales for each of our product lines during each of the three years
ended December 31:
Orthopedic surgery
General surgery
Consolidated net sales
Net sales (in thousands)
Year Ended December 31,
2018
2019
2017
49%
51
100%
52%
48
100%
54%
46
100%
$
955,097
$
859,634
$
796,392
3
Orthopedic Surgery
Our orthopedic surgery product offering includes sports medicine, powered surgical instruments, and sports biologics
and tissue. These products are marketed under a number of brands, including Hall®, CONMED Linvatec®, Concept® and Shutt®.
In 2019, approximately 71% of orthopedic surgery revenue came from single-use products that are expected to be recurring.
We offer a comprehensive range of products to repair injuries in the articulating joint areas of the body. Many of these
injuries are the result of sports related events or similar traumas. Our sports medicine products include powered resection
instruments, arthroscopes, reconstructive systems, tissue repair sets, metal and bioabsorbable implants as well as related disposable
products and fluid management systems. It is our standard practice to place some of these products, such as shaver consoles and
fluid pumps, with certain customers at no charge in exchange for commitments to purchase disposable products over certain time
periods. We loan this capital equipment, and it is subject to return if the customer does not meet certain minimum single-use
purchases. Single-use products include products such as shaver blades, burs and pump tubing. In sports medicine, we compete
with Smith & Nephew, plc; Arthrex, Inc.; Stryker Corporation; Johnson & Johnson: DePuy Mitek, Inc. and Zimmer Biomet, Inc.
Our powered instruments offering is sold principally under the Hall® Surgical brand name, for use in large and small
bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal and cardiothoracic surgeries. Our newest product is the Hall
50™ Powered Instrument System. The modularity and versatility of the Hall 50™ Powered Instrument System allows a facility
to purchase a single power system to perform total joint arthroplasty, trauma, arthroscopy and some small bone procedures. In
powered instruments, our competition includes Stryker Corporation; Medtronic plc; Johnson & Johnson: DePuy Synthes, Inc.;
and Zimmer Biomet, Inc.
Our surgical visualization products offer imaging systems for use in minimally invasive orthopedic and general surgery
procedures including 2DHD and 3DHD vision technologies. In surgical visualization, our competition includes Smith & Nephew,
plc; Arthrex, Inc.; Stryker Corporation; Olympus, Inc.; Richard Wolf and Karl Storz GmbH.
The Company is party to an agreement with Musculoskeletal Transplant Foundation (“MTF”) for the exclusive worldwide
sales representation, marketing and promotion of MTF's allograft tissues in the field of sports medicine and related areas to
customers through our sales force and marketing. The allograft tissues supplied by MTF under this agreement are used in the
reconstruction and/or replacement of tendon, ligament, cartilage or menisci, along with the correction of deformities within the
extremities.
General Surgery
Our general surgery product line offers a large range of products in the areas of advanced surgical, endoscopic technologies
and critical care. In 2019, approximately 87% of general surgery revenue came from single-use products that are expected to be
recurring.
Our advanced surgical product offering includes the leading clinical insufflation system (AirSeal®), an extensive energy
line and a broad offering of endomechanical products. AirSeal® includes proprietary valveless access ports to deliver significant
benefits to traditional minimally invasive surgery and robotic surgery. The electrosurgical offering consists of monopolar and
bipolar generators, Argon beam coagulation generators, handpieces, smoke management systems and other accessories. Our
endomechanical products offer a full line of instruments, including tissue retrieval bags, trocars, suction irrigation devices, graspers,
scissors and dissectors, used in minimally invasive surgery. Our competition includes Medtronic plc; Johnson & Johnson: Ethicon
Endo-Surgery, Inc.; Stryker Endoscopy, Olympus, ERBE Elektromedizin GmbH; and Applied Medical Resources Corporation.
Our endoscopic technologies offering includes a comprehensive line of diagnostic and therapeutic products used in
gastroenterology procedures which utilize flexible endoscopes. This offering includes forceps, snares, infection prevention
accessories, and devices for dilatation, stricture management, hemostasis and for the treatment of diseases of the biliary structures.
Our competition includes Boston Scientific Corporation - Endoscopy; Cook Medical, Inc.; Merit Medical Endotek; Olympus,
Inc.; STERIS Corporation - U.S. Endoscopy and Cantel Medical- Medivators, Inc.
Our cardiology and critical care offering includes a line of vital signs, cardiac monitoring and patient care products
including ECG electrodes & accessories, cardiac defibrillation & pacing pads and a complete line of suction instruments and
tubing. Finally, we offer a physician's office electrosurgical product mainly used by dermatologists. Cardiology and critical care's
main competition includes Cardinal and 3M Company.
4
International
Expanding our international presence is an important component of our long-term growth plan. Our products are sold
in over 100 foreign countries. International sales efforts are coordinated through local country dealers (including sub-distributors
or sales agents) or through direct in-country sales. We distribute our products through sales subsidiaries and branches with offices
located in Australia, Austria, Belgium, Brazil, Canada, China, Denmark, Finland, France, Germany, Italy, Japan, Korea, the
Netherlands, Poland, Spain, Sweden and the United Kingdom. In these countries, our sales are denominated in the local currency
and amounted to approximately 33% of our total net sales in 2019. In the remaining countries where our products are sold through
independent distributors, sales are denominated in United States dollars.
Competition
We compete in orthopedic and general surgery medical device markets across the world. Our competitors range from
large manufacturers with multiple business units to smaller manufacturers with limited product offerings. We believe we have
appropriate product offerings and adequate market share to compete effectively in these markets. The global markets are constantly
changing due to technological advances. We seek to closely align our research and development with our key business objectives,
namely developing and improving products and processes, applying innovative technology to the manufacture of products for
new global markets and reducing the cost of producing core products.
The breadth of our product lines in our key product areas enables us to meet a wide range of customer requirements and
preferences. This has enhanced our ability to market our products to surgeons, hospitals, surgery centers, group purchasing
organizations ("GPOs"), integrated delivery networks ("IDNs") and other customers, particularly as institutions seek to reduce
costs and minimize the number of suppliers.
Marketing
A significant portion of our products are distributed domestically directly to more than 6,000 hospitals, surgery centers
and other healthcare institutions as well as through medical specialty distributors. We are not dependent on any single customer
and no single customer accounted for more than 10% of our net sales in 2019, 2018 and 2017.
A significant portion of our U.S. sales are to customers affiliated with GPOs, IDNs and other large national or regional
accounts, as well as to the Veterans Administration and other hospitals operated by the Federal government. For hospital inventory
management purposes, some of our customers prefer to purchase our products through independent third-party medical product
distributors.
Our employee sales representatives are extensively trained in our various product offerings. Each employee sales
representative is assigned a defined geographic area and compensated on a commission basis or through a combination of salary
and commission. The sales force is supervised and supported by either area directors or district managers. In certain geographies,
sales agent groups are used in the United States to sell our orthopedic products. These sales agent groups are paid a commission
for sales made to customers while home office sales and marketing management provide the overall direction and training for
marketing and positioning of our products. Our sales professionals provide surgeons and medical personnel with information
relating to the technical features and benefits of our products.
Our healthcare systems organization is responsible for interacting with large regional and national accounts (e.g. GPOs,
IDNs, etc.). We have contracts with many such organizations and believe that the loss of any individual group purchasing contract
would not materially impact our business.
We sell to a diversified base of customers around the world and, therefore, believe there is no material concentration of
credit risk.
Manufacturing
Raw material costs constitute a substantial portion of our cost of production. Substantially all of our raw materials and
select components used in the manufacturing process are procured from external suppliers. We work closely with multiple suppliers
to ensure continuity of supply while maintaining high quality and reliability. As a consequence of supply chain best practices,
new product development and acquisitions, we often form strategic partnerships with key suppliers. As a result, components and
raw materials may be sole sourced. Due to the strength of these suppliers and the variety of products we provide, we do not believe
the risk of supplier interruption poses an overall material adverse effect on our financial and operational performance. We schedule
production and maintain adequate levels of safety stock based on a number of factors, including experience, knowledge of customer
5
ordering patterns, demand, manufacturing lead times and optimal quantities required to maintain the highest possible service
levels. Customer orders are generally processed for immediate shipment and backlog of firm orders is therefore not generally
material to an understanding of our business.
Research and Development
New and improved products play a critical role in our continued sales growth. Internal research and development efforts
focus on the development of new products and product technological and design improvements aimed at complementing and
expanding existing product lines. We continually seek to leverage new technologies which improve the durability, performance
and usability of existing products. In addition, we maintain close working relationships with surgeons, inventors and operating
room personnel who often make new product and technology disclosures, principally in procedure-specific areas. In certain cases,
we seek to obtain rights to these ideas through negotiated agreements. Such agreements typically compensate the originator
through payments based upon a percentage of licensed product net sales. Annual royalty expense approximated $2.0 million, $1.5
million and $1.8 million in 2019, 2018 and 2017, respectively.
Amounts expended for Company research and development were approximately $45.5 million, $42.2 million and $32.3
million during 2019, 2018 and 2017, respectively.
Intellectual Property
Patents and other proprietary rights, in general, are important to our business. We have rights to intellectual property,
including United States patents and foreign equivalent patents which cover a wide range of our products. We own a majority of
these patents and have exclusive and non-exclusive licensing rights to the remainder. We believe that the development of new
products and technological and design improvements to existing products will continue to be important to our competitive position.
Government Regulation and Quality Systems
The development, manufacture, sale and distribution of our products are subject to regulation by numerous agencies and
legislative bodies, including the U.S. Food and Drug Administration ("FDA") and comparable foreign counterparts. In the United
States, these regulations were enacted under the Medical Device Amendments of 1976 to the Federal Food, Drug and Cosmetic
Act and its subsequent amendments, and the regulations issued or proposed thereunder.
The FDA’s Quality System Regulations set forth requirements for our product design and manufacturing processes,
require the maintenance of certain records, provide for on-site inspection of our facilities and continuing review by the FDA. Many
of our products are also subject to industry-defined standards. Authorization to commercially market our products in the U.S. is
granted by the FDA under a procedure referred to as a 510(k) pre-market notification and clearance. We believe that our products
and processes presently meet applicable standards in all material respects.
Medical device regulations continue to evolve world-wide. Products marketed in the European Union and other countries
require preparation of technical files and design dossiers which demonstrate compliance with applicable international regulations.
As government regulations continue to change, there is a risk that the distribution of some of our products may be interrupted or
discontinued if they do not meet the country specific requirements.
We market our products in numerous foreign countries and therefore are subject to regulations affecting, among other
things, product standards, sterilization, packaging requirements, labeling requirements, import laws and onsite inspection by
independent bodies with the authority to issue or not issue certifications we may require to be able to sell products in certain
countries. Many of the regulations applicable to our devices and products in these countries are similar to those of the FDA. The
member countries of the European Union have adopted the European Medical Device Directives, which create a single set of
medical device regulations for all member countries. These regulations require companies that wish to manufacture and distribute
medical devices in the European Union to maintain quality system certifications through European Union recognized Notified
Bodies. These Notified Bodies authorize the use of the CE Mark allowing free movement of our products throughout the member
countries. Requirements pertaining to our products vary widely from country to country, ranging from simple product registrations
to detailed submissions such as those required by the FDA. We believe that our products and quality procedures currently meet
applicable standards for the countries in which they are marketed.
As noted above, our facilities are subject to periodic inspection by the United States Food and Drug Administration
(“FDA”) and foreign regulatory agencies or notified bodies for, among other things, conformance to Quality System Regulation
and Current Good Manufacturing Practice (“CGMP”) requirements and foreign or international standards. Refer to Note 13 for
further discussion.
6
We are also subject to various environmental health and safety laws and regulations both in the United States and
internationally, as are our suppliers and sterilization service providers. Our operations involve the use of substances regulated
under environmental laws, primarily in manufacturing and sterilization processes. We believe our policies, practices and procedures
are properly designed to comply, in all material respects, with applicable environmental laws and regulations. We do not expect
internal compliance with these requirements to have a material effect on purchases of property, plant and equipment, cash flows,
net income or our competitive position. Refer to Item 1A, Risk Factors, for further discussion of the use of outside EtO sterilization
service providers.
Employees
As of December 31, 2019, we had approximately 3,300 full-time employees, including approximately 2,100 in operations,
180 in research and development and the remaining in sales, marketing and related administrative support. We believe that we
have good relations with our employees and have never experienced a strike or similar work stoppage. None of our domestic
employees are represented by a labor union.
Item 1A. Risk Factors
An investment in our securities, including our common stock, involves a high degree of risk. Investors should carefully
consider the specific factors set forth below as well as the other information included or incorporated by reference in this Form
10-K. See “Forward Looking Statements”.
(i) Risks Related to Our Business and the Medical Device Industry
Our financial performance is dependent on conditions in the healthcare industry and the broader economy.
The results of our business are directly tied to the economic conditions in the healthcare industry and the broader economy as a
whole. We will continue to monitor and manage the impact of the overall economic environment on the Company.
In this regard, approximately 21% of our revenues are derived from the sale of capital products. The sales of such products may
be negatively impacted if hospitals and other healthcare providers are unable to secure the financing necessary to purchase these
products or otherwise defer purchases.
In addition, some of our products and components are sourced from countries impacted by the Coronavirus. If we cannot source
these products, our revenues may be affected.
Our financial performance may be adversely impacted by healthcare reform legislation.
Provisions of healthcare legislation, including provisions of the Patient Protection and Affordable Care Act ("ACA") in the United
States, and similar attempts to reform or manage health care costs in other markets, could meaningfully change the way health
care is developed and delivered and may adversely affect our business and results of operations. For example, the ACA includes
provisions aimed at improving quality and decreasing costs of Medicare, governing comparative effectiveness research, and
implementing an independent payment advisory board and pilot programs to evaluate alternative payment methodologies. That
legislation also included a 2.3% excise tax imposed upon sales within the U.S. of certain medical device products, which was
repealed in 2019. We also face uncertainties that might result in the modification or repeal of health care laws or reimbursement
in the United States and other markets. The uncertainty associated with modifications or a repeal could generally cause healthcare
markets to be unstable and we could be subject to some interruptions, the magnitude of which are impossible to determine.
Limitations on the availability of Ethylene Oxide (“EtO”) sterilization services may limit our ability to sell certain sterile
products.
Approximately 30% of our products when measured in terms of revenues, are sterilized by third-party sterilizers using ethylene
oxide, a chemical which, when present or used in high levels of concentrations, has raised some environmental concerns in some
areas within the United States, with the result that some EtO sterilization facilities have closed either temporarily or permanently
in connection with government enforcement actions prompted by environmental concerns. We have been able to work to secure
alternate EtO sterilization services to date, and do not currently expect sterilization availability to have a material impact on our
business. If, however, there are further restrictions on capacity or further government actions adverse to EtO sterilization, it is
possible that we could be impacted materially in the future.
7
As a manufacturer of medical devices that interacts with physicians and health care providers domestically and internationally,
we face risks under domestic and foreign regulations, including the Foreign Corrupt Practices Act.
Manufacturers of medical devices have been the subject of various investigations or enforcement actions relating to interactions
with health care providers domestically or internationally. The interactions with domestic health care providers are subject to
regulations, known as the Anti-Kickback Statute, the Stark Act and the False Claims Act, that generally govern incentives for
health care providers, or methods of reimbursement funded in whole or in part by the government. Similarly, the Foreign Corrupt
Practices Act (“FCPA”) prohibits certain conduct by manufacturers, generally described as bribery, with respect to interactions,
either directly through foreign subsidiaries or indirectly through distributors, with health care providers who may be considered
government officials because they are affiliated with public hospitals. The FCPA also imposes obligations on manufacturers listed
on U.S. stock exchanges to maintain accurate books and records, and maintain internal accounting controls sufficient to provide
assurance that transactions are accurately recorded, lawful and in accordance with management’s authorization. The FCPA can
pose unique challenges for manufacturers who operate in foreign cultures where conduct prohibited by the FCPA may not be
viewed as illegal in local jurisdictions, and because, in some cases, a United States manufacturer may face risks under the FCPA
based on the conduct of third parties over whom the manufacturer may not have complete control.
In this regard, from time to time, the Company may receive an information request or subpoena from a government agency, such
as the Securities and Exchange Commission, Department of Justice, Equal Employment Opportunity Commission, the
Occupational Safety and Health Administration, the Department of Labor, the Treasury Department or other federal and state
agencies or foreign governments or government agencies. Alternatively, employees or private parties may provide us with reports
of alleged misconduct. These information requests or subpoenas may or may not be routine inquiries, or may begin as informal
or routine inquiries and over time develop into investigations or enforcement actions of various types under the FCPA or otherwise.
Similarly, the employee and third party reports may prompt us to conduct internal investigations into the alleged misconduct. As
a medical device company, CONMED’s operations and interactions with government hospitals, healthcare professionals and
purchasers may be subject to various federal and state regulations, including the federal False Claims Act, which provides, in part,
that the federal government may bring a lawsuit against any person or entity that it believes has knowingly presented, or caused
to be presented, a false or fraudulent request for payment to the government, or has made or used, or caused to be made or used,
a false statement or false record material to a false claim. In addition, in certain circumstances, private parties may bring so-called
Qui Tam claims as plaintiffs purportedly on behalf of the government asserting claims arising under the False Claims Act. A
violation of the False Claims Act may result in fines up to $11,000 for each false claim, plus up to three times the amount of
damages sustained by the government, and may also provide the basis for the imposition of administrative penalties and exclusion
from participation in federal healthcare programs. Many states have enacted false claims acts that are similar to the federal False
Claims Act. No inquiry or claim that the Company currently faces or has faced to date, and no report of misconduct that the
Company has received to date, has had a material adverse effect on our financial condition, results of operations or cash flows.
There can be no assurance, however, that any pending inquiries will not become investigations or enforcement actions, or the costs
associated with responding to such inquiries, investigations, enforcement actions or investigations relating to reports of misconduct
will not have a material adverse effect on our financial condition, results of operations or cash flows.
Failure to comply with regulatory requirements may result in recalls, loss of revenues, fines or materially adverse implications.
Substantially all of our products are classified as class II medical devices subject to regulation by numerous agencies and legislative
bodies, including the U.S. Food and Drug Administration ("FDA") and comparable international counterparts. As a manufacturer
of medical devices, our manufacturing processes and facilities are subject to on-site inspection and continuing review by the FDA
for compliance with the Quality System Regulations. We may have future inspections at our sites and there can be no assurance
that the costs of responding to such inspections will not be material.
Manufacturing and sales of our products outside the United States are also subject to international regulatory requirements which
vary from country to country. Moreover, we are generally required to obtain regulatory clearance or approval prior to marketing
a new product. The time required to obtain approvals from foreign countries may be longer or shorter than that required for FDA
clearance, and requirements for such approvals may differ from FDA requirements. Failure to comply with applicable domestic
and/or foreign regulatory requirements may result in:
•
•
•
•
•
•
•
fines or other enforcement actions;
recall or seizure of products;
total or partial suspension of production;
loss of certification;
withdrawal of existing product approvals or clearances;
refusal to approve or clear new applications or notices;
increased quality control costs; or
8
•
criminal prosecution.
In addition to the Quality System Regulations, many of our products are also subject to industry-defined standards. We may not
be able to comply with these regulations and standards due to deficiencies in component parts or our manufacturing processes. If
we are not able to comply with the Quality System Regulations or industry-defined standards, we may not be able to fill customer
orders and we may decide to cease production or sale of non-compliant products. Failure to produce products could affect our
revenues, profit margins and could lead to loss of customers.
Our products are subject to product recall and we have conducted product recalls in the past. Although no recall has had a material
adverse effect on our business or financial condition, we cannot assure you that regulatory issues will not have a material adverse
effect on our business, financial condition or results of operations in the future or that product recalls will not harm our reputation
and our customer relationships.
The highly competitive market for our products may create adverse pricing pressures.
The market for our products is highly competitive and our customers have numerous alternatives of supply. Many of our competitors
offer a range of products in areas other than those in which we compete, which may make such competitors more attractive to
surgeons, hospitals, group purchasing organizations and others. In addition, many of our competitors are large, technically
competent firms with substantial assets. Competitive pricing pressures or the introduction of new products by our competitors
could have an adverse effect on our revenues. See “Products” in Item 1 - Business for a further discussion of these competitive
forces.
Factors which may influence our customers’ choice of competitor products include:
•
•
•
•
•
•
changes in surgeon preferences;
increases or decreases in healthcare spending related to medical devices;
our inability to supply products to them as a result of product recall, market withdrawal or back-order;
the introduction by competitors of new products or new features to existing products;
the introduction by competitors of alternative surgical technology; and
advances in surgical procedures, discoveries or developments in the healthcare industry.
Cost reduction efforts in the healthcare industry could put pressures on our prices and margins.
In recent years, the healthcare industry has undergone significant change driven by various efforts to reduce costs. Such efforts
include national healthcare reform, trends towards managed care, cuts in Medicare reimbursement for procedures, consolidation
of healthcare distribution companies and collective purchasing arrangements by GPOs and IDNs. Demand and prices for our
products may be adversely affected by such trends.
We use a variety of raw materials in our businesses, and significant shortages or price increases could increase our
operating costs and adversely impact the competitive positions of our products.
Our reliance on certain suppliers and commodity markets to secure raw materials used in our products exposes us to volatility in
the prices and availability of raw materials. In some instances, we participate in commodity markets that may be subject to
allocations by suppliers. A disruption in deliveries from our suppliers, price increases or decreased availability of raw materials
or commodities could have an adverse effect on our ability to meet our commitments to customers or increase our operating costs.
We believe that our supply management practices are based on an appropriate balancing of the foreseeable risks and the costs of
alternative practices. Nonetheless, price increases or the unavailability of some raw materials may have an adverse effect on our
results of operations or financial condition.
We may not be able to keep pace with technological change or to successfully develop new products with wide market acceptance,
which could cause us to lose business to competitors.
The market for our products is characterized by rapidly changing technology. Our future financial performance will depend in
part on our ability to develop and manufacture new products on a cost-effective basis, to introduce them to the market on a timely
basis and to have them accepted by surgeons.
We may not be able to keep pace with technology or to develop viable new products. In addition, many of our competitors are
substantially larger with greater financial resources which may allow them to more rapidly develop new products. Factors which
may result in delays of new product introductions or cancellation of our plans to manufacture and market new products include:
9
•
•
•
•
capital constraints;
research and development delays;
delays in securing regulatory approvals; and
changes in the competitive landscape, including the emergence of alternative products or solutions which reduce or
eliminate the markets for pending products.
Ordering patterns of our customers may change resulting in reductions in sales.
Our hospital and surgery center customers purchase our products in quantities sufficient to meet their anticipated demand. Likewise,
our healthcare distributor customers purchase our products for ultimate resale to healthcare providers in quantities sufficient to
meet the anticipated requirements of the distributors’ customers. Should inventories of our products owned by our hospital, surgery
center and distributor customers grow to levels higher than their requirements, our customers may reduce the ordering of products
from us. This could result in reduced sales during a financial accounting period.
(ii) Risks Related to Our Indebtedness
The terms of our indebtedness outstanding from time to time, including our senior credit agreement, may restrict our
current and future operations, particularly our ability to respond to changes or to take certain actions.
The senior credit agreement contains, and future credit facilities are expected to contain, a number of restrictive covenants that
impose significant operating and financial restrictions on us and may limit our ability to respond to changes in our business or
competitive activities, or to otherwise engage in acts that may be in our long-term best interest, including restrictions on our ability
to:
•
•
•
•
•
•
•
•
•
•
•
•
incur indebtedness;
allow for liens to be placed on our assets;
make investments;
engage in transactions with affiliates;
make certain restricted payments;
enter into certain restrictive agreements;
enter into certain swap agreements;
change our line of business;
pay dividends or make other distributions on, or redeem or repurchase, capital stock;
consolidate, merge or sell all or substantially all of our assets;
prepay and/or modify the terms of certain indebtedness; and
pursue acquisitions.
These covenants, unless waived, may prevent us from pursuing acquisitions, significantly limit our operating and financial
flexibility and limit our ability to respond to changes in our business or competitive activities. Our ability to comply with such
provisions may be affected by events beyond our control. In the event of any default under our credit agreement, the credit
agreement lenders may elect to declare all amounts borrowed under our credit agreement, together with accrued interest, to be
due and payable. If we were unable to repay such borrowings, the credit agreement lenders could proceed against collateral
securing the credit agreement which consists of substantially all of our property and assets. Our credit agreement also contains a
material adverse effect clause which may limit our ability to access additional funding under our credit agreement should a material
adverse change in our business occur.
We may not be able to generate sufficient cash to service our indebtedness, and, our leverage and debt service requirements
may require us to adopt alternative business strategies.
As of December 31, 2019, we had $820.1 million of debt outstanding, representing 53% of total capitalization. We may not have
sufficient cash flow available to enable us to meet our obligations. If we are unable to service our indebtedness, we will be forced
to adopt an alternative strategy that may include actions such as foregoing acquisitions, reducing or delaying capital expenditures,
selling assets, restructuring or refinancing our indebtedness or seeking additional equity capital. We cannot assure you that any
of these strategies could be implemented on terms acceptable to us, if at all. See “Management’s Discussion and Analysis of
Financial Condition and Results of Operations—Liquidity and Capital Resources” and Note 7.
10
The degree to which we are leveraged could have important consequences to investors, including but not limited to the following:
•
•
•
•
•
•
a portion of our cash flow from operations must be dedicated to debt service and will not be available for operations,
capital expenditures, acquisitions, dividends and other purposes;
our ability to obtain additional financing in the future for working capital, capital expenditures, acquisitions or general
corporate purposes may be limited or impaired or may be at higher interest rates;
we may be at a competitive disadvantage when compared to competitors that are less leveraged;
we may be hindered in our ability to adjust rapidly to market conditions;
our degree of leverage could make us more vulnerable in the event of a downturn in general economic conditions or other
adverse circumstances applicable to us; and
our interest expense could increase if interest rates in general increase because a portion of our borrowings, including
our borrowings under our credit agreement, are and will continue to be at variable rates of interest.
Our variable rate indebtedness subjects us to interest rate risk, which could cause our debt service obligations to increase
significantly.
Borrowings under our senior credit agreement are at variable rates of interest and expose us to interest rate risk. If interest rates
were to increase, our debt service obligations on the variable rate indebtedness would increase even though the amount borrowed
remained the same, and our net income and cash flows, including cash available for servicing our indebtedness, will correspondingly
decrease. In the future, we may enter into interest rate swaps that involve the exchange of floating for fixed rate interest payments
in order to reduce interest rate volatility. However, we may not maintain interest rate swaps with respect to all of our variable rate
indebtedness, and any swaps we enter into may not fully mitigate our interest rate risk.
Our interest rates may be impacted by the phase out of LIBOR.
LIBOR, the London Interbank Offered Rate, is the basic rate of interest used in lending transactions between banks on the London
interbank market and is widely used as a reference for setting the interest rate on loans globally. Certain of the interest rates
applicable to our sixth amended and restated senior credit agreement are calculated using LIBOR. On July 27, 2017, the United
Kingdom’s Financial Conduct Authority, which regulates LIBOR, announced that it intends to phase out LIBOR by the end of
2021. It is unclear if at that time LIBOR will cease to exist or if new methods of calculating LIBOR will be established such that
it continues to exist after 2021. If LIBOR ceases to exist, then any existing LIBOR-based loans outstanding under our sixth
amended and restated credit agreement will become alternative base rate loans (as defined in Note 7) until an alternative rate of
interest is determined. This alternative rate will require an amendment to the sixth amended and restated senior credit agreement,
and may result in exposure to additional interest rate risk.
Despite our current level of indebtedness, we and our subsidiaries may still be able to incur substantially more debt. This
could further exacerbate the risks to our financial condition described above.
We may incur substantial additional indebtedness, including secured indebtedness. As of December 31, 2019, we have $362.5
million of availability under the senior credit agreement. If we incur secured indebtedness and such secured indebtedness is
either accelerated or becomes subject to a bankruptcy, liquidation or reorganization, our assets would be used to satisfy obligations
with respect to the indebtedness secured thereby before any payment could be made on the debt that is not similarly secured. If
new debt or other liabilities are added to our current debt levels, the related risks that we now face could intensify. Our senior
credit agreement restricts our ability to incur additional indebtedness, including secured indebtedness, but if the facilities mature
or are repaid, we may not be subject to such restrictions under the terms of any subsequent indebtedness.
The conditional conversion features of our 2.625% Convertible Notes due 2024 (the “Convertible Notes”), if triggered, may
adversely affect our financial condition.
In the event the conditional conversion features of the Convertible Notes issued on January 29, 2019 are triggered, holders of the
Convertible Notes will be entitled to convert the Convertible Notes at any time during specified periods at their option. If one or
more holders elect to convert their Convertible Notes, unless we elect to satisfy our conversion obligation by delivering solely
shares of our common stock, we would be required to make cash payments to satisfy all or a portion of our conversion obligation
based on the conversion rate, which could adversely affect our liquidity. In addition, even if holders do not elect to convert their
Convertible Notes, we could be required under applicable accounting rules to reclassify all or a portion of the outstanding principal
of the Convertible Notes as a current rather than long-term liability, which could result in a material reduction of our net working
capital. Refer to Item 7. Management and Discussion and Analysis - Financing Cash Flows and Note 7 for further details on the
Convertible Notes.
11
The convertible notes hedge and warrant transactions that we entered into in connection with the offering of the Convertible
Notes may affect the value of the Convertible Notes and our common stock.
In connection with the offering of the Convertible Notes, we entered into convertible notes hedge transactions with certain option
counterparties (each an “option counterparty”). The convertible notes hedge transactions are expected generally to reduce the
potential dilution upon conversion of the Convertible Notes and/or offset any cash payments we are required to make in excess
of the principal amount of converted Convertible Notes, as the case may be. We also entered into warrant transactions with each
option counterparty. The warrant transactions could separately have a dilutive effect on our common stock to the extent that the
market price per share of our common stock exceeds the strike price of the warrants, unless we elect to settle the warrants in
cash. In connection with establishing its initial hedge of the convertible notes hedge and warrant transactions, each option
counterparty or an affiliate thereof may have entered into various derivative transactions with respect to our common stock
concurrently with or shortly after the pricing of the Convertible Notes. This activity could increase (or reduce the size of any
decrease in) the market price of our common stock or the Convertible Notes at that time. In addition, each option counterparty
or an affiliate thereof may modify its hedge position by entering into or unwinding various derivatives with respect to our common
stock and/or purchasing or selling our common stock or other securities of ours in secondary market transactions prior to the
maturity of the Convertible Notes (and is likely to do so during any observation period related to a conversion of the Convertible
Notes). This activity could also cause or avoid an increase or a decrease in the market price of our common stock or the Convertible
Notes. In addition, if any such convertible notes hedge and warrant transactions fail to become effective, each option counterparty
may unwind its hedge position with respect to our common stock, which could adversely affect the value of our common stock
and the value of the Convertible Notes.
We are subject to counterparty risk with respect to the convertible notes hedge transactions.
Each option counterparty to the convertible notes hedge transactions is a financial institution whose obligation to perform under
the convertible notes hedge transaction will not be secured by any collateral. If an option counterparty becomes subject to insolvency
proceedings, we will become an unsecured creditor in those proceedings with a claim equal to our exposure at that time under our
transactions with the option counterparty. Our exposure will generally correlate to the increase in the market price and in the
volatility of our common stock. In addition, upon a default by an option counterparty, we may suffer adverse tax consequences
and more dilution than we currently anticipate with respect to our common stock. Although these counterparties are large, reputable
U.S. financial institutions, we can provide no assurances as to the financial stability or viability of any option counterparty.
(iii) Risks Related to Our Acquisition Strategy
Our financial performance is subject to the risks inherent in any acquisition, including the effects of increased borrowing and
integration of newly acquired businesses or product lines.
A key element of our business strategy has been to expand through acquisitions and we may seek to pursue additional acquisitions
in the future. Our success in pursuing acquisitions depends on our ability to identify target companies or product lines that are
available for sale, and, negotiating successful terms with the sellers, as the sellers may also be negotiating with other bidders with
greater financial resources than we have. Even when we win a bid, our success is also dependent in part upon our ability to
integrate acquired companies or product lines into our existing operations. We may not have sufficient management and other
resources to accomplish the integration of our past and future acquisitions, which may strain our relationship with customers,
suppliers, distributors, personnel or others. There can be no assurance that we will be able to identify and make acquisitions on
acceptable terms or that we will be able to obtain financing for such acquisitions on acceptable terms. In addition, while we are
generally entitled to customary indemnification from sellers of businesses or coverage from representation and warranty insurance
for any difficulties that may have arisen prior to our acquisition of each business, acquisitions may involve exposure to unknown
liabilities and the amount and time for claiming under these indemnification provisions is often limited. As a result, our financial
performance is now, and will continue to be, subject to various risks associated with the acquisition of businesses, including the
financial effects associated with any increased borrowing required to fund such acquisitions or with the integration of such
businesses.
The terms of any future preferred equity or debt financing may give holders of any preferred securities or debt securities rights
that are senior to rights of our common shareholders or impose more stringent operating restrictions on our company.
Debt or equity financing may not be available to us on acceptable terms. If we incur additional debt or raise equity through the
issuance of preferred stock or convertible securities, the terms of the debt or the preferred stock issued may give the holders rights,
preferences and privileges senior to those of holders of our common stock, particularly in the event of liquidation. The terms of
the debt may also impose additional and more stringent restrictions on our operations. If we raise funds through the issuance of
additional equity, the ownership percentage of our existing shareholders would be diluted.
12
(iv) Other Risks Related to Our Business
We could experience a failure of a key information technology system, process or site or a breach of information security,
including a cybersecurity breach or failure of one or more key information technology systems, networks, processes, associated
sites or service providers, and could potentially become liable for a breach of various data privacy regulations.
We rely extensively on information technology (“IT”) systems for the storage, processing, and transmission of our electronic,
business-related, information assets used in or necessary to conduct business. We leverage our internal IT infrastructures, and
those of our business partners, to enable, sustain, and support our global business activities. In addition, we rely on networks and
services, including internet sites, data hosting and processing facilities and tools and other hardware, software and technical
applications and platforms, some of which are managed, hosted, provided and/or used by third-parties or their vendors, to assist
in conducting our business. The data we store and process may include customer payment information, personal information
concerning our employees, confidential financial information, and other types of sensitive business-related information. In limited
instances, we may also come into possession of information related to patients of our physician customers. Numerous and evolving
cybersecurity threats pose potential risks to the security of our IT systems, networks and services, as well as the confidentiality,
availability and integrity of our data. In addition, the laws and regulations governing security of data on IT systems and otherwise
collected, processed, stored, transmitted, disclosed and disposed of by companies are evolving, adding another layer of complexity
in the form of new requirements. We have made, and continue to make investments, seeking to address these threats, including
monitoring of networks and systems, hiring of experts, employee training and security policies for employees and third-party
providers. The techniques used in these attacks change frequently and may be difficult to detect for periods of time and we may
face difficulties in anticipating and implementing adequate preventative measures.
Our worldwide operations mean that we are subject to laws and regulations, including data protection and cybersecurity laws and
regulations, in many jurisdictions. For example, The European Union ("E.U.") General Data Protection Regulation (GDPR) requires
us to manage personal data in the E.U. and may impose fines of up to four percent of our global revenue in the event of certain
violations. Other jurisdictions are also implementing or proposing a variety of data privacy laws and regulations. Further, there
has been a developing trend of civil lawsuits and class actions relating to breaches of consumer data held by large companies or
incidents arising from other cyber-attacks. Any data security breaches, cyber-attacks, malicious intrusions or significant disruptions
could result in actions by regulatory bodies and/or civil litigation, any of which could materially and adversely affect our business,
results of operations, financial condition, cash flows, reputation or competitive position.
While the breaches of our IT systems to date have not been material to our business or results of operations, the costs of attempting
to protect IT systems and data may increase, and there can be no assurance that these added security efforts will prevent all breaches
of our IT systems or thefts of our data. If our IT systems are damaged or cease to function properly, the networks or service
providers we rely upon fail to function properly, we fail to comply with an applicable law or regulation, such as the GDPR, or we
or one of our third-party providers suffer a loss or disclosure of our business or stakeholder information due to any number of
causes ranging from catastrophic events or power outages to improper data handling or security breaches and our business continuity
plans do not effectively address these failures on a timely basis, we may be exposed to potential disruption in operations, loss of
customers, reputational, competitive and business harm as well as significant costs from remediation, litigation and regulatory
actions.
We rely on a third party to obtain, process and distribute sports medicine allograft tissue. If such tissue cannot be obtained,
is not accepted by the market or is not accepted under numerous government regulations, our results of operations could be
negatively impacted.
A portion of our orthopedic revenues relate to our share of the service fees from the MTF allograft tissues for which we have
exclusive worldwide sales representation, marketing and promotion rights, as further described in our revenue recognition policy
in Note 1. Our primary costs related to these revenues come from our commission expense and certain marketing costs. Our
ability to increase the service fees may be constrained by certain factors which are outside of our control, such as the limited supply
of donors and donated tissue that meets the quality standards of MTF. Similarly, under the terms of the agreement, MTF remains
responsible for tissue procurement and processing, shipment of tissues and invoicing of service fees to customers. To the extent
MTF’s performance does not meet customer expectations or otherwise fails, CONMED may be unable to increase the allograft
service fees or to find a suitable replacement for MTF on terms that are acceptable.
The FDA and several states have statutory authority to regulate allograft processing and allograft-based materials. The FDA could
identify deficiencies in future inspections of MTF or MTF's suppliers or promulgate future regulatory rulings that could disrupt
our business, reducing profitability.
13
We distribute some products for third-party companies, and cannot ensure that our rights to distribute such third-party products
will continue indefinitely.
While we generally own the products' designs and rights to the products we sell, in some cases we distribute products for third-
parties. While these third-parties may have business reasons for contracting with us to distribute their products, we may face the
risk that the third-parties may seek alternate distribution partners when their distribution contracts with us expire or are scheduled
for renewal. If we lose the distribution rights to such products, we may not be able to find replacement products that are acceptable
to our customers, or to us.
If we lose our patents or they are held to be invalid, or if our products or services infringe on third party patents, we could
become subject to liability and our competitive position could be harmed.
Much of the technology used in the markets in which we compete is covered by patents. We have numerous U.S. patents and
corresponding international patents on products expiring at various dates from 2020 through 2040 and have additional patent
applications pending. See Item 1 Business “Research and Development” and “Intellectual Property” for a further description of
our patents. The loss of our patents could reduce the value of the related products and any related competitive
advantage. Competitors may also be able to design around our patents and to compete effectively with our products. In addition,
the cost of enforcing our patents against third parties and defending our products against patent infringement actions by others
could be substantial, and we may not prevail.
While we seek to take reasonable steps to avoid infringing on patents we do not own or license, we cannot be sure that our services
and products do not infringe on the intellectual property rights of third parties, and we may have infringement claims asserted
against us. These claims could cost us money, prevent us from offering some services or products, or damage our reputation. We
cannot assure you that:
•
•
•
•
pending patent applications will result in issued patents;
patents issued to or licensed by us will not be challenged by competitors;
our patents will be found to be valid or sufficiently broad to protect our technology or provide us with a competitive
advantage; or
we will be successful in defending against pending or future patent infringement claims asserted against our products.
We can be sued for product liability claims and our insurance coverage may be insufficient to cover the nature and amount of
any product liability claims.
Even if our products are properly designed and perform as intended, we may be sued because the nature of our products as medical
devices and today’s litigious environment should be regarded as potential risks which could significantly and adversely affect our
financial condition and results of operations. The insurance we maintain to protect against claims associated with the use of our
products has deductibles and may not adequately cover the amount or nature of any claim asserted against us. We are also exposed
to the risk that our insurers may become insolvent or that premiums may increase substantially. See “Item 3 - Legal Proceedings”
for a further discussion of the risk of product liability actions and our insurance coverage.
Damage to our physical properties as a result of windstorm, earthquake, fire or other natural or man-made disaster may cause
a financial loss and a loss of customers.
Although we maintain insurance coverage for physical damage to our property and the resultant losses that could occur during a
business interruption, we are required to pay deductibles and our insurance coverage is limited to certain caps. For example, our
deductible for windstorm damage to our Florida property amounts to 2% of any loss.
Further, while insurance reimburses us for our lost gross earnings during a business interruption, if we are unable to supply our
customers with our products for an extended period of time, there can be no assurance that we will regain the customers’ business
once the product supply is returned to normal.
Our significant international operations subject us to foreign currency fluctuations and other risks associated with operating
in countries outside the United States.
A significant portion of our revenues, approximately 46% of 2019 consolidated net sales, were to customers outside the United
States. We have sales subsidiaries in a significant number of countries in Europe as well as Australia, Canada, China, Japan and
Korea. In those countries in which we have a direct presence, our sales are denominated in the local currency and those sales
denominated in local currency amounted to approximately 33% of our total net sales in 2019. The remaining 13% of sales to
14
customers outside the United States was on an export basis and transacted in United States dollars.
Because a significant portion of our operations consist of sales activities in jurisdictions outside the United States, our financial
results may be affected by factors such as changes in foreign currency exchange rates or weak economic conditions in the markets
in which we distribute products. While we have implemented a hedging strategy involving foreign currency forward contracts
for 2019, our revenues and earnings are only partially protected from foreign currency translation if the United States dollar
strengthens as compared with currencies such as the Euro. Further, as of the date of this Form 10-K, we have not entered into any
foreign currency forward contracts beyond 2021. Our international presence exposes us to certain other inherent risks, including:
•
•
•
•
•
•
•
•
imposition of limitations on conversions of foreign currencies into dollars or remittance of dividends and other payments
by international subsidiaries;
imposition or increase of withholding and other taxes on remittances and other payments by international subsidiaries;
trade barriers and tariffs;
compliance with economic sanctions, trade embargoes, export controls, and the customs laws and regulations of the many
countries in which we operate;
political risks, including political instability;
reliance on third parties to distribute our products;
hyperinflation in certain countries outside the United States; and
imposition or increase of investment and other restrictions by foreign governments.
We cannot assure you that such risks will not have a material adverse effect on our business and results of operations.
Our new products may fail to achieve expected levels of market acceptance.
New product introductions may fail to achieve market acceptance. The degree of market acceptance for any of our products will
depend upon a number of factors, including:
•
•
•
•
•
•
our ability to develop and introduce new products and product enhancements in the time frames we currently estimate;
our ability to successfully implement new technologies;
the market’s readiness to accept new products;
having adequate financial and technological resources for future product development and promotion;
the efficacy of our products; and
the prices of our products compared to the prices of our competitors’ products.
If our new products do not achieve market acceptance, we may be unable to recover our investments and may lose business to
competitors.
In addition, some of the companies with which we now compete, or may compete in the future, have or may have more extensive
research, marketing and manufacturing capabilities and significantly greater technical and personnel resources than we do, and
may be better positioned to continue to improve their technology in order to compete in an evolving industry. See “Products” in
Item 1 - Business for a further discussion of these competitive forces.
Our Board of Directors may, in the future, limit or discontinue payment of a dividend on common stock.
We have paid a regular quarterly dividend to our shareholders since 2012. However, we may not declare or pay such dividends
in the future at the prior rate, or at all. All decisions regarding our payment of dividends will be made by our Board of Directors
from time to time and will be subject to an evaluation of our financial condition, results of operations and capital requirements,
as well as applicable law, regulatory constraints, industry practice, contractual restraints and other business considerations that
our Board of Directors considers relevant. In addition, our senior credit agreement contains restrictions on our ability to pay
dividends, and the terms of agreements governing debt that we may incur in the future may also limit or prohibit dividend
payments. We may not have sufficient surplus or net profits under New York law to be able to pay any dividends, which may
result from extraordinary cash expenses, actual expenses exceeding contemplated costs, funding of capital expenditures or
increases in reserves.
Anti-takeover provisions in our organizational documents and New York law could delay or prevent a change in control.
Provisions of our certificate of incorporation and bylaws may delay or prevent a merger or acquisition that a shareholder may
consider favorable. These provisions include:
15
• the ability of our board of directors to determine to issue shares of preferred stock and to determine the price and other terms
of those shares, including preferences and voting rights, without shareholder approval, which could be used to significantly
dilute the ownership of a hostile acquirer;
• the requirement that a special meeting of shareholders may be called only by the board of directors, the chairman of the
board of directors or the president, which may delay the ability of our shareholders to force consideration of a proposal or
to take action;
• providing indemnification to our directors and officers;
• providing that directors may be removed prior to the expiration of their terms by shareholders only for cause; and
• advance notice procedures that shareholders must comply with in order to nominate candidates to our board of directors or
to propose matters to be acted upon at a shareholders’ meeting, which may discourage or deter a potential acquiror from
conducting a solicitation of proxies to elect the acquiror’s own slate of directors or otherwise attempting to obtain control of
us.
As a New York corporation, we are also subject to provisions of New York law, including Section 912 of the New York Business
Corporation Law, which prevents some shareholders holding more than 20% of our outstanding common stock from engaging in
certain business combinations without approval of the board of directors or the holders of substantially all of our outstanding
common stock. Any provision of our certificate of incorporation and bylaws or New York law that has the effect of delaying or
deterring a change in control could limit the opportunity for our shareholders to receive a premium for their shares of our common
stock, and could also affect the price that some investors are willing to pay for our common stock.
Environmental laws and regulations and climate change initiatives could materially and adversely affect our business,
financial condition, and results of operations.
Our business and facilities and those of our suppliers are subject to a number of federal, state, local and international laws and
regulations governing the protection of human health and the environment. In addition, concern over climate change and
sustainability has led to foreign and domestic legislative and regulatory initiatives directed at limiting carbon dioxide and other
greenhouse gas emissions. A failure to comply with current or future environmental laws and regulations could result in fines or
penalties. Any such expenses or liability could have a material adverse effect on our financial condition, results of operations or
cash flows.
Our ability to attract and retain qualified employees is critical to our success.
CONMED’s employees are its most important resource, and in many areas of the medical industry, competition for qualified
personnel is intense. CONMED seeks to attract talented and diverse new employees and retain and motivate its existing employees.
If we are unable to continue to attract or retain qualified employees, including our executives, CONMED’s performance, including
its competitive position, could be materially and adversely affected.
Item 1B. Unresolved Staff Comments
None.
16
Item 2. Properties
Facilities
The following table sets forth certain information with respect to our principal operating facilities. We believe that our
facilities are generally well maintained, are suitable to support our business and adequate for present and anticipated needs.
Location
Square Feet
Own or Lease
Lease Expiration
Utica, NY
Largo, FL
Chihuahua, Mexico
Chihuahua, Mexico
Lithia Springs, GA
Brussels, Belgium
Mississauga, Canada
Greenwood Village, CO
Westborough, MA
Frenchs Forest, Australia
500,000
278,000
207,720
40,626
188,400
58,276
22,421
22,162
19,515
16,912
Own
Own
Lease
Lease
Lease
Lease
Lease
Lease
Lease
Lease
—
—
October 2024
March 2028
January 2025
June 2024
December 2023
July 2024
November 2025
July 2020
Our principal manufacturing facilities are located in Utica, NY, Largo, FL and Chihuahua, Mexico. Lithia Springs, GA
and Brussels, Belgium are our principal distribution centers. We also maintain sales and administrative offices in countries
throughout the world.
Item 3. Legal Proceedings
We are involved in various proceedings, legal actions and claims arising in the normal course of business, including
proceedings related to product, labor and intellectual property and other matters that are more fully described in Note 13. We are
not a party to any pending legal proceedings other than ordinary routine litigation incidental to our business.
Item 4. Mine Safety Disclosures
Not applicable.
17
PART II
Item 5. Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity
Securities
Our common stock, par value $.01 per share, is traded on the New York Stock Exchange, effective February 10, 2020,
under the symbol “CNMD”. Prior to this date, our common stock was traded on the NASDAQ Global Market under the same
symbol. At January 31, 2020, there were 524 registered holders of our common stock and approximately 28,900 accounts held
in “street name”.
Our Board of Directors has authorized a share repurchase program; see Note 9.
The Board of Directors declared a quarterly cash dividend of $0.20 per share in 2018 and 2019. The fourth quarter
dividend for 2019 was paid on January 7, 2020 to shareholders of record as of December 13, 2019. The total dividend payable at
December 31, 2019 was $5.7 million and is included in other current liabilities in the consolidated balance sheet. Future decisions
as to the payment of dividends will be at the discretion of the Board of Directors, subject to conditions then existing, including
our financial requirements and condition and the limitation and payment of cash dividends contained in debt agreements.
Refer to Item 12 for information relating to compensation plans under which equity securities of CONMED Corporation
are authorized for issuance.
18
Performance Graph
The performance graph below compares the yearly percentage change in the Company’s Common Stock with the
cumulative total return of the NASDAQ Composite Index and the cumulative total return of the Standard & Poor’s Health Care
Equipment Index. In each case, the cumulative total return assumes reinvestment of dividends into the same class of equity
securities at the frequency with which dividends are paid on such securities during the applicable fiscal year.
19
Item 6. Selected Financial Data
The following table sets forth selected historical financial data for the years ended December 31, 2019, 2018, 2017, 2016
and 2015. The financial data set forth below should be read in conjunction with the information under “Management’s Discussion
and Analysis of Financial Condition and Results of Operations” included in Item 7 of this Form 10-K and the Consolidated Financial
Statements of the Company and the notes thereto.
FIVE YEAR SUMMARY OF SELECTED FINANCIAL DATA
(In thousands, except per share data)
2019
Years Ended December 31,
2017
2018
2016
2015
Statements of Operations Data (1):
Net sales
Cost of sales
Gross profit
Selling and administrative expense
Research and development expense
Income from operations
Interest expense
Other expense
Income before income taxes
Provision (benefit) for income taxes
Net income
Per Share Data:
Basic earnings per share
Diluted earnings per share
Dividends per share of common stock
Other Financial Data:
Depreciation and amortization
Capital expenditures
Balance Sheet Data (at period end):
Cash and cash equivalents
Total assets
Long-term obligations
Total shareholders’ equity
$ 955,097
430,382
524,715
400,141
45,460
79,114
42,701
5,188
31,225
2,605
28,620
$
$ 859,634
390,524
469,110
355,617
42,188
71,305
20,652
—
50,653
9,799
40,854
$
$ 796,392
365,351
431,041
351,799
32,307
46,935
18,203
—
28,732
(26,755)
55,487
$
$ 763,520
355,190
408,330
338,400
32,254
37,676
15,359
2,942
19,375
4,711
14,664
$
$ 719,168
337,466
381,702
303,091
27,436
51,175
6,031
—
45,144
14,646
30,498
$
$
$
$
$
$
1.01
0.97
0.80
72,323
20,066
25,856
1,775,095
876,541
710,467
$
$
$
$
$
$
$
$
$
$
1.45
1.41
0.80
60,761
16,507
17,511
1,369,138
545,924
662,270
1.99
1.97
0.80
57,506
12,842
32,622
1,357,961
576,526
631,432
$
$
$
$
$
0.53
0.52
0.80
54,267
14,753
27,428
1,328,983
634,455
580,576
$
$
$
$
$
1.10
1.09
0.80
43,285
15,009
72,504
1,101,700
396,909
585,073
(1)
Results of operations of acquired businesses have been recorded in the financial statements since the date of acquisition.
Refer to Note 2 and Note 14 for discussion of the Buffalo Filter acquisition. On January 4, 2016 we acquired SurgiQuest,
Inc. During 2016, we incurred $17.0 million in acquisition and integration related costs associated with this acquisition.
20
Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The following discussion should be read in conjunction with Selected Financial Data (Item 6), and our Consolidated
Financial Statements and related notes contained elsewhere in this report.
This section of
this Form 10-K generally discusses 2019 and 2018 items and year-to-year comparisons
between 2019 and 2018. Discussions of 2017 items and year-to-year comparisons between 2018 and 2017 that are not included
in this Form 10-K can be found in “Management’s Discussion and Analysis of Financial Condition and Results of Operations”
in Part II, Item 7 of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2018.
Overview of CONMED Corporation
CONMED Corporation (“CONMED”, the “Company”, “we” or “us”) is a medical technology company that provides
surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians
in a variety of specialties including orthopedics, general surgery, gynecology, neurosurgery, thoracic surgery and gastroenterology.
Our product lines consist of orthopedic surgery and general surgery. Orthopedic surgery consists of sports medicine
instrumentation and small bone, large bone and specialty powered surgical instruments as well as, imaging systems for use in
minimally invasive surgery procedures including 2DHD and 3DHD vision technologies and service fees related to the promotion
and marketing of sports medicine allograft tissue. General surgery consists of a complete line of endo-mechanical instrumentation
for minimally invasive laparoscopic and gastrointestinal procedures, a line of cardiac monitoring products as well as electrosurgical
generators and related instruments. These product lines as a percentage of consolidated net sales are as follows:
Orthopedic surgery
General surgery
Consolidated net sales
2019
2018
2017
49%
51
100%
52%
48
100%
54%
46
100%
A significant amount of our products are used in surgical procedures with approximately 79% of our revenues derived
from the sale of single-use products. Our capital equipment offerings also facilitate the ongoing sale of related single-use products
and accessories, thus providing us with a recurring revenue stream. We manufacture substantially all of our products in facilities
located in the United States and Mexico. We market our products both domestically and internationally directly to customers and
through distributors. International sales approximated 46% in 2019 and 48% in 2018 and 2017.
Buffalo Filter Acquisition
On February 11, 2019, we acquired Buffalo Filter and all of the issued and outstanding common stock of Palmerton
Holdings, Inc. from Filtration Group FGC LLC (the “Buffalo Filter Acquisition”) for approximately $365 million, in cash. Buffalo
Filter develops, manufactures and markets smoke evacuation technologies that are complementary to our general surgery offering.
See Note 2 for further information on this business acquisition.
We financed the purchase price for the Buffalo Filter Acquisition using a combination of the issuance of $345.0 million
of 2.625% convertible notes due 2024 issued on January 29, 2019 (the Convertible Notes”) and the incurrence of indebtedness
under our sixth amended and restated senior secured credit agreement, which closed on February 7, 2019. Refer to Financing
Cash Flows and Note 7 for further details.
Critical Accounting Policies
Preparation of our financial statements requires us to make estimates and assumptions which affect the reported amounts
of assets, liabilities, revenues and expenses. Note 1 describes the significant accounting policies used in preparation of the
consolidated financial statements. The most significant areas involving management judgments and estimates are described below
and are considered by management to be critical to understanding the financial condition and results of operations of CONMED
Corporation. Actual results may or may not differ from these estimates.
21
Goodwill and Intangible Assets
We have a history of growth through acquisitions. Assets and liabilities of acquired businesses are recorded at their
estimated fair values as of the date of acquisition. Goodwill represents costs in excess of fair values assigned to the underlying
net assets of acquired businesses. Factors that contribute to the recognition of goodwill include synergies that are specific to our
business and are expected to increase net sales and profits; acquisition of a talented workforce; cost savings opportunities; the
strategic benefit of expanding our presence in core and adjacent markets; and diversifying our product portfolio. Customer and
distributor relationships, trademarks, tradenames, developed technology, patents and other intangible assets primarily represent
allocations of purchase price to identifiable intangible assets of acquired businesses. Sales representation, marketing and
promotional rights represent intangible assets created under our agreement with Musculoskeletal Transplant Foundation
(“MTF”). Determining the fair value of intangible assets acquired as part of a business combination requires us to make significant
estimates. These estimates include the amount and timing of projected future cash flows of each project or technology, revenue
growth rates, projected cost of sales, customer attrition rates, the discount rate used to discount those cash flows to present value,
the assessment of the asset’s useful life, and the consideration of legal, technical, regulatory, economic, and competitive risks. As
these are significant estimates, we would obtain the assistance of a third-party valuation specialist in estimating fair values of
intangible assets for significant acquisitions.
Goodwill and intangible assets deemed to have indefinite lives are not amortized, but are subject to at least annual
impairment testing. It is our policy to perform our annual impairment testing in the fourth quarter. The identification and
measurement of goodwill impairment involves the estimation of the fair value of our business. Estimates of fair value are based
on the best information available as of the date of the assessment. We completed our goodwill impairment testing during the
fourth quarter of 2019. We performed our impairment test utilizing the market capitalization approach to determine whether the
fair value of a reporting unit is less than its carrying amount. Based upon our assessment, the fair value continues to exceed
carrying value.
Intangible assets with a finite life are amortized over the estimated useful life of the asset and are evaluated each reporting
period to determine whether events and circumstances warrant a revision to the remaining period of amortization. Intangible
assets subject to amortization are reviewed for impairment whenever events or changes in circumstances indicate that its carrying
amount may not be recoverable. The carrying amount of an intangible asset subject to amortization is not recoverable if it exceeds
the sum of the undiscounted cash flows expected to result from the use of the asset. An impairment loss is recognized by reducing
the carrying amount of the intangible asset to its current fair value.
For all other indefinite-lived intangible assets, we perform a qualitative impairment test. Based upon this assessment,
we have determined that our indefinite-lived intangible assets are not impaired.
See Note 6 for further discussion of goodwill and other intangible assets.
Consolidated Results of Operations
The following table presents, as a percentage of net sales, certain categories included in our consolidated statements of
comprehensive income for the periods indicated:
Years Ended December 31,
2018
2017
2019
Net sales
Cost of sales
Gross profit
Selling and administrative expense
Research and development expense
Income from operations
Interest expense
Other expense
Income before income taxes
Provision (benefit) for income taxes
Net income
100.0%
45.1
54.9
41.9
4.8
8.3
4.5
0.5
3.3
0.3
3.0%
100.0%
45.4
54.6
41.4
4.9
8.3
2.4
—
5.9
1.1
4.8%
100.0%
45.9
54.1
44.2
4.1
5.9
2.3
—
3.6
(3.4)
7.0%
22
Net Sales
The following table presents net sales by product line for the years ended December 31, 2019, 2018 and 2017:
Orthopedic surgery
General surgery
Net sales
Single-use products
Capital products
Net sales
Orthopedic surgery
General surgery
Net sales
Single-use products
Capital products
Net sales
$
$
$
$
$
$
$
$
2018
446.7
412.9
859.6
681.1
178.5
859.6
$
$
$
$
2019
2018
As
Reported
463.3
491.8
955.1
756.3
198.8
955.1
$
$
$
$
446.7
412.9
859.6
681.1
178.5
859.6
2017
As
Reported
ASC 606
Impact
428.9
367.5
796.4
637.0
159.4
796.4
4.1%
12.4%
7.9%
6.9%
12.0%
7.9%
0.7%
1.7%
1.2%
1.4%
—%
1.2%
% Change from
2018 to 2019
Impact of
Foreign
Currency Adjusted a
4.5%
0.8%
3.7%
19.1%
11.1%
11.0%
11.3%
11.1%
0.3%
0.6%
0.6%
0.7%
0.6%
19.4%
11.7%
11.6%
12.0%
11.7%
% Change from
2017 to 2018
Impact of
Foreign
Currency Adjusted a
3.9%
13.8%
-0.9%
-0.3%
-0.7%
-0.7%
-0.5%
-0.7%
8.4%
7.6%
11.5%
8.4%
(a) Adjusted net sales growth is measured in constant currency. For 2018 to 2017 comparison, adjusted net sales growth is also adjusted for administrative fees
that we began recording as a reduction of revenue under Accounting Standards Codification 606, Revenue from Contracts with Customers ("ASC 606") on
January 1, 2018. Refer to Non-GAAP Financial Measures below for further details.
Net sales increased 11.1% to $955.1 million in 2019 from $859.6 million in 2018. The increase in 2019 was due to
growth in both the orthopedic and general surgery product lines, as described below. Buffalo Filter sales were $49.6 million during
the year ended December 31, 2019.
• Orthopedic surgery sales increased 3.7% in 2019 to $463.3 million from $446.7 million in 2018. The increase was driven
by new product innovations in the procedure specific categories and strength in capital sales.
• General surgery sales increased 19.1% in 2019 to $491.8 million from $412.9 million in 2018. The increase was driven
by sales from the Buffalo Filter acquisition, as well as growth across the portfolio.
Cost of Sales
Cost of sales was $430.4 million in 2019 compared to $390.5 million in 2018. Gross profit margins were 54.9% in 2019
and 54.6% in 2018. The increase in gross profit margin of 0.3 percentage points in 2019 was driven by improved performance
by our manufacturing plants offset by charges related to inventory adjustments associated with the Buffalo Filter Acquisition and
manufacturing consolidation costs.
Selling and Administrative Expense
Selling and administrative expense was $400.1 million in 2019 compared to $355.6 million in 2018. Selling and
administrative expense as a percentage of net sales was 41.9% in 2019 and 41.4% in 2018.
23
The 0.5 percentage point increase in selling and administrative expense as a percentage of net sales in 2019 as compared
to the same period a year ago is primarily due to business acquisition costs of $13.1 million which included charges for investment
banking fees, consulting fees, legal fees, severance and integration related costs as further described in Note 14, and the associated
amortization of the intangible assets. Offsetting these increases is lower spending as a percentage of net sales as we continue to
leverage our operating structure.
Research and Development Expense
Research and development expense was $45.5 million in 2019 and $42.2 million in 2018. As a percentage of net sales,
research and development expense was 4.8% in 2019 and 4.9% in 2018. 2019 expense increased from our continued efforts to
increase new product development. 2018 expense included a net charge of $4.2 million associated with the impairment of an in-
process research and development asset, net of the release of previously accrued contingent consideration, as further described in
Note 13 and Note 14.
Other Expense
Other expense during the year ended December 31, 2019 was mainly related to costs associated with our sixth amended
and restated senior credit agreement entered into on February 7, 2019 as further described in Note 7. These costs include a $3.6
million charge related to commitment fees paid to certain of our lenders, which provided a financing commitment for the Buffalo
Filter acquisition, and a loss on the early extinguishment of debt of $0.3 million. Also included in 2019 are non-service pension
costs.
Interest Expense
Interest expense increased to $42.7 million in 2019 compared to $20.7 million in 2018. Interest expense increased in
2019 due to the additional borrowings under the sixth amended and restated senior credit agreement and the issuance of $345.0
million in 2.625% convertible notes due in 2024, as further described in Note 7. The weighted average interest rates on our
borrowings were 3.71% in 2019 decreasing from 4.35% in 2018.
Provision for Income Taxes
A provision for income taxes was recorded at an effective rate of 8.3% and 19.3% in 2019 and 2018, respectively, as
compared to the federal statutory rate of 21.0%. The effective tax rate in 2019 is lower than that recorded in 2018 due primarily
to stock compensation income tax benefits and the release of reserves following settlement with tax authorities, with a partially
offsetting increase due to benefits taken in 2018 related to tax reform that did not recur in 2019. A reconciliation of the United
States statutory income tax rate to our effective tax rate is included in Note 8.
Non-GAAP Financial Measures
Net sales on an "adjusted" basis is a non-GAAP measure that presents net sales in "constant currency" and in the 2018
to 2017 comparison adjusts for the adoption impact of ASC 606. The Company analyzes net sales on a constant currency basis
to better measure the comparability of results between periods. To measure percentage sales growth in constant currency, the
Company removes the impact of changes in foreign currency exchange rates that affect the comparability and trend of net sales.
In addition, the Company adjusts for the adoption impact of ASC 606. For GAAP purposes, we applied the modified retrospective
transition approach which requires certain costs previously included in selling and administrative expense and principally related
to administrative fees paid to group purchasing organizations, to be recorded as a reduction of revenue for periods subsequent to
January 1, 2018. Amounts reported in prior years remain unchanged with these administrative fees included in selling and
administrative expense. To improve comparability between reporting periods, we assumed ASC 606 had been applied as of January
1, 2017 thereby reducing net sales by the administrative fees for both periods when calculating adjusted sales growth.
Because non-GAAP financial measures are not standardized, it may not be possible to compare this financial measure
with other companies' non-GAAP financial measures having the same or similar names. This adjusted financial measure should
not be considered in isolation or as a substitute for reported net sales growth, the most directly comparable GAAP financial measure.
This non-GAAP financial measure is an additional way of viewing net sales that, when viewed with our GAAP results, provides
a more complete understanding of our business. The Company strongly encourages investors and shareholders to review our
financial statements and publicly-filed reports in their entirety and not to rely on any single financial measure.
24
Liquidity and Capital Resources
Our liquidity needs arise primarily from capital investments, working capital requirements and payments on indebtedness
under the amended and restated senior credit agreement, described below. We have historically met these liquidity requirements
with funds generated from operations and borrowings under our revolving credit facility. In addition, we have historically used
term borrowings, including borrowings under the sixth amended and restated senior credit agreement and borrowings under separate
loan facilities, in the case of real property purchases, to finance our acquisitions. We also have the ability to raise funds through
the sale of stock or we may issue debt through a private placement or public offering. Management believes that cash flow from
operations, including cash and cash equivalents on hand and available borrowing capacity under our amended and restated senior
credit agreement, will be adequate to meet our anticipated operating working capital requirements, debt service, funding of capital
expenditures and common stock repurchases in the foreseeable future.
We had total cash on hand at December 31, 2019 of $25.9 million, of which approximately $20.2 million was held by
our foreign subsidiaries outside the United States with unremitted earnings. During 2019, we redeployed $12.5 million of cash
from certain non-U.S. subsidiaries primarily for U.S. debt reduction which consisted primarily of earnings that were taxed in 2017
as part of the deemed repatriation toll charge implemented by Tax Reform. We may repatriate funds from certain foreign subsidiaries
in the future. Refer to Note 8 for further details.
Operating Cash Flows
Our net working capital position was $209.3 million at December 31, 2019. Net cash provided by operating activities
was $95.1 million in 2019 and $74.7 million in 2018 generated on net income of $28.6 million in 2019 and $40.9 million in
2018. Although there was a decline in net income in the period, this decline was driven by non-cash amortization associated with
the intangible assets acquired with the Buffalo Filter Acquisition and amortization of the debt discount associated with the 2.625%
convertible notes further described below. In addition, other significant changes in assets and liabilities affecting cash flows
include the following:
• An increase in cash flows from inventory is driven primarily by improved inventory management coupled with sales
growth;
• A decrease in cash flows from accounts payable is primarily due to timing of payments;
• An increase in cash flows from other liabilities is primarily caused by a trial verdict payment during 2018 as further
described in Note 14.
Investing Cash Flows
Net cash used in investing activities increased to $387.7 million in 2019 compared to $16.5 million in 2018 primarily
due to the $365 million payment for the Buffalo Filter Acquisition in 2019. Capital expenditures were $20.1 million and $16.5
million in 2019 and 2018, respectively.
Financing Cash Flows
Financing activities in 2019 provided cash of $300.9 million compared to using cash of $72.3 million in 2018. Below
is a summary of the significant financing activities:
• During 2019, we received proceeds of $345.0 million related to the issuance of 2.625% convertible notes as further
described below.
• During 2019, we entered into a $265.0 million term loan in conjunction with the refinancing of our senior credit agreement.
This new term loan replaced the previous term loan and resulted in net proceeds of $110.7 million during the year
ended December 31, 2019 compared to $13.1 million in payments in the prior year.
• We had net repayments on our revolving line of credit of $92.0 million and $15.0 million in 2019 and 2018, respectively.
In 2019, we paid $51.2 million to purchase hedges related to our convertible notes. Partially offsetting this, were proceeds
•
of $30.6 million from the issuance of warrants as further described below.
• We paid $6.5 million and $21.3 million in 2019 and 2018, respectively, in contingent consideration related to a prior asset
•
acquisition.
In 2019 and 2018, we paid debt issuance costs of $16.2 million and $0.9 million, respectively, related to the sixth amended
and restated senior credit agreement and 2.625% convertible notes.
25
On February 7, 2019 we entered into a sixth amended and restated senior credit agreement consisting of: (a) a $265.0
million term loan facility and (b) a $585.0 million revolving credit facility. The revolving credit facility will terminate and the
loans outstanding under the term loan facility will mature on the earlier of (i) February 7, 2024 or (ii) 91 days prior to the earliest
scheduled maturity date of the 2.625% convertible notes due in 2024 described below, (if, as of such date, more than $150.0 million
in aggregate principal amount of such convertible notes (or any refinancing thereof) remains outstanding). The term loan facility
is payable in quarterly installments increasing over the term of the facility. Proceeds from the term loan facility and borrowings
under the revolving credit facility were used to repay the then existing senior credit agreement and in part to finance the acquisition
of Buffalo Filter. Interest rates are at LIBOR plus an interest rate margin of 1.750% (3.563% at December 31, 2019). For those
borrowings where we elect to use the alternate base rate, the base rate will be the greatest of (i) the Prime Rate, (ii) the Federal
Funds Rate plus 0.50% or (iii) the one-month Eurocurrency Rate plus 1.00%, plus, in each case, an interest rate margin.
There were $255.1 million in borrowings outstanding on the term loan facility as of December 31, 2019. There were
$220.0 million in borrowings outstanding under the revolving credit facility as of December 31, 2019. Our available borrowings
on the revolving credit facility at December 31, 2019 were $362.5 million with approximately $2.5 million of the facility set aside
for outstanding letters of credit.
The sixth amended and restated senior credit agreement is collateralized by substantially all of our personal property and
assets. The sixth amended and restated senior credit agreement contains covenants and restrictions which, among other things,
require the maintenance of certain financial ratios and restrict dividend payments and the incurrence of certain indebtedness and
other activities, including acquisitions and dispositions. We were in full compliance with these covenants and restrictions as of
December 31, 2019. We are also required, under certain circumstances, to make mandatory prepayments from net cash proceeds
from any issuance of equity and asset sales.
On January 29, 2019, we issued $345.0 million in 2.625% convertible notes due in 2024 (the "Notes"). Interest is payable
semi-annually in arrears on February 1 and August 1 of each year, commencing August 1, 2019. The Notes will mature on February
1, 2024, unless earlier repurchased or converted. The Notes represent subordinated unsecured obligations and are convertible
under certain circumstances, as defined in the indenture, into a combination of cash and CONMED common stock. The Notes
may be converted at an initial conversion rate of 11.2608 shares of our common stock per $1,000 principal amount of Notes
(equivalent to an initial conversion price of approximately $88.80 per share of common stock). Holders of the Notes may convert
the Notes at their option at any time on or after November 1, 2023 through the second scheduled trading day preceding the maturity
date. Holders of the Notes will also have the right to convert the Notes prior to November 1, 2023, but only upon the occurrence
of specified events. The conversion rate is subject to anti-dilution adjustments if certain events occur. A portion of the net proceeds
from the offering of the Notes were used as part of the financing for the Buffalo Filter acquisition and $21.0 million were used to
pay the cost of certain convertible notes hedge transactions as further described below.
In connection with the offering of the Notes, we entered into convertible notes hedge transactions with a number of
financial institutions (each, an “option counterparty”). The convertible notes hedge transactions cover, subject to anti-dilution
adjustments substantially similar to those applicable to the Notes, the number of shares of our common stock underlying the Notes.
Concurrently with entering into the convertible notes hedge transactions, we also entered into separate warrant transactions with
each option counterparty whereby we sold to such option counterparty warrants to purchase, subject to customary anti-dilution
adjustments, the same number of shares of our common stock.
The convertible notes hedge transactions are expected generally to reduce the potential dilution upon conversion of the
Notes and/or offset any cash payments we are required to make in excess of the principal amount of converted Notes, as the case
may be, in the event that the market price per share of our common stock, as measured under the terms of the convertible notes
hedge transactions, is greater than the strike price ($114.92) of the convertible notes hedge transactions, which initially corresponds
to the conversion price of the Notes and is subject to anti-dilution adjustments substantially similar to those applicable to the
conversion rate of the Notes. If, however, the market price per share of our common stock, as measured under the terms of the
warrant transactions, exceeds the strike price of the warrants, there would nevertheless be dilution to the extent that such market
price exceeds the strike price of the warrants.
During 2019, we paid in full our mortgage notes in connection with the Largo, Florida property and facilities.
Our Board of Directors has authorized a $200.0 million share repurchase program. Through December 31, 2019, we
have repurchased a total of 6.1 million shares of common stock aggregating $162.6 million under this authorization and have
$37.4 million remaining available for share repurchases. The repurchase program calls for shares to be purchased in the open
market or in private transactions from time to time. We may suspend or discontinue the share repurchase program at any time. We
did not purchase any shares of common stock under the share repurchase program during 2019. We have financed the repurchases
26
and may finance additional repurchases through operating cash flow and from available borrowings under our revolving credit
facility.
Management believes that cash flow from operations, including cash and cash equivalents on hand and available borrowing
capacity under our sixth amended and restated senior credit agreement, will be adequate to meet our anticipated operating working
capital requirements, debt service, funding of capital expenditures, dividend payments and common stock repurchases in the
foreseeable future. See “Item 1A. Risk Factors - Risks Related to Our Indebtedness."
Contractual Obligations
The following table summarizes our contractual obligations for the next five years and thereafter (amounts in thousands)
as of December 31, 2019. Purchase obligations represent purchase orders for goods and services placed in the ordinary course of
business.
Payments Due by Period
1-3
Years
Less than
1 Year
3-5
Years
More than
5 Years
Total
Long-term debt
Purchase obligations
Lease obligations
Total contractual obligations
$
$
820,063
69,127
28,344
917,534
$
$
13,250
65,730
7,646
86,626
$
$
43,063
3,120
11,824
58,007
$
$
763,750
277
7,394
771,421
$
$
—
—
1,480
1,480
In addition to the above contractual obligations, we are required to make periodic interest payments on our long-term
debt obligations (see additional discussion under Item 7A. “Quantitative and Qualitative Disclosures About Market Risk—Interest
Rate Risk” and Note 7). The above table also does not include unrecognized tax benefits of approximately $2.2 million, the timing
and certainty of recognition for which is not known (See Note 8).
Stock-based Compensation
We have reserved shares of common stock for issuance to employees and directors under two shareholder-approved
share-based compensation plans (the "Plans"). The Plans provide for grants of stock options, stock appreciation rights (“SARs”),
dividend equivalent rights, restricted stock, restricted stock units (“RSUs”), performance share units (“PSUs”) and other equity-
based and equity-related awards. The exercise price on all outstanding stock options and SARs is equal to the quoted fair market
value of the stock at the date of grant. RSUs and PSUs are valued at the market value of the underlying stock on the date of
grant. Stock options, SARs, RSUs and PSUs are generally non-transferable other than on death and generally become exercisable
over a four to five year period from date of grant. Stock options and SARs expire ten years from date of grant. SARs are only
settled in shares of the Company’s stock (See Note 9). Total pre-tax stock-based compensation expense recognized in the
consolidated statements of comprehensive income was $11.8 million, $10.0 million and $8.5 million for the years ended
December 31, 2019, 2018 and 2017, respectively.
Other Matters
Our credit facility allows us to seek to sell products to certain customers in Iran in compliance with applicable laws and
regulations and subject to certain terms and conditions, including pre-approval by us and our lenders of the identity of any distributor
and prior review of each of the end-customers. We had sales to a third-party distributor in Iran during 2019 and expect there may
be sales during the first quarter of 2020. We intend to limit sales into Iran to products that qualify as “medical supplies” within
the meaning of the general license, or covered by specific licenses, provided by the Iranian Transactions and Sanctions Regulations
set forth in the regulations promulgated by the Office of Foreign Assets Control (“OFAC”) of the United States Department of the
Treasury set forth at 31 C.F.R. § 560.530. We have implemented certain controls and processes designed to ensure that the ultimate
end-users for the products are those permitted under the OFAC general license, and that the sales and transactions with the Iranian
distributor otherwise comply with the requirements of the OFAC regulations. The expected revenues and net profits associated
with sales to the Iranian distributor are not expected to be material to our results of operations.
We do not believe that our activities to date, and do not expect that our activities in the future, will be subject to required
disclosure under Section 13(r) of the Securities Exchange Act of 1934 (the “Exchange Act”), which, among other things, requires
disclosure of transactions and activities knowingly entered into with the Government of Iran that do not benefit from an OFAC
27
license and with certain designated parties. If, however, any activities in future periods are within the scope of the transactions
and activities captured by Section 13(r) of the Exchange Act, we will make the required disclosures and notices.
New Accounting Pronouncements
See Note 17 for a discussion of new accounting pronouncements.
Item 7A. Quantitative and Qualitative Disclosures About Market Risk
Market risk is the potential loss arising from adverse changes in market rates and prices such as commodity prices, foreign
currency exchange rates and interest rates. In the normal course of business, we are exposed to various market risks, including
changes in foreign currency exchange rates and interest rates. We manage our exposure to these and other market risks through
regular operating and financing activities and as necessary through the use of derivative financial instruments.
Foreign currency risk
Approximately 46% of our total 2019 consolidated net sales were to customers outside the United States. We have sales
subsidiaries in a significant number of countries in Europe as well as Australia, Canada, China, Japan and Korea. In those countries
in which we have a direct presence, our sales are denominated in the local currency amounting to approximately 33% of our total
net sales in 2019. The remaining 13% of sales to customers outside the United States was on an export basis and transacted in
United States dollars.
Because a significant portion of our operations consist of sales activities in foreign jurisdictions, our financial results
may be affected by factors such as changes in foreign currency exchange rates or weak economic conditions in the markets in
which we distribute products. During 2019, foreign currency exchange rates, including the effects of the hedging program, caused
sales to decrease by approximately $4.9 million.
We hedge forecasted intercompany sales denominated in foreign currencies through the use of forward contracts. We
account for these forward contracts as cash flow hedges. To the extent these forward contracts meet hedge accounting criteria,
changes in their fair value are not included in current earnings but are included in accumulated other comprehensive loss. These
changes in fair value will be recognized into earnings as a component of sales or cost of sales when the forecasted transaction
occurs.
We also enter into forward contracts to exchange foreign currencies for United States dollars in order to hedge our currency
transaction exposures on intercompany receivables denominated in foreign currencies. These forward contracts settle each month
at month-end, at which time we enter into new forward contracts. We have not designated these forward contracts as hedges and
have not applied hedge accounting to them.
Refer to Note 16 for further discussion.
Interest rate risk
At December 31, 2019, we had approximately $475.1 million of variable rate long-term debt outstanding under our senior
credit agreement. Assuming no repayments, if market interest rates for similar borrowings averaged 1.0% more in 2020 than they
did in 2019, interest expense would increase, and income before income taxes would decrease by $4.8 million. Comparatively,
if market interest rates for similar borrowings average 1.0% less in 2020 than they did in 2019, our interest expense would decrease,
and income before income taxes would increase by $4.8 million.
Item 8. Financial Statements and Supplementary Data
Our 2019 Financial Statements are included in this Form 10-K beginning on page 39 and incorporated by reference herein.
Item 9. Changes In and Disagreements with Accountants on Accounting and Financial Disclosures
There were no changes in or disagreement with accountants on accounting and financial disclosure.
Item 9A. Controls and Procedures
28
As of the end of the period covered by this report, an evaluation was carried out by CONMED Corporation’s management,
with the participation of our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls
and procedures (as defined in Rule 13a-15(e) under the Securities Exchange Act of 1934). Based upon that evaluation, our Chief
Executive Officer and Chief Financial Officer concluded that these disclosure controls and procedures were effective as of the
end of the period covered by this report. In addition, no change in our internal control over financial reporting (as defined in Rule
13a-15 under the Securities Exchange Act of 1934) occurred during the fourth quarter of the year ended December 31, 2019 that
has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
Management’s Report on Internal Control over Financial Reporting and the Report of Independent Registered Public
Accounting Firm thereon are set forth in Part IV, Item 15 of the Annual Report on Form 10-K.
Item 9B. Other Information
Not applicable.
29
Item 10. Directors, Executive Officers and Corporate Governance
PART III
The information required by this item is incorporated herein by reference to the sections captioned “Proposal One: Election
of Directors”, “Directors, Executive Officers, Other Company Officers and Nominees for the Board of Directors”, “Delinquent
Section 16(a) Reports", “Ethics Disclosure” and "Meetings of the Board of Directors and Committees, Leadership Structure and
Risk Oversight” in CONMED Corporation’s definitive Proxy Statement or other informational filing to be filed with the Securities
and Exchange Commission on or about April 10, 2020.
Item 11. Executive Compensation
The information required by this item is incorporated herein by reference to the sections captioned “Compensation
Discussion and Analysis”, “Compensation Committee Report on Executive Compensation”, “Summary Compensation Table”,
“Grants of Plan-Based Awards”, “Outstanding Equity Awards at Fiscal Year-End”, “Option Exercises and Stock Vested”, “Non-
Qualified Deferred Compensation”, “Potential Payments on Termination or Change-in-Control”, “Director Compensation,” “Pay
Ratio” and “Board of Directors and Compensation Committee Interlocks and Insider Participation; Certain Relationships and
Related Transactions” in CONMED Corporation’s definitive Proxy Statement or other informational filing to be filed with the
Securities and Exchange Commission on or about April 10, 2020.
Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
The information required by this item is incorporated herein by reference to the section captioned “Security Ownership
of Certain Beneficial Owners and Management” in CONMED Corporation’s definitive Proxy Statement or other informational
filing to be filed with the Securities and Exchange Commission on or about April 10, 2020.
Information relating to shareholder approved compensation plans under which equity securities of CONMED Corporation
are authorized for issuance is set forth below:
Equity Compensation Plan Information
Number of securities to
be issued upon exercise
of outstanding options,
warrants and rights
(a)
Weighted-average
exercise price of
outstanding options,
warrants and rights
(b)
Number of securities
remaining available for
future issuance under
equity compensation
plans (excluding
securities reflected in
column (a))
(c)
3,352,653
$
—
3,352,653
55.97
—
55.97
4,058,708
—
4,058,708
Plan category
Equity compensation plans
approved by security holders
Equity compensation plans not
approved by security holders
Total
The number of securities included in column (a) above consists of outstanding stock options, share appreciation rights
(“SARs”) and performance share units, however the weighted-average exercise price in column (b) is for stock options and SARs
only.
During 2018, the Company granted employment inducement awards in conjunction with the hiring of the Executive Vice
President & Chief Financial Officer. This included 48,000 stock options, that would be issued upon exercise, at an exercise price
of $50.61 per share. These shares are not part of a shareholder approved plan and no shares remain available for future issuance.
30
Item 13. Certain Relationships and Related Transactions, and Director Independence
The information required by this item is incorporated herein by reference to the section captioned “Directors, Executive
Officers and Nominees for the Board of Directors” and “Board of Directors and Compensation Committee Interlocks and Insider
Participation; Certain Relationships and Related Transactions” in CONMED Corporation’s definitive Proxy Statement or other
informational filing to be filed with the Securities and Exchange Commission on or about April 10, 2020.
Item 14. Principal Accounting Fees and Services
The information required by this item is incorporated herein by reference to the section captioned “Principal Accounting
Fees and Services” in CONMED Corporation’s definitive Proxy Statement or other informational filing to be filed with the
Securities and Exchange Commission on or about April 10, 2020.
31
PART IV
Item 15. Exhibits, Financial Statement Schedules
Index to Financial Statements
(a)(1) List of Financial Statements
Management’s Report on Internal Control Over Financial Reporting
Report of Independent Registered Public Accounting Firm
Consolidated Balance Sheets at December 31, 2019 and 2018
Consolidated Statements of Comprehensive Income for the Years Ended December 31, 2019,
2018 and 2017
Consolidated Statements of Shareholders’ Equity for the Years Ended December 31, 2019, 2018
and 2017
Consolidated Statements of Cash Flows for the Years Ended December 31, 2019, 2018 and 2017
Notes to Consolidated Financial Statements
(2)
List of Financial Statement Schedules
Valuation and Qualifying Accounts (Schedule II) for the Years Ended December 31, 2019, 2018
and 2017
All other schedules have been omitted because they are not applicable, or the required information
is shown in the financial statements or notes thereto.
(3)
List of Exhibits
The exhibits listed on the accompanying Exhibit Index on page 35 below are filed as part of this
Form 10-K.
Page in Form 10-K
39
40
42
43
44
45
47
77
32
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned, thereunto duly authorized.
CONMED CORPORATION
By: /s/ Curt R. Hartman
Curt R. Hartman
(President and Chief
Executive Officer)
Date:
February 24, 2020
33
Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the
following persons on behalf of the registrant and in the capacities and on the dates indicated.
Signature
Title
Date
/s/ MARK E. TRYNISKI
Mark E. Tryniski
/s/ CURT R. HARTMAN
Curt R. Hartman
/s/ TODD W. GARNER
Todd W. Garner
Chair of the Board
of Directors
President, Chief Executive
Officer and Director
Executive Vice President
and Chief Financial Officer
/s/ TERENCE M. BERGE
Terence M. Berge
Vice President-
Corporate Controller
/s/ DAVID BRONSON
David Bronson
/s/ BRIAN P. CONCANNON
Brian P. Concannon
/s/ LAVERNE COUNCIL
Laverne Council
/s/ CHARLES M. FARKAS
Charles M. Farkas
Director
Director
Director
Director
February 24, 2020
February 24, 2020
February 24, 2020
February 24, 2020
February 24, 2020
February 24, 2020
February 24, 2020
February 24, 2020
/s/ MARTHA GOLDBERG ARONSON
Martha Goldberg Aronson
Director
February 24, 2020
/s/ JEROME J. LANDE
Jerome J. Lande
/s/ BARBARA SCHWARZENTRAUB
Barbara Schwarzentraub
/s/ JOHN L. WORKMAN
John L. Workman
Director
Director
Director
February 24, 2020
February 24, 2020
February 24, 2020
34
Exhibit No.
Description
Exhibit Index
3.1
3.2
4.1*
10.1+
10.2
10.3
10.4
10.5
10.6
10.7
10.8
10.9
10.10
10.11
10.12
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Amended and Restated By-Laws, as adopted by the Board of Directors on April 29, 2011 (Incorporated
by reference to the Company’s Current Report on Form 10-Q filed with the Securities and Exchange
Commission on May 2, 2011).
1999 Amendment to Certificate of Incorporation and Restated Certificate of Incorporation of CONMED
Corporation (Incorporated by reference to Exhibit 3.2 of the Company’s Annual Report on Form 10-K
for the year ended December 31, 1999).
Description of Registrant’s Securities to be Registered
Employment Agreement between the Company and Curt R. Hartman, dated November 9, 2014
(Incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the
Securities and Exchange Commission on November 10, 2014).
Amended and Restated 1999 Long Term Incentive Plan (Incorporated by reference to Exhibit 4.3 of the
Company’s Registration Statement on Form S-8 on November 3, 2009).
2002 Employee Stock Purchase Plan (Incorporated by reference to the Company’s Definitive Proxy
Statement for the 2002 Annual Meeting filed with the Securities and Exchange Commission on April 17,
2002).
Amendment to CONMED Corporation 2002 Employee Stock Purchase Plan (Incorporated by reference
to Exhibit 10.11 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2005).
2006 Stock Incentive Plan (Incorporated by reference to Exhibit 4.3 of the Company’s Registration
Statement on Form S-8 on August 8, 2006).
Amended and Restated 2007 Non-Employee Director Equity Compensation Plan of CONMED
Corporation (Incorporated by reference to Exhibit 4.3 of the Company’s Registration Statement on Form
S-8 on August 3, 2010).
Amended and Restated Long Term Incentive Plan (Incorporated by reference to Exhibit 4.3 of the
Company’s Registration Statement on Form S-8 on July 27, 2012).
CONMED Corporation Executive Severance Plan (Incorporated by reference to Exhibit 10.1 of the
Company’s Current Report on Form 10-Q filed with the Securities and Exchange Commission on July
27, 2015).
Amended and Restated 2015 Long-Term Incentive Plan (Incorporated by reference to Exhibit 4.3 of the
Company's Registration Statement on Form S-8 on October 23, 2015).
Amended and Restated 2016 Non-Employee Director Equity Compensation Plan (Incorporated by
reference to Exhibit 4.3 of the Company's Registration Statement on Form S-8 on October 28, 2016).
2018 Long-Term Incentive Plan (incorporated by reference to Exhibit 4.3 of the Registrants Form S-8
filed on November 5, 2018).
Guarantee and Collateral Agreement, dated August 28, 2002, made by CONMED Corporation and
certain of its subsidiaries in favor of JP Morgan Chase Bank (Incorporated by reference to Exhibit 10.2
of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2002).
35
10.13
10.14
10.15
10.16
10.17
10.18
10.19+
10.20
10.21+
10.22+
10.23
10.24
10.25
10.26
-
-
-
-
-
-
-
-
-
-
-
-
-
-
First Amendment to Guarantee and Collateral Agreement, dated June 30, 2003, made by CONMED
Corporation and certain of its subsidiaries in favor of JP Morgan Chase Bank and the several banks and
other financial institutions or entities from time to time parties thereto (Incorporated by reference to
Exhibit 10.2 of the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2003).
Second Amendment to Guarantee and Collateral Agreement, dated April 13, 2006, made by CONMED
Corporation and certain of its subsidiaries in favor of JP Morgan Chase Bank and the several banks and
other financial institutions or entities from time to time parties thereto (Incorporated by reference to the
Company’s Current Report on Form 8-K filed with the Securities and Exchange Commission on April
19, 2006).
Third Amendment to Guarantee and Collateral Agreement, dated as of January 17, 2013, made by
CONMED Corporation and certain of its subsidiaries in favor of JP Morgan Chase Bank (Incorporated
by reference to Exhibit 4.6 of the Company's Annual Report on Form 10-K for the year ended December
31, 2012).
Fourth Amendment to Guarantee and Collateral Agreement, dated as of January 4, 2016, made by
CONMED Corporation and certain of its subsidiaries in favor of JP Morgan Chase Bank (Incorporated
by reference to Exhibit 10.2 of the Company's Current Report on Form 8-K filed with the Securities and
Exchange Commission on January 4, 2016).
Sixth Amended and Restated Credit Agreement, dated February 7, 2019, among CONMED Corporation,
the foreign subsidiary borrowers from time to time party thereto, the several lenders from time to time
party thereto and JPMorgan Chase Bank, N.A., as administrative agent (Incorporated by reference to
Exhibit 10.1 of the Company’s Current Report on Form 8-K filed with the Securities and Exchange
Commission on February 7, 2019).
Sports Medicine Joint Development and Distribution Agreement by and between Musculoskeletal
Transplant Foundation, Inc. and CONMED Corporation dated as of January 3, 2012 (Incorporated by
reference to Exhibit 10.1 of the Company's Current Report on Form 8-K dated January 3, 2012).
Employment Agreement between the Company and Patrick Beyer, dated December 9, 2014
(Incorporated by reference to Exhibit 10.21 of the Company's Annual Report on Form 10-K for the year
ended December 31, 2014).
Agreement and Plan of Merger, dated November 15, 2015, by and among CONMED Corporation, Nemo
Acquisition Sub, Inc., SurgiQuest, Inc. and Shareholder Representative Services LLC (Incorporated by
reference to Exhibit 10.1 of the Company's Current Report on Form 8-K filed with the Securities and
Exchange Commission on November 16, 2015).
Separation Agreement, by and between CONMED Corporation and Luke A. Pomilio, dated November 1,
2017. (Incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K filed
with the Securities and Exchange Commission on November 2, 2017).
Offer Letter from CONMED Corporation to Todd W. Garner dated January 2, 2018. (Incorporated by
reference to Exhibit 10.2 of the Company's Current Report on Form 8-K filed with the Securities and
Exchange Commission on January 2, 2018).
Stock Option Inducement Award (incorporated by reference to Exhibit 4.3 of the Registrants Form S-8
filed on February 27, 2018).
Restricted Stock Unit Inducement Award (incorporated by reference to Exhibit 4.4 of the Registrants
Form S-8 filed on February 27, 2018).
Securities Purchase Agreement, dated as of December 13, 2018, by and between CONMED Corporation
and Filtration Group FGC LLC (Incorporated by reference to Exhibit 10.1 of the Company's Current
Report on Form 8-K filed with the Securities and Exchange Commission on December 13, 2018).
Indenture, dated as of January 29, 2019, by and between CONMED Corporation and MUFG Union
Bank, N.A., as trustee (Incorporated by reference to Exhibit 4.1 of the Company's Current Report on
Form 8-K filed with the Securities and Exchange Commission on January 29, 2019).
36
10.27
10.28
10.29
10.30
10.31
10.32
10.33
10.34
10.35
10.36
10.37
10.38
10.39
10.40
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Base Notes Hedge Transaction Confirmation, dated as of January 24, 2019, between CONMED
Corporation and Barclays Bank PLC (Incorporated by reference to Exhibit 10.1 of the Company's
Current Report on Form 8-K filed with the Securities and Exchange Commission on January 29, 2019).
Base Notes Hedge Transaction Confirmation, dated as of January 24, 2019, between CONMED
Corporation and Bank of America, N.A (Incorporated by reference to Exhibit 10.2 of the Company's
Current Report on Form 8-K filed with the Securities and Exchange Commission on January 29, 2019).
Base Notes Hedge Transaction Confirmation, dated as of January 24, 2019, between CONMED
Corporation and Wells Fargo Bank, National Association (Incorporated by reference to Exhibit 10.3 of
the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on
January 29, 2019).
Base Notes Hedge Transaction Confirmation, dated as of January 24, 2019, between CONMED
Corporation and J.P. Morgan Securities LLC, as agent for JPMorgan Chase Bank, National Association,
London Branch (Incorporated by reference to Exhibit 10.4 of the Company's Current Report on Form 8-
K filed with the Securities and Exchange Commission on January 29, 2019).
Base Warrant Transaction Confirmation, dated as of January 24, 2019, between CONMED Corporation
and Barclays Bank PLC (Incorporated by reference to Exhibit 10.5 of the Company's Current Report on
Form 8-K filed with the Securities and Exchange Commission on January 29, 2019).
Base Warrant Transaction Confirmation, dated as of January 24, 2019, between CONMED Corporation
and Bank of America, N.A (Incorporated by reference to Exhibit 10.6 of the Company's Current Report
on Form 8-K filed with the Securities and Exchange Commission on January 29, 2019).
Base Warrant Transaction Confirmation, dated as of January 24, 2019, between CONMED Corporation
and Wells Fargo Bank, National Association (Incorporated by reference to Exhibit 10.7 of the
Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on January
29, 2019).
Base Warrant Transaction Confirmation, dated as of January 24, 2019, between CONMED Corporation
and J.P. Morgan Securities LLC, as agent for JPMorgan Chase Bank, National Association, London
Branch (Incorporated by reference to Exhibit 10.8 of the Company's Current Report on Form 8-K filed
with the Securities and Exchange Commission on January 29, 2019).
Additional Notes Hedge Transaction Confirmation, dated as of January 25, 2019, between CONMED
Corporation and Barclays Bank PLC (Incorporated by reference to Exhibit 10.9 of the Company's
Current Report on Form 8-K filed with the Securities and Exchange Commission on January 29, 2019).
Additional Notes Hedge Transaction Confirmation, dated as of January 25, 2019, between CONMED
Corporation and Bank of America, N.A. (Incorporated by reference to Exhibit 10.10 of the Company's
Current Report on Form 8-K filed with the Securities and Exchange Commission on January 29, 2019).
Additional Notes Hedge Transaction Confirmation, dated as of January 25, 2019, between CONMED
Corporation and Wells Fargo Bank, National Association (Incorporated by reference to Exhibit 10.11 of
the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on
January 29, 2019).
Additional Notes Hedge Transaction Confirmation, dated as of January 25, 2019, between CONMED
Corporation and J.P. Morgan Securities LLC, as agent for JPMorgan Chase Bank, National Association,
London Branch (Incorporated by reference to Exhibit 10.12 of the Company's Current Report on Form
8-K filed with the Securities and Exchange Commission on January 29, 2019).
Additional Warrant Transaction Confirmation, dated as of January 25, 2019, between CONMED
Corporation and Barclays Bank PLC (Incorporated by reference to Exhibit 10.13 of the Company's
Current Report on Form 8-K filed with the Securities and Exchange Commission on January 29, 2019).
Additional Warrant Transaction Confirmation, dated as of January 25, 2019, between CONMED
Corporation and Bank of America, N.A. (Incorporated by reference to Exhibit 10.14 of the Company's
Current Report on Form 8-K filed with the Securities and Exchange Commission on January 29, 2019).
37
10.41
10.42
14
21*
23*
31.1*
31.2*
32.1*
101.INS*
101.SCH*
101.CAL*
101.DEF*
101.LAB*
101.PRE*
104*
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Additional Warrant Transaction Confirmation, dated as of January 25, 2019, between CONMED
Corporation and Wells Fargo Bank, National Association (Incorporated by reference to Exhibit 10.15 of
the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission on
January 29, 2019).
Additional Warrant Transaction Confirmation, dated as of January 25, 2019, between CONMED
Corporation and J.P. Morgan Securities LLC, as agent for JPMorgan Chase Bank, National Association,
London Branch (Incorporated by reference to Exhibit 10.16 of the Company's Current Report on Form
8-K filed with the Securities and Exchange Commission on January 29, 2019).
Code of Ethics. The CONMED code of ethics may be accessed via the Company’s website at http://
www.conmed.com/en/about-us/investors/investor-relations
Subsidiaries of the Registrant.
Consent of Independent Registered Public Accounting Firm.
Certification of Curt R. Hartman pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities
Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
Certification of Todd W. Garner. pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities
Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
Certifications of Curt R. Hartman and Todd W. Garner pursuant to 18 U.S.C. Section 1350, as adopted
pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
XBRL Instance Document - The instance document does not appear in the Interactive Data File because
its XBRL tags are embedded within the Inline XBRL document.
XBRL Taxonomy Extension Schema Document
XBRL Taxonomy Extension Calculation Linkbase Document
XBRL Taxonomy Extension Definition Linkbase Document
XBRL Taxonomy Extension Label Linkbase Document
XBRL Taxonomy Extension Presentation Linkbase Document
Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL
document (included in Exhibit 101)
*
Filed herewith
+ Management contract or compensatory plan or arrangement
38
MANAGEMENT’S REPORT ON INTERNAL CONTROL
OVER FINANCIAL REPORTING
The management of CONMED Corporation is responsible for establishing and maintaining adequate internal control over financial
reporting. Internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability
of financial reporting and the preparation of financial statements for external reporting purposes in accordance with generally
accepted accounting principles. Our internal control over financial reporting includes policies and procedures that pertain to the
maintenance of records that, in reasonable detail, accurately and fairly reflect transactions and dispositions of assets; provide
reasonable assurances that transactions are recorded as necessary to permit preparation of financial statements in accordance with
accounting principles generally accepted in the United States of America, and that receipts and expenditures are being made only
in accordance with authorizations of management and the directors of the Company; and provide reasonable assurance regarding
prevention or timely detection of unauthorized acquisition, use or disposition of our assets that could have a material effect on our
financial statements. Because of its inherent limitations, internal control over financial reporting may not prevent or detect
misstatements. Management assessed the effectiveness of CONMED’s internal control over financial reporting as of December 31,
2019. In making its assessment, management utilized the criteria set forth by the Committee of Sponsoring Organizations of the
Treadway Commission (“COSO”) in “Internal Control-Integrated Framework”, released in 2013. Management has concluded
that based on its assessment, CONMED’s internal control over financial reporting was effective as of December 31, 2019. The
effectiveness of the Company’s internal control over financial reporting as of December 31, 2019 has been audited by
PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report which appears herein.
/s/ Curt R. Hartman
Curt R. Hartman
President and
Chief Executive Officer
/s/ Todd W. Garner
Todd W. Garner
Executive Vice President and
Chief Financial Officer
39
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors and Shareholders of CONMED Corporation
Opinions on the Financial Statements and Internal Control over Financial Reporting
We have audited the accompanying consolidated balance sheets of CONMED Corporation and its subsidiaries (the "Company")
as of December 31, 2019 and 2018, and the related consolidated statements of comprehensive income, shareholders’ equity and
cash flows for each of the three years in the period ended December 31, 2019, including the related notes and financial statement
schedule listed in the index appearing under Item 15(a)(2) (collectively referred to as the “consolidated financial statements”).
We also have audited the Company's internal control over financial reporting as of December 31, 2019, based on criteria established
in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway
Commission (COSO).
In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position
of the Company as of December 31, 2019 and 2018, and the results of their operations and their cash flows for each of the three
years in the period ended December 31, 2019 in conformity with accounting principles generally accepted in the United States of
America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting
as of December 31, 2019 based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO.
Change in Accounting Principle
As discussed in Note 17 to the consolidated financial statements, the Company changed the manner in which it accounts for
leases in 2019.
Basis for Opinions
The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control
over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in the
accompanying Management’s Report on Internal Control over Financial Reporting. Our responsibility is to express opinions on
the Company’s consolidated financial statements and on the Company's internal control over financial reporting based on our
audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States)
("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws
and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.
We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the
audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether
due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.
Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement
of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks.
Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial
statements. Our audits also included evaluating the accounting principles used and significant estimates made by management,
as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial
reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness
exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits
also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits
provide a reasonable basis for our opinions.
Definition and Limitations of Internal Control over Financial Reporting
A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability
of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted
accounting principles. A company’s internal control over financial reporting includes those policies and procedures that (i) pertain
to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets
of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial
40
statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are
being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable
assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that
could have a material effect on the financial statements.
Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also,
projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because
of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.
Critical Audit Matters
The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial
statements that was communicated or required to be communicated to the audit committee and that (i) relates to accounts or
disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or
complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial
statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on
the critical audit matter or on the accounts or disclosures to which it relates.
Valuation of acquired customer relationships intangible asset
As described in Note 2 to the consolidated financial statements, the Company recorded $124 million of a customer relationships
intangible asset in conjunction with the Buffalo Filter acquisition on February 11, 2019. The assets acquired and liabilities assumed
were recorded at their respective estimated fair values. Management applied significant judgment in estimating the fair value of
the customer relationships intangible asset acquired, which involved the use of significant estimates and assumptions with respect
to the timing and amounts of cash flow projections, including revenue growth rates, customer attrition rates, the discount rate and
projected cost of sales.
The principal considerations for our determination that performing procedures relating to the valuation of the acquired customer
relationships intangible asset is a critical audit matter are (i) there was a high degree of auditor judgment and subjectivity in
applying procedures relating to the fair value measurement of the customer relationships intangible asset acquired due to the
significant amount of judgment by management when developing the estimate, (ii) significant audit effort was required in evaluating
the significant assumptions relating to the estimate, including revenue growth rates, customer attrition rates, the discount rate and
projected cost of sales, and (iii) the audit effort involved the use of professionals with specialized skill and knowledge to assist in
performing these procedures and evaluating the audit evidence obtained from these procedures.
Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall
opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls related to
management’s valuation of the customer relationships intangible asset and controls over the development of the assumptions
related to revenue growth rates, customer attrition rates, the discount rate and projected cost of sales. These procedures also
included, among others, (i) reading the purchase agreement and (ii) testing management’s process for estimating the fair value of
the customer relationships intangible asset. Testing management’s process for estimating the fair value of the customer relationships
intangible asset included evaluating the appropriateness of the valuation method and the reasonableness of significant assumptions,
including revenue growth rates, customer attrition rates, the discount rate and projected cost of sales. Evaluating the reasonableness
of revenue growth rates, customer attrition rates and projected cost of sales involved considering the past performance of the
acquired business, as well as economic and industry forecasts. Professionals with specialized skill and knowledge were used to
assist in the evaluation of the Company’s valuation method used in the valuation of the acquired customer relationships intangible
asset and certain significant assumptions, including customer attrition rates and the discount rate.
/s/ PricewaterhouseCoopers LLP
Rochester, New York
February 24, 2020
We have served as the Company’s auditor since 1982.
41
CONMED CORPORATION
CONSOLIDATED BALANCE SHEETS
December 31, 2019 and 2018
(In thousands except share and per share amounts)
ASSETS
Current assets:
Cash and cash equivalents
Accounts receivable, less allowance for doubtful
accounts of $2,786 in 2019 and $2,660 in 2018
Inventories
Prepaid expenses and other current assets
Total current assets
Property, plant and equipment, net
Deferred income taxes
Goodwill
Other intangible assets, net
Other assets
Total assets
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Current portion of long-term debt
Accounts payable
Accrued compensation and benefits
Other current liabilities
Total current liabilities
Long-term debt
Deferred income taxes
Other long-term liabilities
Total liabilities
Commitments and contingencies (Note 13)
Shareholders' equity:
Preferred stock, par value $.01 per share; authorized
500,000 shares, none issued or outstanding
Common stock, par value $.01 per share; 100,000,000
authorized; 31,299,194 issued in 2019 and 2018, respectively
Paid-in capital
Retained earnings
Accumulated other comprehensive loss
Less: Treasury stock, at cost;
2,876,729 and 3,167,422 shares in
2019 and 2018, respectively
Total shareholders' equity
Total liabilities and shareholders' equity
2019
2018
$
25,856
$
17,511
$
$
189,097
164,616
17,794
397,363
118,883
5,659
618,042
532,800
102,348
1,775,095
13,596
55,968
53,690
64,833
188,087
755,211
74,488
46,842
1,064,628
$
$
181,550
154,599
20,691
374,351
113,245
5,162
400,440
413,193
62,747
1,369,138
18,336
53,498
42,924
46,186
160,944
438,564
81,061
26,299
706,868
—
—
313
379,324
470,844
(59,277)
313
341,738
464,851
(55,737)
(80,737)
710,467
1,775,095
$
(88,895)
662,270
1,369,138
$
The accompanying notes are an integral part of the consolidated financial statements.
42
CONMED CORPORATION
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
Years Ended December 31, 2019, 2018 and 2017
(In thousands except per share amounts)
Net sales
Cost of sales
Gross profit
2019
2018
2017
$
955,097
$
859,634
$
796,392
430,382
390,524
365,351
524,715
469,110
431,041
Selling and administrative expense
400,141
355,617
351,799
Research and development expense
45,460
42,188
32,307
Operating expenses
Income from operations
Interest expense
Other expense
445,601
397,805
384,106
79,114
71,305
46,935
42,701
20,652
18,203
5,188
—
—
Income before income taxes
31,225
50,653
28,732
Provision (benefit) for income taxes
2,605
9,799
(26,755)
Net income
Per share data:
Basic
Diluted
Other comprehensive income (loss), before tax:
Foreign currency translation adjustments
Pension liability
Cash flow hedging gain (loss)
Other comprehensive income, before tax
Provision (benefit) for income taxes related to items in other
comprehensive income
Comprehensive income
$
$
$
$
$
28,620
$
40,854
$
55,487
$
$
$
1.01
0.97
25
35
(4,736)
23,944
1.45
1.41
$
$
1.99
1.97
(8,369) $
(885)
10,985
42,585
13,879
1,023
(8,051)
62,338
(1,136)
25,080
$
2,441
40,144
$
(2,597)
64,935
The accompanying notes are an integral part of the consolidated financial statements.
43
CONMED CORPORATION
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
Years Ended December 31, 2019, 2018 and 2017
(In thousands)
Common Stock
Shares
Amount
Paid-in
Capital
Retained
Earnings
Accumulated
Other
Comprehensive
Loss
Treasury
Stock
Shareholders’
Equity
Balance at December 31, 2016
31,299 $
313 $ 329,276 $ 406,932 $
(58,526) $
(97,419) $
580,576
Common stock issued under
employee plans
Stock-based compensation
Dividends on common stock ($.80
per share)
Comprehensive income (loss):
Foreign currency translation
adjustments
Pension liability, net
Cash flow hedging loss, net
Net income
Total comprehensive income
Balance at December 31, 2017
Common stock issued under
employee plans
Stock-based compensation
Dividends on common stock ($.80
per share)
Comprehensive income (loss):
Foreign currency translation
adjustments
Pension liability, net
Cash flow hedging gain, net
Net income
Total comprehensive income
Cumulative effect of change in
accounting principle(1)
3,736
(217)
8,472
(22,334)
(3,953)
8,472
(22,334)
55,487
13,879
645
(5,076)
31,299 $
313 $ 333,795 $ 440,085 $
(49,078) $
(93,683) $
(2,094)
10,037
4,788
(22,477)
40,854
(8,369)
(672)
8,331
6,389
(5,949)
64,935
631,432
2,694
10,037
(22,477)
40,144
440
Balance at December 31, 2018
31,299 $
313 $ 341,738 $ 464,851 $
(55,737) $
(88,895) $
662,270
Common stock issued under
employee plans
Stock-based compensation
Dividends on common stock ($.80
per share)
Convertible notes discount, net
Convertible notes debt issuance
costs
Convertible notes hedge, net
Issuance of warrants
Comprehensive income (loss):
Foreign currency
translation adjustments
Pension liability, net
Cash flow hedging loss, net
Net income
Total comprehensive income
8,158
(22,627)
(3,843)
11,779
39,145
(1,233)
(38,829)
30,567
25
27
(3,592)
28,620
Balance at December 31, 2019
31,299 $
313 $ 379,324 $ 470,844 $
(59,277) $
(80,737) $
4,315
11,779
(22,627)
39,145
(1,233)
(38,829)
30,567
25,080
710,467
(1)We recorded the cumulative impact of adopting ASU 2014-09, Revenue from Contracts with Customers, (and its amendments) and ASU 2018-02, Income
Statement - Reporting Comprehensive Income (Topic 220) in 2018.
The accompanying notes are an integral part of the consolidated financial statements.
44
CONMED CORPORATION
CONSOLIDATED STATEMENTS OF CASH FLOWS
Years Ended December 31, 2019, 2018 and 2017
(In thousands)
Cash flows from operating activities:
Net income
Adjustments to reconcile net income to net cash provided by operating activities:
2019
2018
2017
$
28,620
$
40,854
$
55,487
Depreciation
Amortization of debt discount
Amortization of deferred debt issuance costs
Amortization
Stock-based compensation
Impairment charges
Deferred income taxes
Loss on early extinguishment of debt
Increase (decrease) in cash flows from changes in assets and
liabilities, net of acquired assets:
Accounts receivable
Inventories
Accounts payable
Income taxes
Accrued compensation and benefits
Other assets
Other liabilities
Net cash provided by operating activities
Cash flows from investing activities:
Payments related to business and asset acquisitions, net of cash acquired
Purchases of property, plant and equipment
Net cash used in investing activities
Cash flows from financing activities:
Payments on term loan
Proceeds from term loan
Payments on revolving line of credit
Proceeds from revolving line of credit
Proceeds from convertible notes
Payments on mortgage notes
Payments related to contingent consideration
Payments related to debt issuance costs
Dividends paid on common stock
Purchases of convertible notes hedges
Proceeds from issuance of warrants
Other, net
Net cash provided by (used in) financing activities
Effect of exchange rate changes on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents
18,688
8,302
3,454
53,635
11,779
312
(6,310)
300
(13,943)
(117)
38
(1,867)
9,957
(22,263)
4,548
66,513
95,133
(367,596)
(20,066)
(387,662)
(154,312)
265,000
(484,000)
392,000
345,000
(836)
(6,466)
(16,210)
(22,600)
(51,198)
30,567
3,936
300,881
18,530
—
1,042
42,231
10,037
4,212
2,063
—
(17,460)
(15,037)
12,109
(2,193)
9,044
(24,216)
(6,515)
33,847
74,701
—
(16,507)
(16,507)
(13,125)
—
(168,000)
153,000
—
(1,574)
(21,323)
(913)
(22,443)
—
—
2,113
(72,265)
(7)
(1,040)
8,345
(15,111)
20,079
—
1,042
37,427
8,472
—
(40,021)
—
(13,631)
(3,926)
(286)
4,288
336
(22,401)
18,700
10,079
65,566
(16,212)
(12,842)
(29,054)
(8,750)
—
(157,000)
155,000
—
(1,452)
—
—
(22,307)
—
—
(372)
(34,881)
3,563
5,194
Cash and cash equivalents at beginning of year
17,511
32,622
27,428
Cash and cash equivalents at end of year
$
25,856
$
17,511
$
32,622
45
Non-cash investing and financing activities:
Contractual obligations from asset acquisition
Dividends payable
Supplemental disclosures of cash flow information:
Cash paid during the year for:
Interest
Income taxes
2019
2018
2017
$
$
$
$
5,639
5,684
27,274
10,576
$
$
8,360
5,626
19,660
11,048
—
5,592
16,157
8,869
The accompanying notes are an integral part of the consolidated financial statements.
46
CONMED CORPORATION
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
(In thousands except per share amounts)
Note 1 — Operations and Significant Accounting Policies
Organization and operations
CONMED Corporation (“CONMED”, the “Company”, “we” or “us”) is a medical technology company that provides
surgical devices and equipment for minimally invasive procedures. The Company’s products are used by surgeons and physicians
in a variety of specialties including orthopedics, general surgery, gynecology, neurosurgery, thoracic surgery and gastroenterology.
Principles of consolidation
The consolidated financial statements include the accounts of CONMED Corporation and its controlled subsidiaries. All
significant intercompany accounts and transactions have been eliminated.
Use of estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States
of America requires management to make estimates and judgments which affect the reported amounts of assets, liabilities, related
disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and
expenses during the reporting period. Due to the inherent uncertainty involved in making estimates, actual results reported in
future periods may differ from those estimates.
Cash and cash equivalents
We consider all highly liquid investments with an original maturity of three months or less to be cash equivalents.
Inventories
Inventories are valued at the lower of cost and net realizable value determined on the FIFO (first-in, first-out) cost method.
We write-off excess and obsolete inventory resulting from the inability to sell our products at prices in excess of current
carrying costs. We make estimates regarding the future recoverability of the costs of our products and record a provision for excess
and obsolete inventories based on historical experience and expected future trends.
Property, plant and equipment
Property, plant and equipment are stated at cost and depreciated using the straight-line method over the following estimated
useful lives:
Building and improvements
Leasehold improvements
Machinery and equipment
12 to 40 years
Shorter of life of asset or life of lease
2 to 15 years
47
Leases
The Company leases various manufacturing facilities, office facilities and equipment under operating and finance leases.
We determine if an arrangement is a lease at inception. Right-of-use ("ROU") assets represent our right to use an underlying asset
for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease
ROU assets and liabilities are recognized at the lease commencement date based on the present value of lease payments over the
lease term. We use the implicit rate when readily determinable. As most of our leases do not provide an implicit rate, we use our
incremental borrowing rate based on the information available at commencement date in determining the present value of lease
payments. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise
that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Certain of our leases
include variable lease payments, mainly when a lease is tied to an index rate. These variable lease payments are recorded as
expense in the period incurred and are not material.
The Company has lease agreements with lease and non-lease components, which we account for separately. For certain
equipment leases, we apply a portfolio approach to efficiently account for the operating lease ROU assets and lease liabilities. We
also elected the short-term lease exemption and do not recognize leases with terms less than one year on the balance sheet. The
related short-term lease expense is not material.
Our leases have remaining lease terms of one year to eleven years, some of which include options to extend the leases
for up to five years, and some of which include options to terminate the leases within one year. We only account for such extensions
or early terminations when it is reasonably certain we will exercise such options. Refer to Note 5 for further detail on leases.
The Company places certain of our capital equipment with customers on a loaned basis and at no charge in exchange for
commitments to purchase related single-use products over time periods generally ranging from one to three years. Placed equipment
is loaned and subject to return if minimum single-use purchases are not met. The Company accounts for these placements as
operating leases but applies a practical expedient and does not separate the non-lease and lease components from the combined
component. Accordingly, the Company accounts for the combined component as a single performance obligation with revenue
recognized upon shipment of the related single use-products. The cost of the equipment is amortized over its estimated useful life
which is generally five years.
Goodwill and other intangible assets
We have a history of growth through acquisitions. Assets and liabilities of acquired businesses are recorded at their
estimated fair values as of the date of acquisition. Goodwill represents costs in excess of fair values assigned to the underlying
net assets of acquired businesses. Factors that contribute to the recognition of goodwill include synergies that are specific to our
business and are expected to increase net sales and profits; acquisition of a talented workforce; cost savings opportunities; the
strategic benefit of expanding our presence in core and adjacent markets; and diversifying our product portfolio. Customer and
distributor relationships, trademarks, tradenames, developed technology, patents and other intangible assets primarily represent
allocations of purchase price to identifiable intangible assets of acquired businesses. Sales representation, marketing and
promotional rights represent intangible assets created under our agreement with Musculoskeletal Transplant Foundation (“MTF”).
Goodwill and intangible assets deemed to have indefinite lives are not amortized, but are subject to at least annual
impairment testing. It is our policy to perform our annual impairment testing in the fourth quarter. The identification and
measurement of goodwill impairment involves the estimation of the fair value of our business. Estimates of fair value are based
on the best information available as of the date of the assessment. We completed our goodwill impairment testing during the
fourth quarter of 2019. We performed our impairment test utilizing the market capitalization approach to determine whether the
fair value of a reporting unit is less than its carrying amount. Based upon our assessment, the fair value continues to exceed
carrying value.
Intangible assets with a finite life are amortized over the estimated useful life of the asset and are evaluated each reporting
period to determine whether events and circumstances warrant a revision to the remaining period of amortization. Intangible
assets subject to amortization are reviewed for impairment whenever events or changes in circumstances indicate that its carrying
amount may not be recoverable. The carrying amount of an intangible asset subject to amortization is not recoverable if it exceeds
the sum of the undiscounted cash flows expected to result from the use of the asset. An impairment loss is recognized by reducing
the carrying amount of the intangible asset to its current fair value.
For all other indefinite-lived intangible assets, including unamortized trademarks and tradenames, we perform a qualitative
impairment test. Based upon this assessment, we have determined that our indefinite-lived intangible assets are not impaired.
48
Other long-lived assets
We review other long-lived assets consisting of property, plant and equipment and field inventory for impairment whenever
events or circumstances indicate that such carrying amounts may not be recoverable. If the sum of the expected future undiscounted
cash flows is less than the carrying amount of the asset, an impairment loss is recognized by reducing the recorded value to its
current fair value.
The Company maintains field inventory consisting of capital equipment for customer demonstration and evaluation
purposes. Field inventory is generally not sold to customers but rather continues to be used over its useful life for demonstration,
evaluation and loaner purposes. An annual wear and tear provision has been recorded on field inventory. The net book value of
such equipment at December 31, 2019 and 2018 is $50.3 million and $50.4 million, respectively.
Translation of foreign currency financial statements
Assets and liabilities of foreign subsidiaries have been translated into United States dollars at the applicable rates of
exchange in effect at the end of the period reported. Revenues and expenses have been translated at the applicable weighted
average rates of exchange in effect during the period reported. Translation adjustments are reflected in accumulated other
comprehensive loss. Transaction gains and losses are included in net income.
Foreign exchange and hedging activity
We manage our foreign currency transaction risks through the use of forward contracts to hedge forecasted cash flows
associated with foreign currency transaction exposures. We account for these forward contracts as cash flow hedges. To the extent
these forward contracts meet hedge accounting criteria, changes in their fair value are not included in current earnings but are
included in accumulated other comprehensive loss. These changes in fair value will be reclassified into earnings as a component
of sales or cost of sales when the forecasted transaction occurs.
We also enter into forward contracts to exchange foreign currencies for United States dollars in order to hedge our currency
transaction exposures on intercompany receivables denominated in foreign currencies. These forward contracts settle each month
at month-end, at which time we enter into new forward contracts. We have not designated these forward contracts as hedges and
have not applied hedge accounting to them. We record these forward contracts at fair value with resulting gains and losses included
in selling and administrative expense in the consolidated statements of comprehensive income.
Income taxes
Deferred income tax assets and liabilities are based on the difference between the financial statement and tax basis of
assets and liabilities and operating loss and tax credit carryforwards as measured by the enacted tax rates that are anticipated to
be in effect in the respective jurisdictions when these differences reverse. The deferred income tax provision generally represents
the net change in the assets and liabilities for deferred income taxes. A valuation allowance is established when it is necessary to
reduce deferred income tax assets to amounts for which realization is likely. In assessing the need for a valuation allowance, we
estimate future taxable income, considering the feasibility of ongoing tax planning strategies and the realizability of tax loss
carryforwards following tax law ordering rules. Valuation allowances related to deferred tax assets may be impacted by changes
to tax laws, changes to statutory tax rates, reversal of temporary differences and ongoing and future taxable income levels.
Deferred income taxes are not provided on the unremitted earnings of certain subsidiaries outside of the United States
earned after December 31, 2017 as it is expected that these earnings are permanently reinvested. Such earnings may become
taxable upon a repatriation of assets from a subsidiary or the sale or liquidation of a subsidiary. Deferred income taxes are provided
when the Company no longer considers subsidiary earnings to be permanently invested, such as in situations where the Company’s
subsidiaries plan to make future dividend distributions.
Revenue recognition
The Company recognizes revenue when we have satisfied a performance obligation by transferring a promised good or
service (that is an asset) to a customer. An asset is transferred when the customer obtains control of that asset. The following
policies apply to our major categories of revenue transactions:
• Revenue is recognized when product is shipped at which point the performance obligation is satisfied and the customer
obtains control of the product.
49
• We place certain of our capital equipment with customers on a loaned basis and at no charge in exchange for commitments
to purchase related single-use products over time periods generally ranging from one to three years. In these
circumstances, no revenue is recognized upon capital equipment shipment as the equipment is loaned and subject to
return if certain minimum single-use purchases are not met. Revenue is recognized upon the sale and shipment of the
related single-use products. The cost of the equipment is amortized over its estimated useful life which is generally five
years.
• We recognize revenues in accordance with the terms of our agreement with MTF on a net basis as our role is that of an
agent earning a commission or fee. MTF is responsible for the sourcing, processing and distribution of allograft tissue
for sports medicine procedures while the Company represents, markets and promotes MTF’s sports medicine allograft
tissues to customers. The Company is paid a fee by MTF which is calculated as a percentage of the net amounts invoiced
by MTF to customers for sports medicine allograft tissues. The Company accounts for the services provided to MTF as
a series of distinct performance obligations and each service is recognized over time as MTF simultaneously receives
and consumes the benefit.
•
Product returns are only accepted at the discretion of the Company and in accordance with our “Returned Goods
Policy”. Historically, the level of product returns has not been significant. We accrue for sales returns, rebates and
allowances based upon an analysis of historical customer returns and credits, rebates, discounts and current market
conditions.
• Our terms of sale to customers generally do not include any obligations to perform future services. Limited warranties
are provided for capital equipment sales and provisions for warranty are provided at the time of product sale based upon
an analysis of historical data.
• Amounts billed to customers related to shipping and handling have been included in net sales. Shipping and handling
costs included in selling and administrative expense were $15.4 million, $14.0 million and $13.1 million for 2019, 2018
and 2017, respectively.
• We sell to a diversified base of customers around the world and, therefore, believe there is no material concentration of
credit risk.
• We assess the risk of loss on accounts receivable and adjust the allowance for doubtful accounts based on this risk
assessment. Historically, losses on accounts receivable have not been material. Management believes that the allowance
for doubtful accounts is adequate to provide for probable losses resulting from accounts receivable.
• We sell extended warranties to customers that are typically for a period of one to three years. The related revenue is
recorded as a contract liability and recognized over the life of the contract on a straight-line basis, which is reflective of
our obligation to stand ready to provide repair services.
Please refer to Note 10 for further detail on revenue.
50
Earnings per share
Basic earnings per share (“basic EPS”) is computed by dividing net income by the weighted average number of common
shares outstanding for the reporting period. Diluted earnings per share (“diluted EPS”) gives effect to all dilutive potential shares
outstanding resulting from employee stock options, restricted stock units, performance share units and stock appreciation rights
during the period. The following table sets forth the computation of basic and diluted earnings per share at December 31, 2019,
2018 and 2017, respectively:
Net income
Basic-weighted average shares outstanding
Effect of dilutive potential securities
Diluted-weighted average shares outstanding
Net income (per share)
Basic
Diluted
2019
2018
2017
$ 28,620
$ 40,854
$ 55,487
28,325
28,118
27,939
1,170
772
232
29,495
28,890
28,171
$
$
1.01
0.97
$
1.45
1.41
1.99
1.97
The shares used in the calculation of diluted EPS exclude options and stock appreciation rights ("SARs") to purchase
shares where the exercise price was greater than the average market price of common shares for the year and the effect of the
inclusion would be anti-dilutive. Such shares aggregated approximately 0.7 million, 0.7 million and 1.2 million at December 31,
2019, 2018 and 2017, respectively. As more fully described in Note 7, our 2.625% convertible notes due in 2024 (the “Notes”)
are convertible under certain circumstances, as defined in the indenture, into a combination of cash and CONMED common stock.
The calculation of diluted EPS would include potential diluted shares upon conversion of the Notes when the average market price
per share of our common stock for the period, is greater than the conversion price of the Notes of $88.80. We intend to settle in
cash the principal outstanding and use the treasury stock method when calculating their potential dilutive effect, if any. We have
entered into convertible notes hedge transactions to increase the effective conversion price of the Notes to $114.92. However, our
convertible notes hedges are not included when calculating potential dilutive shares since their effect is always anti-dilutive.
During the year ended December 31, 2019, our average share price has not exceeded the conversion price of the Notes; therefore,
under the net share settlement method, there were no potential shares issuable under the Notes to be used in the calculation of
diluted EPS.
Stock-based compensation
All share-based payments to employees, including grants of employee stock options, restricted stock units, performance
share units and stock appreciation rights are recognized in the financial statements based at their fair values. Compensation expense
is generally recognized using a straight-line method over the vesting period. Compensation expense for performance share units
is recognized using the graded vesting method.
We issue shares under our stock based compensation plans out of treasury stock whereby treasury stock is reduced by
the weighted average cost of such treasury stock. To the extent there is a difference between the cost of the treasury stock and the
exercise price of shares issued under stock based compensation plans, we record gains to paid in capital; losses are recorded to
paid in capital to the extent any gain was previously recorded, otherwise the loss is recorded to retained earnings.
51
Accumulated other comprehensive loss
Accumulated other comprehensive loss consists of the following:
Cash Flow
Hedging
Gain (Loss)
Pension
Liability
Foreign
Currency
Translation
Adjustments
Accumulated
Other
Comprehensive
Loss
Balance, December 31, 2016
$
1,546
$
(26,458) $
(33,614) $
(58,526)
Other comprehensive income (loss) before
reclassifications, net of tax
Amounts reclassified from accumulated other
comprehensive income before tax(a)
Income tax
(5,529)
(1,142)
13,879
718
(265)
2,835
(1,048)
—
—
7,208
3,553
(1,313)
Net current-period other comprehensive income (loss)
(5,076)
645
13,879
9,448
Balance, December 31, 2017
$
(3,530) $
(25,813) $
(19,735) $
(49,078)
Other comprehensive income (loss) before
reclassifications, net of tax
Amounts reclassified from accumulated other
comprehensive income before tax(a)
Income tax
7,639
(2,711)
(8,369)
(3,441)
913
(221)
2,689
(650)
—
—
3,602
(871)
(710)
Net current-period other comprehensive income (loss)
8,331
(672)
(8,369)
Cumulative effect of change in accounting principle(b)
(716)
(5,233)
—
(5,949)
Balance, December 31, 2018
$
4,085
$
(31,718) $
(28,104) $
(55,737)
Other comprehensive income (loss) before
reclassifications, net of tax
Amounts reclassified from accumulated other
comprehensive income (loss) before tax(a)
Income tax
2,936
(2,158)
(8,607)
2,079
2,881
(696)
Net current-period other comprehensive income (loss)
(3,592)
27
25
—
—
25
803
(5,726)
1,383
(3,540)
Balance, December 31, 2019
$
493
$
(31,691) $
(28,079) $
(59,277)
(a) The cash flow hedging gain (loss) and pension liability accumulated other comprehensive income components are included in sales or cost of sales and as a
component of net periodic pension cost, respectively. Refer to Note 16 and Note 12, respectively, for further details.
(b) We recorded the cumulative impact of adopting ASU 2018-02 in 2018, which allows for the elimination of the stranded tax effects of Tax Reform through a
reclassification between accumulated other comprehensive income (loss) and retained earnings.
Note 2 – Business Acquisitions
On February 11, 2019 we acquired Buffalo Filter, LLC and all of the issued and outstanding common stock of Palmerton
Holdings, Inc. from Filtration Group FGC LLC (the "Buffalo Filter Acquisition") for approximately $365 million in cash. Buffalo
Filter develops, manufactures and markets smoke evacuation technologies that are complementary to our general surgery offering.
The business combination was funded through a combination of cash on hand and long-term borrowings as further described in
Note 7.
52
The following table summarizes the estimated fair values of the assets acquired and liabilities assumed as a result of the
Buffalo Filter Acquisition.
Cash
Accounts receivable
Inventory
Other current assets
Current assets
Property, plant & equipment
Deferred income taxes
Goodwill
Customer relationships
Developed technology
Trademarks & tradenames
Other non-current assets
Total assets acquired
Current liabilities assumed
Total liabilities assumed
Net assets acquired
$
$
$
119
4,587
4,582
146
9,434
4,036
80
215,793
124,000
9,000
7,000
166
369,509
4,462
4,462
365,047
The goodwill recorded as part of the acquisition primarily represents revenue synergies, as well as operating efficiencies
and cost savings. The goodwill deductible for tax purposes is $215.8 million. The weighted amortization period for intangibles
acquired is 16 years. Customer relationships were valued using the multi-period excess earnings model, and are being amortized
over a weighted average life of 16 years. Developed technology and trademarks and tradenames were valued using the relief from
royalty method, and are being amortized over a weighted average life of 10 and 20 years, respectively. Significant judgment was
applied in estimating the fair value of the customer relationships intangible asset acquired, which involved the use of significant
estimates and assumptions with respect to the timing and amounts of cash flow projections, including revenue growth rates,
customer attrition rates, the discount rate and projected cost of sales.
The unaudited pro forma information for the years ended December 31, 2019 and 2018, assuming the Buffalo Filter
Acquisition occurred as of January 1, 2018 are presented below. This information has been prepared for comparative purposes
only and does not purport to be indicative of the results of operations which actually would have resulted had the Buffalo Filter
acquisition occurred on the dates indicated, or which may result in the future.
Net sales
Net income
2019
2018
$
960,115
$
44,361
898,545
10,407
These pro forma results include certain adjustments, primarily due to increases in amortization expense due to fair value
adjustments of intangible assets, increases in interest expense due to additional borrowings incurred to finance the acquisition,
and acquisition related costs including transaction costs such as legal, accounting, valuation and other professional services as
well as integration costs such as severance and retention.
Acquisition related costs included in the determination of pro forma net income for the year ended December 31,
2018 included $1.3 million in cost of goods sold and $13.1 million in selling and administrative expense on the consolidated
statement of comprehensive income. Such amounts are excluded from the determination of pro forma net income for the year
ended December 31, 2019.
53
Net sales associated with Buffalo Filter of $49.6 million have been recorded in the consolidated statement of
comprehensive income for the year ended December 31, 2019. It is impracticable to determine the earnings recorded in the
consolidated statement of comprehensive income for the year ended December 31, 2019 as these amounts are not separately
measured.
On December 4, 2019, we acquired, through a share purchase agreement, the operations of a distributor for total estimated
consideration of approximately $13.9 million. The purchase price included $4.1 million of identifiable intangible assets and $1.7
million of goodwill. Pro forma results of operations for the acquisition have not been presented as they are not material to our
results of operations, either individually or in aggregate, for the period ended December 31, 2019.
Note 3 — Inventories
Inventories consist of the following at December 31:
Raw materials
Work in process
Finished goods
Note 4 — Property, Plant and Equipment
Property, plant and equipment consist of the following at December 31:
Land
Building and improvements
Machinery and equipment
Construction in progress
Less: Accumulated depreciation
2019
51,103
15,142
98,371
164,616
2019
4,686
95,632
233,140
13,318
346,776
(227,893)
118,883
2018
45,898
15,000
93,701
154,599
2018
4,027
92,470
227,795
8,043
332,335
(219,090)
113,245
$
$
$
$
$
$
$
$
Internal-use software, included in gross machinery and equipment at December 31, 2019 and 2018 was $49.6 million
and $47.8 million, respectively, with related accumulated depreciation of $38.7 million and $34.5 million, respectively. Internal
use software depreciation expense was $4.8 million, $4.7 million and $4.5 million for the years ended December 31, 2019, 2018
and 2017, respectively.
54
Note 5 – Leases
Lease costs for the year ended December 31, consist of the following:
Operating lease cost:
Straight-line lease cost
Right-of-use asset impairment cost
Total operating lease cost
Finance lease cost:
Depreciation
Interest on lease liabilities
Total finance lease cost
Total lease cost
2019
7,780
312
8,092
238
27
265
8,357
$
$
Rent expense on operating leases was approximately $8.7 million and $6.5 million for the years ended December 31,
2018 and 2017, respectively, in accordance with ASC 840. During 2018, we entered into capital lease obligations of $0.2 million,
in connection with the purchase of equipment, in accordance with ASC 840.
Supplemental balance sheet information related to leases as of December 31, is as follows:
Operating leases
Other assets (net of lease impairment of $1,001)
Other current liabilities
Other long-term liabilities
Total operating lease liabilities
Finance leases
Property, plant and equipment, gross
Accumulated depreciation
Property, plant and equipment, net
Current portion of long-term debt
Long-term debt
Total finance lease liabilities
Weighted average remaining lease term (in years)
Operating leases
Finance leases
Weighted average discount rate
Operating leases
Finance leases
55
$
$
$
$
$
$
$
2019
23,099
7,268
17,096
24,364
1,684
(479)
1,205
346
490
836
4.43 years
3.61 years
4.84%
4.70%
Supplemental cash flow information related to leases for the year ended December 31, was as follows:
Cash paid for amounts included in the measurement of lease liabilities:
Operating cash flows from operating leases
Financing cash flows from finance leases
Right-of-use assets obtained in exchange for lease obligations:
Operating leases
Finance leases
Maturities of lease liabilities as of December 31, 2019 are as follows:
$
2019
8,459
380
12,800
563
2020
2021
2022
2023
2024
Thereafter
Total lease payments
Less imputed interest
Total lease liabilities
Finance Lease
Operating Lease
$
$
$
378
178
230
112
—
—
898
7,268
6,131
5,285
4,177
3,105
1,480
27,446
(62)
(3,082)
836
$
24,364
As of December 31, 2019, we have entered into approximately $0.3 million of operating leases that have not yet
commenced. As of December 31, 2019, we have entered into no additional finance leases that have not yet commenced. Maturities
of lease liabilities under ASC 840 are consistent with the above disclosure.
Note 6 – Goodwill and Other Intangible Assets
The changes in the net carrying amount of goodwill for the years ended December 31, are as follows:
Balance as of January 1,
Goodwill resulting from business combinations
Foreign currency translation
Balance as of December 31,
2019
400,440
$
2018
401,954
$
217,482
—
120
(1,514)
$
618,042
$
400,440
During 2019, the Company acquired Buffalo Filter as further described in Note 2. Goodwill resulting from the acquisition
amounted to $215.8 million and acquired intangible assets including customer and distributor relationships, developed technology
and trademarks and tradenames amounted to $140.0 million. Total accumulated goodwill impairment losses aggregated
56
$107.0 million at December 31, 2019 and 2018, respectively. During 2019, the Company acquired a distributor as further described
in Note 2 resulting in goodwill of $1.7 million and identifiable intangible assets of $4.1 million.
Other intangible assets consist of the following:
December 31, 2019
December 31, 2018
Weighted
Average
Amortization
Period
(Years)
Gross
Carrying
Amount
Accumulated
Amortization
Gross
Carrying
Amount
Accumulated
Amortization
24
25
15
16
$ 342,568
$
(115,311) $ 214,577
$
(97,131)
149,376
(48,000)
149,376
(42,000)
70,646
(46,456)
61,473
(44,242)
106,604
(13,171)
91,965
(7,369)
Intangible assets with definite lives:
Customer and distributor relationships
Sales representation, marketing and promotional
rights
Patents and other intangible assets
Developed technology
Intangible assets with indefinite lives:
Trademarks and tradenames
86,544
—
86,544
—
22
$ 755,738
$
(222,938) $ 603,935
$
(190,742)
Amortization expense related to intangible assets which are subject to amortization totaled $32.3 million, $23.2 million
and $21.3 million for the years ending December 31, 2019, 2018 and 2017, respectively, and is included as a reduction of revenue
(for amortization related to our sales representation, marketing and promotional rights) and in selling and administrative expense
(for all other intangible assets) in the consolidated statements of comprehensive income. Included in developed technology is $6.5
million and $21.3 million of earn-out consideration that was paid during 2019 and 2018, respectively, and an additional accrual of
$7.5 million that is considered probable as of December 31, 2019 associated with a prior asset acquisition. The accrual is recorded
in other current liabilities at December 31, 2019.
The estimated amortization expense related to intangible assets at December 31, 2019 and for each of the five succeeding
years is as follows:
2020
2021
2022
2023
2024
Amortization
included in
expense
Amortization
recorded as a
reduction of
revenue
$
$
28,059
27,268
26,122
25,329
24,526
$
6,000
6,000
6,000
6,000
6,000
Total
34,059
33,268
32,122
31,329
30,526
57
Note 7 — Long Term Debt
Long-term debt consists of the following at December 31:
Revolving line of credit
Term loan, net of deferred debt issuance costs of $1,528 and $311 in 2019 and 2018,
respectively
2.625% convertible notes, net of deferred debt issuance costs of $7,252 and unamortized
discount of $43,312 in 2019
Financing leases
Mortgage notes
Total debt
Less: Current portion
Total long-term debt
2019
2018
$
220,000
$
312,000
253,535
144,064
294,436
836
—
768,807
13,596
755,211
$
—
—
836
456,900
18,336
438,564
$
On February 7, 2019, we entered into a sixth amended and restated senior credit agreement consisting of: (a) a $265.0
million term loan facility and (b) a $585.0 million revolving credit facility. The revolving credit facility will terminate and the
loans outstanding under the term loan facility will mature on the earlier of (i) February 7, 2024 or (ii) 91 days prior to the earliest
scheduled maturity date of the 2.625% convertible notes due in 2024 described below, (if, as of such date, more than $150.0 million
in aggregate principal amount of such convertible notes (or any refinancing thereof) remains outstanding). The term loan facility
is payable in quarterly installments increasing over the term of the facility. Proceeds from the term loan facility and borrowings
under the revolving credit facility were used to repay the then existing senior credit agreement and in part to finance the acquisition
of Buffalo Filter. Interest rates are at LIBOR plus an interest rate margin of 1.750% (3.563% at December 31, 2019). For those
borrowings where we elect to use the alternate base rate, the base rate will be the greatest of (i) the Prime Rate, (ii) the Federal
Funds Rate plus 0.50% or (iii) the one-month Eurocurrency Rate plus 1.00%, plus, in each case, an interest rate margin.
There were $255.1 million in borrowings outstanding on the term loan facility as of December 31, 2019. There were
$220.0 million in borrowings outstanding under the revolving credit facility as of December 31, 2019. Our available borrowings
on the revolving credit facility at December 31, 2019 were $362.5 million with approximately $2.5 million of the facility set aside
for outstanding letters of credit.
The sixth amended and restated senior credit agreement is collateralized by substantially all of our personal property and
assets. The sixth amended and restated senior credit agreement contains covenants and restrictions which, among other things,
require the maintenance of certain financial ratios and restrict dividend payments and the incurrence of certain indebtedness and
other activities, including acquisitions and dispositions. We were in full compliance with these covenants and restrictions as of
December 31, 2019. We are also required, under certain circumstances, to make mandatory prepayments from net cash proceeds
from any issuance of equity and asset sales.
On January 29, 2019, we issued $345.0 million in 2.625% convertible notes due in 2024 (the "Notes"). Interest is payable
semi-annually in arrears on February 1 and August 1 of each year, commencing August 1, 2019. The Notes will mature on February
1, 2024, unless earlier repurchased or converted. The Notes represent subordinated unsecured obligations and are convertible
under certain circumstances, as defined in the indenture, into a combination of cash and CONMED common stock. The Notes
may be converted at an initial conversion rate of 11.2608 shares of our common stock per $1,000 principal amount of Notes
(equivalent to an initial conversion price of approximately $88.80 per share of common stock). Holders of the Notes may convert
the Notes at their option at any time on or after November 1, 2023 through the second scheduled trading day preceding the maturity
date. Holders of the Notes will also have the right to convert the Notes prior to November 1, 2023, but only upon the occurrence
of specified events. The conversion rate is subject to anti-dilution adjustments if certain events occur. A portion of the net proceeds
from the offering of the Notes were used as part of the financing for the Buffalo Filter acquisition and $21.0 million were used to
pay the cost of certain convertible notes hedge transactions as further described below.
Our effective borrowing rate for nonconvertible debt at the time of issuance of the Notes was estimated to be 6.14%,
which resulted in $51.6 million of the $345.0 million aggregate principal amount of Notes issued, or $39.1 million after taxes,
being attributable to equity. For the year ended December 31, 2019, we have recorded interest expense related to the amortization
of debt discount on the Notes of $8.3 million at the effective interest rate of 6.14%. The debt discount on the Notes is being
amortized through February 2024. For the year ended December 31, 2019, we have recorded interest expense on the Notes of
$8.4 million at the contractual coupon rate of 2.625%.
58
In connection with the offering of the Notes, we entered into convertible notes hedge transactions with a number of
financial institutions (each, an “option counterparty”). The convertible notes hedge transactions cover, subject to anti-dilution
adjustments substantially similar to those applicable to the Notes, the number of shares of our common stock underlying the Notes.
Concurrently with entering into the convertible notes hedge transactions, we also entered into separate warrant transactions with
each option counterparty whereby we sold to such option counterparty warrants to purchase, subject to customary anti-dilution
adjustments, the same number of shares of our common stock.
The convertible notes hedge transactions are expected generally to reduce the potential dilution upon conversion of the
Notes and/or offset any cash payments we are required to make in excess of the principal amount of converted Notes, as the case
may be, in the event that the market price per share of our common stock, as measured under the terms of the convertible notes
hedge transactions, is greater than the strike price ($114.92) of the convertible notes hedge transactions, which initially corresponds
to the conversion price of the Notes and is subject to anti-dilution adjustments substantially similar to those applicable to the
conversion rate of the Notes. If, however, the market price per share of our common stock, as measured under the terms of the
warrant transactions, exceeds the strike price of the warrants, there would nevertheless be dilution to the extent that such market
price exceeds the strike price of the warrants.
During 2019, we paid in full our mortgage notes in connection with the Largo, Florida property and facilities.
The scheduled maturities of long-term debt outstanding at December 31, 2019 are as follows:
2020
2021
2022
2023
2024
Thereafter
Note 8 — Income Taxes
$
13,250
18,219
24,844
418,750
345,000
—
The provision (benefit) for income taxes for the years ended December 31, 2019, 2018 and 2017 consists of the
following:
Current tax expense:
Federal
State
Foreign
Deferred income tax expense (benefit):
Federal
State
Foreign
2019
2018
2017
$
$
96
444
8,375
8,915
(3,970)
(938)
(1,402)
(6,310)
(1,077) $
777
8,036
7,736
4,478
62
(2,477)
2,063
1,744
2,101
9,421
13,266
(44,456)
(1,036)
5,471
(40,021)
Provision (benefit) for income taxes
$
2,605
$
9,799
$
(26,755)
59
A reconciliation between income taxes computed at the statutory federal rate and the provision (benefit) for income taxes
for the years ended December 31, 2019, 2018 and 2017 follows:
Tax provision at statutory rate based on income before income taxes
21.0%
21.0%
35.0 %
2019
2018
2017
Stock-based compensation
Settlement of taxing authority examinations
Federal research credit
Tax treaty protocols
US tax on worldwide earnings at different rates
Foreign income taxes
Non deductible/non-taxable items
State income taxes, net of federal tax benefit
International tax reform
US tax reform
Consolidated group restructuring
(15.4)
(7.7)
(4.0)
(2.9)
7.9
6.4
2.8
0.3
—
—
—
(1.6)
(0.7)
(2.8)
—
2.9
3.6
(1.4)
1.6
(3.6)
1.8
—
Other, net
(0.1)
(1.5)
(2.1)
(2.1)
(2.8)
—
—
(5.3)
(1.0)
2.8
—
(111.0)
(7.4)
0.8
8.3%
19.3%
(93.1)%
The 2017 Tax Cuts and Jobs Act ("Tax Reform") was enacted on December 22, 2017. The Tax Reform included a number
of changes in existing tax law impacting businesses, including a one-time deemed repatriation of cumulative undistributed foreign
earnings and a permanent reduction in the U.S. federal statutory rate from 35% to 21%, effective on January 1, 2018. Under U.S.
GAAP, changes in tax rates and tax law were accounted for in 2017, the period of enactment, and deferred tax assets and liabilities
were measured at the enacted tax rate. The 2017 rate reconciliation included the Company’s assessment of the accounting under
the Tax Reform which was preliminary based on information that was available to management at the time the consolidated
financial statements were prepared. Estimated provisional amounts were recorded for the deemed repatriation toll charge
implemented by the Tax Reform, related foreign tax credits, deferred tax revaluation amounts and deferred tax liabilities on
unremitted earnings. Accordingly, the Company had determined a preliminary $31.9 million of tax benefit related to Tax Reform.
Staff Accounting Bulletin No. 118 provided for a one-year measurement period to finalize these estimated provisional
amounts. During 2018, the Company finalized its accounting and recorded $1.3 million of tax expense related to the revaluation
of certain deferred tax items. This expense was offset in part by $0.4 million of tax benefit primarily resulting from finalization
of the deemed repatriation toll charge, related foreign tax credits and adjustments to foreign withholding amounts. The final tax
benefit related to Tax Reform was $31.0 million.
The Company has elected to account for Global Intangible Low Tax Income ("GILTI") using the period cost method.
The net impact of GILTI including the allowable GILTI deduction is presented in the rate reconciliation as a component of “US
tax on worldwide earnings at different rates” and is offset in part by the Foreign Derived Intangible Income deduction (“FDII”).
60
The tax effects of the significant temporary differences which comprise the deferred income tax assets and liabilities at
December 31, 2019 and 2018 are as follows:
Assets:
Inventory
Net operating losses
Capitalized research and development
Deferred compensation
Accounts receivable
Compensation and benefits
Accrued pension
Research and development credit
Interest limitation
Convertible notes hedge
Lease liabilities
Other
Less: valuation allowances
Liabilities:
Goodwill and intangible assets
Depreciation
State taxes
Unremitted foreign earnings
Convertible notes debt discount
Lease right-of-use assets
$
2019
2018
$
4,085
3,679
6,201
2,102
2,556
6,049
3,710
10,321
5,702
9,004
5,688
4,336
(1,732)
61,701
102,015
301
11,161
2,619
9,096
5,338
130,530
4,096
7,358
7,214
2,085
2,296
5,434
3,205
8,585
—
—
—
2,235
(1,159)
41,349
100,108
1,345
12,212
3,583
—
—
117,248
Net liability
$
(68,829) $
(75,899)
Income before income taxes consists of the following U.S. and foreign income:
U.S. income
Foreign income
Total income
2019
2018
2017
$
$
5,332
25,893
31,225
$
$
24,320
26,333
50,653
$
$
1,492
27,240
28,732
As of December 31, 2019, the amount of federal net operating loss carryforward was $9.3 million and begins to expire
in 2027. As of December 31, 2019, the amount of federal research credit carryforward available was $10.3 million. These credits
begin to expire in 2027.
We have accrued tax liabilities related to the amount of unremitted earnings at December 31, 2017 and certain subsequent
unremitted earnings as these are not considered permanently reinvested. Deferred taxes have not been accrued on unremitted
earnings subsequent to December 31, 2017 that are considered permanently reinvested. The amount of such untaxed foreign
earnings for the periods occurring after December 2017 totaled $33.9 million. If we were to repatriate these funds, we would be
required to accrue and pay taxes on such amounts. The Company has estimated foreign withholding taxes of $1.0 million would
be due if these earnings were repatriated.
The Company is subject to taxation in the United States and various states and foreign jurisdictions. Taxing authority
examinations can involve complex issues and may require an extended period of time to resolve. Our federal income tax returns
have been examined by the Internal Revenue Service (“IRS”) for calendar years ending through 2017.
61
We recognize tax liabilities in accordance with the provisions for accounting for uncertainty in income taxes. Such
guidance prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement
of a tax position taken or expected to be taken in a tax return.
The following table summarizes the activity related to our unrecognized tax benefits for the years ending December 31,:
Balance as of January 1,
2019
2018
2017
$
3,073
$
2,943
$
1,839
Increases (decreases) for positions taken in prior periods
—
(250)
(246)
Increases for positions taken in current periods
1,650
1,017
1,957
Decreases in unrecorded tax positions related to settlement with the
taxing authorities
(2,404)
(370)
(607)
Decreases in unrecorded tax positions related to lapse of statute of
limitations
(149)
(267)
—
Balance as of December 31,
$
2,170
$
3,073
$
2,943
If the total unrecognized tax benefits of $2.2 million at December 31, 2019 were recognized, it would reduce our annual
effective tax rate. The amount of interest accrued in 2017, 2018 and 2019 related to these unrecognized tax benefits was not
material and is included in the provision (benefit) for income taxes in the consolidated statements of comprehensive income.
Note 9 – Shareholders’ Equity
On February 29, 2012, the Board of Directors adopted a cash dividend policy and declared an initial quarterly dividend
of $0.15 per share. On October 28, 2013, the Board of Directors increased the quarterly dividend to $0.20 per share. The total
dividend per share was $0.80 for each of 2019, 2018 and 2017. The fourth quarter dividend for 2019 was paid on January 7, 2020
to shareholders of record as of December 13, 2019. The total dividend payable was $5.7 million and $5.6 million at December
31, 2019 and 2018, respectively, and is included in other current liabilities in the consolidated balance sheet.
Our shareholders have authorized 500,000 shares of preferred stock, par value $.01 per share, which may be issued in
one or more series by the Board of Directors without further action by the shareholders. As of December 31, 2019 and 2018, no
preferred stock had been issued.
Our Board of Directors has authorized a $200.0 million share repurchase program. Through December 31, 2019, we
have repurchased a total of 6.1 million shares of common stock aggregating $162.6 million under this authorization and have
$37.4 million remaining available for share repurchases. The repurchase program calls for shares to be purchased in the open
market or in private transactions from time to time. We may suspend or discontinue the share repurchase program at any
time. During 2019, 2018, and 2017 we did not repurchase any shares.
We have reserved 7.3 million shares of common stock for issuance to employees and directors under two shareholder
approved share-based compensation plans (the "Plans") of which approximately 4.1 million shares remain available for grant at
December 31, 2019. The exercise price on all outstanding stock options and stock appreciation rights (“SARs”) is equal to the
quoted fair market value of the stock at the date of grant. Restricted stock units (“RSUs”) and performance stock units (“PSUs”)
are valued at the market value of the underlying stock on the date of grant. Stock options, SARs, RSUs and PSUs are generally
non-transferable other than on death and generally become exercisable over a 4 to 5 year period from date of grant. Stock options
and SARs expire 10 years from date of grant. SARs are only settled in shares of the Company’s stock. The issuance of shares
pursuant to the exercise of stock options and SARs and vesting of RSUs and PSUs are from the Company’s treasury stock.
Total pre-tax stock-based compensation expense recognized in the consolidated statements of comprehensive income
was $11.8 million, $10.0 million and $8.5 million for the years ended December 31, 2019, 2018 and 2017, respectively. These
amounts are included in selling and administrative expense. Tax related benefits of $2.8 million, $2.3 million and $2.0 million
62
were also recognized for the years ended December 31, 2019, 2018 and 2017, respectively. Cash received from the exercise of
stock options was $7.7 million, $3.5 million and $1.0 million for the years ended December 31, 2019, 2018 and 2017, respectively,
and is reflected in cash flows from financing activities in the consolidated statements of cash flows.
The Company uses the Black-Scholes option pricing model to estimate the fair value of stock options and SARs at the
date of grant. Use of a valuation model requires management to make certain assumptions with respect to select model inputs.
Expected volatilities are based upon historical volatility of the Company’s stock over a period equal to the expected life of each
stock option and SAR grant. The risk free interest rate is based on the stock option and SAR grant date for a traded U.S. Treasury
bond with a maturity date closest to the expected life. The expected annual dividend yield is based on the Company's anticipated
cash dividend payouts. The expected life represents the period of time that the stock options and SARs are expected to be
outstanding based on a study of historical data of option holder exercise and termination behavior. Forfeitures are recognized as
incurred.
The following table illustrates the assumptions used in estimating fair value in the years ended December 31, 2019, 2018
and 2017:
Grant date fair value of stock options and SARs
Expected stock price volatility
Risk-free interest rate
Expected annual dividend yield
Expected life of options & SARs (years)
$
2019
2018
2017
$
20.59
26.59%
2.58%
1.08%
5.6
$
14.78
25.69%
2.62%
1.34%
5.7
10.07
27.63%
2.11%
1.87%
5.8
The following table illustrates the stock option and SAR activity for the year ended December 31, 2019:
Outstanding at December 31, 2018
Granted
Forfeited
Exercised
Outstanding at December 31, 2019
Exercisable at December 31, 2019
Stock options & SARs expected to vest
Number
of
Shares
(in 000’s)
Weighted-
Average
Exercise
Price
2,851
$
860
$
(106) $
(352) $
3,253
1,036
2,217
$
$
$
47.67
78.78
58.50
43.75
55.97
46.05
60.61
The weighted average remaining contractual term for SARs and stock options outstanding and exercisable at December 31,
2019 was 7.5 years and 6.3 years, respectively. The aggregate intrinsic value of SARs and stock options outstanding and exercisable
at December 31, 2019 was $181.7 million and $68.2 million, respectively. The aggregate intrinsic value of stock options and
SARs exercised during the years ended December 31, 2019, 2018 and 2017 was $17.0 million, $4.2 million and $2.7 million,
respectively.
63
The following table illustrates the RSU and PSU activity for the year ended December 31, 2019:
Outstanding at December 31, 2018
Granted
Vested
Forfeited
Outstanding at December 31, 2019
Number
of
Shares
(in 000’s)
Weighted-
Average
Grant-Date
Fair Value
187
$
38
$
(55) $
(1) $
169
$
43.46
78.64
51.43
43.68
48.94
The weighted average fair value of awards of RSUs granted in the years ended December 31, 2019, 2018 and 2017 was
$78.64, $61.76 and $48.32, respectively.
The total fair value of RSUs and PSUs vested was $2.8 million, $3.0 million and $3.4 million for the years ended
December 31, 2019, 2018 and 2017, respectively.
As of December 31, 2019, there was $28.7 million of total unrecognized compensation cost related to nonvested stock
options, SARs, RSUs and PSUs granted under the Plans which is expected to be recognized over a weighted average period of
3.4 years.
We offer to our employees a shareholder-approved Employee Stock Purchase Plan (the “Employee Plan”), under which
we reserved 1.0 million shares of common stock for issuance to our employees. The Employee Plan provides employees with the
opportunity to invest from 1% to 10% of their annual salary to purchase shares of CONMED common stock at a purchase price
equal to 95% of the fair market value of the common stock on the exercise date. During 2019, we issued approximately 18,104
shares of common stock under the Employee Plan. No stock-based compensation expense has been recognized in the accompanying
consolidated financial statements as a result of common stock issuances under the Employee Plan.
Note 10 — Revenues
The following tables present revenue disaggregated by product line and timing of revenue recognition for the years ended
December 31, 2019, 2018 and 2017:
Orthopedic Surgery
2019
General Surgery
Total
Timing of Revenue Recognition
Goods transferred at a point in time
Services transferred over time
Total sales from contracts with customers
$
$
426,893
36,429
463,322
$
$
489,313
2,462
491,775
Orthopedic Surgery
General Surgery
2018
Timing of Revenue Recognition
Goods transferred at a point in time
Services transferred over time
Total sales from contracts with customers
$
$
413,630
33,098
446,728
$
$
411,391
1,515
412,906
$
$
$
$
916,206
38,891
955,097
825,021
34,613
859,634
Total
64
Orthopedic Surgery
2017
General Surgery
Total
Timing of Revenue Recognition
Goods transferred at a point in time
Services transferred over time
Total sales from contracts with customers
$
$
396,147
32,797
428,944
$
$
366,672
776
367,448
$
$
762,819
33,573
796,392
Revenue disaggregated by primary geographic market where the products are sold is included in Note 11.
Contract liability balances related to the sale of extended warranties to customers are as follows:
December 31, 2019 December 31, 2018
Contract Liability
$
14,276
$
11,043
Revenue recognized during years ended December 31, 2019, 2018 and 2017 from amounts included in contract liabilities
at the beginning of the period were $6.8 million, $5.0 million and $3.9 million, respectively. There were no material contract assets
as of December 31, 2019 and December 31, 2018.
Note 11 — Business Segments and Geographic Areas
We are accounting and reporting for our business as a single operating segment entity engaged in the development,
manufacturing and sale on a global basis of surgical devices and related equipment. Our chief operating decision maker (the CEO)
evaluates the various global product portfolios on a net sales basis and evaluates profitability, investment, cash flow metrics and
allocates resources on a consolidated worldwide basis due to shared infrastructure and resources. Our product lines consist of
orthopedic surgery and general surgery. Orthopedic surgery consists of sports medicine instrumentation and small bone, large
bone and specialty powered surgical instruments as well as imaging systems for use in minimally invasive surgery procedures
including 2DHD and 3DHD vision technologies and fees related to sales representation, promotion and marketing of sports
medicine allograft tissue. General surgery consists of a complete line of endo-mechanical instrumentation for minimally invasive
laparoscopic and gastrointestinal procedures, a line of cardiac monitoring products as well as electrosurgical generators and related
instruments. These product lines' net sales and primary geographic market where the products are sold, are as follows for the
years ended December 31, 2019, 2018 and 2017:
Orthopedic Surgery
2019
General Surgery
Total
Primary Geographic Markets
United States
Americas (excluding the United States)
Europe, Middle East & Africa
Asia Pacific
$
Total sales from contracts with customers
$
179,419
64,269
118,301
101,333
463,322
$
$
337,246
31,004
64,248
59,277
491,775
$
$
2018
Orthopedic Surgery
General Surgery
Total
Primary Geographic Markets
United States
Americas (excluding the United States)
Europe, Middle East & Africa
Asia Pacific
$
172,462
$
276,186
$
66,519
112,998
94,749
31,009
53,565
52,146
Total sales from contracts with customers
$
446,728
$
412,906
$
516,665
95,273
182,549
160,610
955,097
448,648
97,528
166,563
146,895
859,634
65
Orthopedic Surgery
2017
General Surgery
Total
Primary Geographic Markets
United States
Americas (excluding the United States)
Europe, Middle East & Africa
Asia Pacific
$
167,602
$
243,439
$
60,439
106,921
93,982
30,730
48,928
44,351
Total sales from contracts with customers
$
428,944
$
367,448
$
411,041
91,169
155,849
138,333
796,392
Sales are attributed to countries based on the location of the customer. There were no significant investments in long-
lived assets located outside the United States at December 31, 2019 and 2018. No single customer represented over 10% of our
consolidated net sales for the years ended December 31, 2019, 2018 and 2017.
Note 12 — Employee Benefit Plans
We sponsor an employee savings plan (“401(k) plan”) covering substantially all of our United States based employees.
We also sponsor a defined benefit pension plan (the “pension plan”) that was frozen in 2009. It covered substantially all our United
States based employees at the time it was frozen.
Total employer contributions to the 401(k) plan were $9.1 million, $8.3 million and $7.5 million during the years ended
December 31, 2019, 2018 and 2017, respectively.
We use a December 31, measurement date for our pension plan. Cumulative gains and losses in excess of 10% of the
greater of the benefit obligation or the market-related value of assets are amortized on a straight-line basis over the lesser of the
expected average remaining life expectancy of the plan's participants or 12 years. The limit of 12 years is adjusted to reflect the
percentage change in the average remaining service period for the plan's active membership.
The following table provides a reconciliation of the projected benefit obligation, plan assets and funded status of the
pension plan at December 31:
Accumulated benefit obligation
Change in benefit obligation
Projected benefit obligation at beginning of year
Service cost
Interest cost
Actuarial gain (loss)
Benefits paid
Settlements
Projected benefit obligation at end of year
Change in plan assets
Fair value of plan assets at beginning of year
Actual gain (loss) on plan assets
Benefits paid
Settlements
Fair value of plan assets at end of year
Funded status
66
2019
2018
92,052
$
80,776
80,776
1,010
3,130
10,561
(2,299)
(1,126)
92,052
66,307
12,439
(2,299)
(1,126)
75,321
$
$
$
$
87,765
675
2,806
(7,430)
(2,104)
(936)
80,776
74,932
(5,585)
(2,104)
(936)
66,307
(16,731) $
(14,469)
$
$
$
$
$
$
Amounts recognized in the consolidated balance sheets consist of the following at December 31,:
Other long-term liabilities
Accumulated other comprehensive loss
2019
2018
$
(16,731) $
(41,787)
(14,469)
(41,822)
Accumulated other comprehensive loss for the years ended December 31, 2019 and 2018 consists of net actuarial losses
not yet recognized in net periodic pension cost (before income taxes).
The following actuarial assumptions were used to determine our accumulated and projected benefit obligations as of
December 31,:
Discount rate
2019
2018
3.33%
4.37%
Other changes in plan assets and benefit obligations recognized in other comprehensive income in 2019 and 2018 are as
follows:
Current year actuarial loss
Amortization of actuarial loss
Total recognized in other comprehensive loss
2019
2018
$
$
(2,846) $
2,881
35
$
(3,574)
2,689
(885)
The estimated portion of net actuarial loss in accumulated other comprehensive loss that is expected to be recognized as
a component of net periodic pension cost in 2020 is $2.8 million.
Net periodic pension cost for the years ended December 31, consists of the following:
Service cost
Interest cost on projected benefit obligation
Expected return on plan assets
Amortization of loss
Net periodic pension cost
2019
2018
2017
$
$
1,010
3,130
(4,725)
2,881
2,296
$
$
675
2,806
(5,418)
2,689
752
$
$
603
2,773
(5,300)
2,835
911
Non-service cost of $1.3 million is included in other expense in the consolidated statement of comprehensive income for
the year ended 2019.
The following actuarial assumptions were used to determine our net periodic pension benefit cost for the years ended
December 31,:
Discount rate on benefit obligation
Effective rate for interest on benefit obligation
Expected return on plan assets
2019
2018
2017
4.37%
4.01%
7.50%
3.69%
3.28%
7.50%
4.28%
3.49%
8.00%
We use a full yield curve approach in the estimation of the interest cost component of net periodic pension cost by applying
the specific spot rates along the yield curve used in the determination of the benefit obligation that correlates to the relevant
projected cash flows ("spot rate approach").
67
In determining the expected return on pension plan assets, we consider the relative weighting of plan assets, the historical
performance of total plan assets and individual asset classes and economic and other indicators of future performance. In addition,
we consult with financial and investment management professionals in developing appropriate targeted rates of return.
Asset management objectives include maintaining an adequate level of diversification to reduce interest rate and market
risk and providing adequate liquidity to meet immediate and future benefit payment requirements.
The allocation of pension plan assets by category is as follows at December 31,:
Equity securities
Debt securities
Total
Percentage of Pension
Plan Assets
2019
2018
Target
Allocation
2020
74%
26%
100%
71%
29%
100%
75%
25%
100%
As of December 31, 2019, the pension plan held 27,562 shares of our common stock, which had a fair value of $3.1
million. We believe that our long-term asset allocation on average will approximate the targeted allocation. We regularly review
our actual asset allocation and periodically rebalance the pension plan’s investments to our targeted allocation when deemed
appropriate.
FASB guidance defines fair value and establishes a framework for measuring fair value and related disclosure requirements
as described in Note 16. Following is a description of the valuation methodologies used for our pension assets. There have been
no changes in the methodologies used at December 31, 2019 and 2018:
Common
Stock:
Common stock is valued at the closing price reported on the common stock’s respective stock exchange
and is classified within level 1 of the valuation hierarchy.
Fixed Income
Securities:
Valued at the closing price reported on the active market on which the individual securities are traded
and are classified within level 1 of the valuation hierarchy.
Money
Market Fund:
Mutual
Funds:
These investments are public investment vehicles valued using the Net Asset Value (NAV).
These investments are public investment vehicles valued using the Net Asset Value (NAV) provided by
the administrator of the fund. The NAV is based on the value of the underlying assets owned by the fund,
minus its liabilities, and then divided by the number of shares outstanding.
The methods described above may produce a fair value calculation that may not be indicative of net realizable value or
reflective of future fair values. Furthermore, while the pension plan believes its valuation methods are appropriate and consistent
with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial
instruments could result in a different fair value measurement at the reporting date.
68
The following table sets forth the value of the pension plan's assets as of December 31, 2019 and December 31, 2018:
Investments measured at fair value:
Level 1
Common Stock
Fixed Income Securities
Total Investments measured at fair value
Investments measured at NAV:
Money Market Fund
Mutual Funds
Total Investments measured at NAV
2019
2018
$
$
8,307
18,609
26,916
789
47,616
48,405
6,362
17,640
24,002
1,385
40,920
42,305
Total Investments
$
75,321
$
66,307
We do not expect to make any contributions to our pension plan for 2020.
The following table summarizes the benefits and settlements expected to be paid by our pension plan in each of the next
five years and in aggregate for the following five years. The expected payments are estimated based on the same assumptions
used to measure the Company’s projected benefit obligation at December 31, 2019 and reflect the impact of expected future
employee service.
2020
2021
2022
2023
2024
2025-2029
$6,489
5,290
5,815
5,637
5,245
26,725
Note 13 — Legal Matters and Contingencies
From time to time, the Company may receive an information request or subpoena from a government agency such as the
Securities and Exchange Commission, Department of Justice, Equal Employment Opportunity Commission, the Occupational
Safety and Health Administration, the United States Food and Drug Administration, the Department of Labor, the Treasury
Department or other federal and state agencies or foreign governments or government agencies. These information requests or
subpoenas may or may not be routine inquiries, or may begin as routine inquiries and over time develop into enforcement actions
of various types. Likewise, if we receive reports of alleged misconduct from employees and third parties, we investigate as
appropriate.
Manufacturers of medical devices have been the subject of various enforcement actions relating to interactions with health
care providers domestically or internationally whereby companies are claimed to have provided health care providers with
inappropriate incentives to purchase their products. Similarly, the Foreign Corrupt Practices Act ("FCPA") imposes obligations
on manufacturers with respect to interactions with health care providers who may be considered government officials based on
their affiliation with public hospitals. The FCPA also requires publicly listed manufacturers to maintain accurate books and records,
and maintain internal accounting controls sufficient to provide assurance that transactions are accurately recorded, lawful and in
accordance with management's authorization. The FCPA poses unique challenges both because manufacturers operate in foreign
cultures in which conduct illegal under the FCPA may not be illegal in local jurisdictions, and because, in some cases, a United
States manufacturer may face risks under the FCPA based on the conduct of third parties over whom the manufacturer may not
have complete control. While CONMED has not experienced any material enforcement action to date, there can be no assurance
that the Company will not be subject to a material enforcement action in the future, or that the Company will not incur costs
including, in the form of fees for lawyers and other consultants, that are material to the Company’s results of operations in the
course of responding to a future inquiry or investigation.
69
Manufacturers of medical products may face exposure to significant product liability claims, as well as patent infringement
and other claims incurred in the ordinary course of business. To date, we have not experienced any claims that have been material
to our financial statements or financial condition, but any such claims arising in the future could have a material adverse effect
on our business, results of operations or cash flows. We currently maintain commercial product liability insurance of $30 million
per incident and $30 million in the aggregate annually, which we believe is adequate. This coverage is on a claims-made basis.
There can be no assurance that claims will not exceed insurance coverage, that the carriers will be solvent or that such insurance
will be available to us in the future at a reasonable cost.
Our operations are subject, and in the past have been subject, to a number of environmental laws and regulations governing,
among other things, air emissions; wastewater discharges; the use, handling and disposal of hazardous substances and wastes; soil
and groundwater remediation and employee health and safety. Likewise, the operations of our suppliers and sterilizers are subject
to similar environmental laws and regulations. In some jurisdictions, environmental requirements may be expected to become
more stringent in the future. In the United States, certain environmental laws can impose liability for the entire cost of site
restoration upon each of the parties that may have contributed to conditions at the site regardless of fault or the lawfulness of the
party’s activities. While we do not believe that the present costs of environmental compliance and remediation are material, there
can be no assurance that future compliance or remedial obligations would not have a material adverse effect on our financial
condition, results of operations or cash flows.
In 2014, the Company acquired EndoDynamix, Inc. The agreement governing the terms of the acquisition provides that,
if various conditions are met, certain contingent payments relating to the first commercial sale of the products (the milestone
payment), as well as royalties based on sales (the revenue based payments), are due to the seller. In 2016, we notified the seller
that there was a need to redesign the product, and that, as a consequence, the first commercial sale had been delayed. Consequently,
the payment of contingent milestone and revenue-based payments were delayed. On January 18, 2017, the seller provided notice
("the Notice") seeking $12.7 million, which essentially represents the seller's view as to the sum of the projected contingent
milestone and revenue-based payments on an accelerated basis. CONMED responded to the Notice denying that there was any
basis for acceleration of the payments due under the acquisition agreement. On February 22, 2017, the representative of the former
shareholders of EndoDynamix filed a complaint in Delaware Chancery Court claiming breach of contract with respect to the duty
to commercialize the product and seeking the contingent payments on an accelerated basis. We believe that there was a substantive
contractual basis to support the Company's decision to redesign the product, such that there was no legitimate basis for seeking
the acceleration of the contingent payments at that time. In the third quarter of 2018, the Company decided to halt the development
of the EndoDynamix clip applier. We previously recorded a charge to write off assets and released a previously accrued contingent
consideration liability as described in Note 14. A non-jury trial is now scheduled to take place in July 2020. We expect to defend
the claims asserted by the sellers of EndoDynamix in the Delaware Court, although there can be no assurance that we will prevail
in the litigation.
We record reserves sufficient to cover probable and estimable losses associated with any such pending claims. We do
not expect that the resolution of any pending claims, investigations or reports of alleged misconduct will have a material adverse
effect on our financial condition, results of operations or cash flows. There can be no assurance, however, that future claims or
investigations, or the costs associated with responding to such claims, investigations or reports of misconduct, especially claims
and investigations not covered by insurance, will not have a material adverse effect on our financial condition, results of operations
or cash flows.
70
Note 14 — Acquisition and Other Expense
Acquisition and other expense for the year ended December 31, consists of the following:
2019
2018
2017
Business acquisition costs
Manufacturing consolidation costs
Acquisition and other expense included in cost of sales
Business acquisition costs
Restructuring costs
Legal matters
Acquisition and other expense included in selling and administrative
expense
Impairment charges included in research and development expense
Debt refinancing costs included in other expense
$
$
$
$
$
$
$
$
$
1,335
2,858
4,193
13,066
—
—
13,066
$
— $
—
— $
2,372
—
—
2,372
$
$
$
— $
4,212
3,904
$
— $
—
2,903
2,903
2,336
1,347
17,480
21,163
—
—
During 2019, we incurred $1.3 million in costs for inventory adjustments and other costs associated with the acquisition
of Buffalo Filter as further described in Note 2. These costs were charged to cost of sales.
During 2019, we incurred $2.9 million in severance and other costs related to the consolidation of certain manufacturing
operations. These costs were charged to cost of sales.
During 2017, we incurred $2.9 million in costs associated with consolidation of certain manufacturing operations. These
costs were charged to cost of sales and included severance, inventory and other charges.
During 2019 and 2018, we incurred $13.1 million and $1.3 million, respectively, in costs associated with the February 11,
2019 acquisition of Buffalo Filter as further described in Note 2 that were included in selling and administrative expense. These
costs include investment banking fees, consulting fees, legal fees, severance and integration related costs.
During 2018 and 2017 we incurred $1.1 million and $2.3 million respectively, in costs associated with a prior acquisition
and were also included in selling and administrative expense. The 2018 cost consists of a charge to selling and administrative
expense associated with a vacant lease related to the acquisition. The 2017 costs include the expensing of unvested options acquired
and integration related costs.
During 2017, we consolidated certain selling and administrative functions and incurred $1.3 million in related costs
consisting principally of severance charges.
During 2017, we incurred $12.2 million in costs associated with a litigation verdict whereby SurgiQuest, Inc. was found
liable for $2.2 million in compensatory damages with an additional $10.0 million in punitive damages. These costs were paid
on July 10, 2018. In addition, during the years ended December 31, 2017, we incurred $5.3 million in costs associated with this
litigation and other legal matters. These costs were charged to selling and administrative expense.
During 2018, we recorded a net charge of $4.2 million to research and development expense mainly associated with the
impairment of an in-process research and development asset, net of the release of previously accrued contingent consideration in
other current and long-term liabilities, as further described in Note 13.
During 2019, we incurred a $3.6 million charge related to commitment fees paid to certain of our lenders, which provided
a financing commitment for the Buffalo Filter acquisition and recorded a loss on the early extinguishment of debt of $0.3 million
in conjunction with the sixth amended and restated senior credit agreement as further described in Note 7.
71
Note 15 — Guarantees
We provide warranties on certain of our products at the time of sale and sell extended warranties. The standard warranty
period for our capital equipment is generally one year and our extended warranties typically vary from one to three years. Liability
under service and warranty policies is based upon a review of historical warranty and service claim experience. Adjustments are
made to accruals as claim data and historical experience warrant.
Changes in the carrying amount of service and product standard warranties for the year ended December 31, are as
follows:
Balance as of January 1,
Provision for warranties
Claims made
Balance as of December 31,
2019
2018
2017
1,585
$
1,750
$
1,954
1,699
(1,098)
1,099
(1,264)
1,034
(1,238)
2,186
$
1,585
$
1,750
$
$
Costs associated with extended warranty repairs are recorded as incurred and amounted to $5.3 million, $4.9 million and
$4.6 million for the years ended December 31, 2019, 2018 and 2017 respectively.
Note 16 – Fair Value Measurement
We enter into derivative instruments for risk management purposes only. We operate internationally and, in the normal
course of business, are exposed to fluctuations in interest rates, foreign exchange rates and commodity prices. These fluctuations
can increase the costs of financing, investing and operating the business. We use forward contracts, a type of derivative instrument,
to manage certain foreign currency exposures.
By nature, all financial instruments involve market and credit risks. We enter into forward contracts with major investment
grade financial institutions and have policies to monitor the credit risk of those counterparties. While there can be no assurance,
we do not anticipate any material non-performance by any of these counterparties.
Foreign Currency Forward Contracts. We hedge forecasted intercompany sales denominated in foreign currencies
through the use of forward contracts. We account for these forward contracts as cash flow hedges. To the extent these forward
contracts meet hedge accounting criteria, changes in their fair value are not included in current earnings but are included in
accumulated other comprehensive loss. These changes in fair value will be recognized into earnings as a component of sales or
cost of sales when the forecasted transaction occurs.
We also enter into forward contracts to exchange foreign currencies for United States dollars in order to hedge our currency
transaction exposures. These forward contracts settle each month at month-end, at which time we enter into new forward
contracts. We have not designated these forward contracts as hedges and have not applied hedge accounting to them.
The following table presents the notional contract amounts for forward contracts outstanding:
Forward exchange contracts
Forward exchange contracts
As of
FASB ASC Topic 815
Designation
Cash flow hedge
$
Non-designated
December 31, 2019
December 31, 2018
156,818
$
33,867
155,313
39,631
The remaining time to maturity as of December 31, 2019 is within two years for hedge designated foreign exchange
contracts and approximately one month for non-hedge designated forward exchange contracts.
72
Statement of comprehensive income presentation
Derivatives designated as cash flow hedges
Foreign exchange contracts designated as cash flow hedges had the following effects on accumulated other comprehensive
income (loss) and net earnings on our consolidated statements of comprehensive income and our consolidated balance sheets:
Amount of Gain (Loss)
Recognized in AOCI
Consolidated Statements of Comprehensive
Income
Amount of Gain (Loss)
Reclassified from AOCI
Years Ended
Total Amount of Line Item
Presented
Years Ended
Derivative Instrument
2019
2018
2017
Location of
amount
reclassified
2019
2018
2017
2019
2018
2017
Foreign exchange contracts
$ 3,871 $10,073 $ (7,290) Net Sales
$955,097 $859,634 $796,392
$ 7,969 $ (1,278) $ (573)
Cost of Sales
430,382
390,524
365,351
638
365
(145)
Pre-tax gain (loss)
$ 3,871 $10,073 $ (7,290)
Tax expense (benefit)
935
2,434
(1,761)
Net gain (loss)
$ 2,936 $ 7,639 $ (5,529)
$ 8,607 $ (913) $ (718)
2,079
(221)
(265)
$ 6,528 $ (692) $ (453)
At December 31, 2019, $0.7 million of net unrealized gains on forward contracts accounted for as cash flow hedges, and
included in accumulated other comprehensive loss, are expected to be recognized in earnings in the next twelve months.
Derivatives not designated as cash flow hedges
Net gains and losses from derivative instruments not accounted for as hedges offset by gains and losses on our intercompany
receivables on our consolidated statements of comprehensive income were:
Derivative Instrument
Net gain (loss) on currency forward contracts
Net gain (loss) on currency transaction
exposures
Location on Consolidated Statements
of Comprehensive Income
Selling and administrative expense
Selling and administrative expense
2019
2018
2017
(573) $
69
$ (1,577)
(653) $
(804) $ 1,058
$
$
Years Ended
73
Balance sheet presentation
We record these forward foreign exchange contracts at fair value; the following tables summarize the fair value for forward
foreign exchange contracts outstanding at December 31, 2019 and 2018:
December 31, 2019
Derivatives designated as hedging instruments:
Foreign exchange contracts
Foreign exchange contracts
Other long-term liabilities
Prepaids and other current assets
Location on Consolidated Balance
Sheet
Asset
Fair
Value
Liabilities
Fair
Value
Net
Fair
Value
$
$
2,307
38
2,345
$
$
(1,341) $
(353)
(1,694) $
966
(315)
651
Derivatives not designated as hedging
instruments:
Foreign exchange contracts
Other current liabilities
22
(159)
(137)
Total derivatives
$
2,367
$
(1,853) $
514
December 31, 2018
Derivatives designated as hedging instruments:
Foreign exchange contracts
Derivatives not designated as hedging
instruments:
Foreign exchange contracts
Location on Consolidated Balance
Sheet
Asset
Fair
Value
Liabilities
Fair
Value
Net
Fair
Value
Prepaids and other current assets
$
5,817
$
(431) $
5,386
Other current liabilities
19
(217)
(198)
Total derivatives
$
5,836
$
(648) $
5,188
Our forward foreign exchange contracts are subject to a master netting agreement and qualify for netting in the consolidated
balance sheets.
Fair Value Disclosure. FASB guidance defines fair value and establishes a framework for measuring fair value and
related disclosure requirements. This guidance applies when fair value measurements are required or permitted. The guidance
indicates, among other things, that a fair value measurement assumes that the transaction to sell an asset or transfer a liability
occurs in the principal market for the asset or liability or, in the absence of a principal market, the most advantageous market for
the asset or liability. Fair value is defined based upon an exit price model.
Valuation Hierarchy. A valuation hierarchy was established for disclosure of the inputs to the valuations used to measure
fair value. This hierarchy prioritizes the inputs into three broad levels as follows. Level 1 inputs are quoted prices (unadjusted)
in active markets for identical assets or liabilities. Level 2 inputs are quoted prices for similar assets and liabilities in active
markets, quoted prices for identical or similar assets in markets that are not active, inputs other than quoted prices that are observable
for the asset or liability, including interest rates, yield curves and credit risks, or inputs that are derived principally from or
corroborated by observable market data through correlation. Level 3 inputs are unobservable inputs based on our own assumptions
used to measure assets and liabilities at fair value. A financial asset or liability’s classification within the hierarchy is determined
based on the lowest level input that is significant to the fair value measurement. There have been no significant changes in the
assumptions.
Valuation Techniques. Assets and liabilities carried at fair value and measured on a recurring basis as of December 31,
2019 consist of forward foreign exchange contracts. The Company values its forward foreign exchange contracts using quoted
prices for similar assets. The most significant assumption is quoted currency rates. The value of the forward foreign exchange
contract assets and liabilities were valued using Level 2 inputs and are listed in the table above.
74
The carrying amounts reported in our balance sheets for cash and cash equivalents, accounts receivable, accounts payable
and long-term debt approximate fair value.
Note 17 - New Accounting Pronouncements
Recently Adopted Accounting Standards
In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) (“ASU 2016-02”), along with amendments
issued in 2017 and 2018. This ASU requires lessees to record leases on their balance sheets but recognize the expenses on their
income statements in a manner similar to current practice. ASU 2016-02 states that a lessee would recognize a lease liability for
the obligation to make lease payments and a right-of-use asset for the right to use the underlying asset for the lease term.
The Company adopted the new standard on January 1, 2019, and applied the modified retrospective approach along with
the package of transition practical expedients. The Company has lease agreements with lease and non-lease components, which
we account for separately. For certain equipment leases, we apply a portfolio approach to efficiently account for the operating
lease ROU assets and lease liabilities. We also elected the short-term lease exemption and do not recognize leases with terms less
than one year on the balance sheet. The related short-term lease expense is not material. On January 1, 2019, we recorded initial
right-of-use assets and lease liabilities, that were previously unrecorded under prior GAAP, of $17.9 million. Operating lease ROU
assets are included in other assets and lease liabilities are included in other current liabilities and other long-term liabilities. Our
accounting for finance leases, which were capital leases under prior GAAP, remained substantially unchanged. Finance leases are
included in property and equipment, current portion of long-term debt and long-term debt in our consolidated balance sheets. This
update did not have a material impact on our net income, earnings per share or cash flows. Refer to Note 5 for further detail on
leases.
In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to
Accounting for Hedging Activities. This ASU makes more financial and non-financial hedging strategies eligible for hedge
accounting. It also amends the presentation and disclosure requirements and changes how companies assess effectiveness. It is
intended to more closely align hedge accounting with companies’ risk management strategies, simplify the application of hedge
accounting and increase transparency as to the scope and results of hedging programs. This guidance is effective for fiscal years
beginning after December 15, 2018, including interim periods within that reporting period. Early adoption is permitted. We
adopted this update on January 1, 2019 and it did not have a material impact on our consolidated financial statements.
Recently Issued Accounting Standards, Not Yet Adopted
In June 2016, the FASB issued ASU No. 2016-13 Financial Instruments-Credit Losses (Topic 326): Measurement of
Credit Losses on Financial Instruments, along with subsequent amendments issued in 2019. This ASU requires instruments
measured at amortized cost, including accounts receivable, to be presented at the net amount expected to be collected. The new
model requires an entity to estimate credit losses based on historical information, current information, and reasonable and
supportable forecasts, including estimates of prepayments. This ASU is effective for fiscal years beginning after December 31,
2019 and early adoption is permissible during any interim period after December 31, 2018. The Company adopted the new standard
on January 1, 2020. We assessed the impact of adopting this ASU and the impact of the current expected credit loss model on
trade receivables. We do not expect this update to have a material impact on our net income, earnings per share or cash flows.
In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework-Changes
to the Disclosure Requirements for Fair Value Measurement, which modifies the disclosure requirements on fair value
measurements. This ASU is effective for fiscal years beginning after December 15, 2019 and early adoption is permitted. We do
not expect this update to have a material impact on disclosures on our consolidated financial statements.
In August 2018, the FASB issued ASU 2018-14, Compensation-Retirement Benefits-Defined Benefit Plans-General
(Topic 715-20): Disclosure Framework-Changes to the Disclosure Requirements for Defined Benefit Plans, which modifies the
disclosure requirements for defined benefit pension plans and other postretirement plans. This ASU is effective for fiscal years
beginning after December 15, 2020 and early adoption is permitted. The Company is currently assessing the impact of this guidance
on our consolidated financial statements.
In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income
Taxes, which results in the removal of certain exceptions to the general principles of ASC 740 and simplifies other aspects of the
accounting for income taxes. This ASU is effective for fiscal years beginning after December 15, 2020 and early adoption is
permitted. The Company is currently assessing the impact of this guidance on our consolidated financial statements.
75
Note 18 — Selected Quarterly Financial Data (Unaudited)
Selected quarterly financial data for 2019 and 2018 are as follows:
2019
Net sales
Gross profit
Net income
EPS:
Basic
Diluted
2018
Net sales
Gross profit
Net income
EPS:
Basic
Diluted
March(1)
Three Months Ended
June(2)
September(3)
December(4)
$
$
$
$
218,378
121,438
1,021
.04
.04
March
202,064
109,557
10,657
.38
.37
$
$
$
$
238,263
131,190
5,695
.20
.19
$
$
233,590
130,111
6,970
.25
.23
Three Months Ended
June
September(5)
212,820
116,271
8,719
.31
.30
$
$
202,307
110,627
5,825
.21
.20
$
$
$
$
264,865
141,975
14,933
.53
.49
December(6)
242,444
132,655
15,653
.56
.54
Items Included In Selected Quarterly Financial Data:
(1) The first quarter of 2019 includes pre-tax business acquisition costs of $7.9 million and debt refinancing costs of $3.9 million.
(2) The second quarter of 2019 includes pre-tax business acquisition costs of $3.0 million.
(3) The third quarter of 2019 includes pre-tax business acquisition costs of $1.7 million and manufacturing consolidation costs
of $1.4 million. In the third quarter of 2019, our average share price exceeded the conversion price of our 2.625% convertible
notes due in 2024 (the "Notes") and we included 0.2 million shares assumed to be issued if the Notes were converted in our
diluted share count for the computation of diluted earnings per share.
(4) The fourth quarter of 2019 includes pre-tax business acquisition costs of $1.9 million and manufacturing consolidation costs
of $1.4 million. In the fourth quarter of 2019, our average share price exceeded the conversion price of our 2.625% convertible
notes due in 2024 (the "Notes") and we included 0.6 million shares assumed to be issued if the Notes were converted in our
diluted share count for the computation of diluted earnings per share.
(5) The third quarter of 2018 includes pre-tax business acquisition costs of $1.1 million and in-process research and development
impairment charges of $4.2 million.
(6) The fourth quarter of 2018 includes pre-tax business acquisition costs of $1.3 million.
76
SCHEDULE II—Valuation and Qualifying Accounts
(In thousands)
Description
Balance at
Beginning of
Period
Additions
Charged to
Costs and
Expenses
Deductions
Balance at End
of Period
2019
Allowance for bad debts
Sales returns and
allowance
Deferred tax asset
valuation allowance
2018
Allowance for bad debts
Sales returns and
allowance
Deferred tax asset
valuation allowance
2017
Allowance for bad debts
Sales returns and
allowance
Deferred tax asset
valuation allowance
Item 16. Form 10-K Summary
$
2,660
$
852
$
(726) $
3,246
1,159
518
573
(97)
—
$
2,137
$
1,485
$
(962) $
2,219
1,050
570
589
(23)
—
$
2,031
$
1,031
$
(925) $
1,817
441
424
129
(22)
—
2,786
3,667
1,732
2,660
3,246
1,159
2,137
2,219
570
Registrants may voluntarily provide a summary of information required by Form 10-K under this Item 16. The
Company has elected not to include such summary information.
77
Exhibit 4.1
Description of Registrant’s Securities to be Registered.
Description of Common Stock
The following is a description of the general terms, provisions and rights of Common Stock and related provisions of the
Company’s certificate of incorporation (the “Certificate of Incorporation”) and bylaws (the “Bylaws”) and applicable New York
law. This description is qualified in its entirety by, and should be read in conjunction with, the Certificate of Incorporation, Bylaws
and applicable New York law.
Authorized Shares
We have the authority to issue an aggregate of 100,000,000 shares of Common Stock. As of February 19, 2020, there
were 31,299,194 shares of our Common Stock issued and 28,492,005 shares of our Common Stock outstanding.
Dividend Rights
Subject to the preferences, limitations and relative rights of holders of our preferred stock, the holders of Common Stock
are entitled to share ratably in dividends if, when and as declared by our board of directors out of funds legally available therefor.
Voting Rights
Subject to the preferences, limitations and relative rights of holders of our preferred stock, the holders of Common Stock
are entitled to one vote for each share held of record on all matters at all meetings of shareholders.
Liquidation Rights
Subject to the preferences, limitations and relative rights of holders of our preferred stock, the holders of Common Stock
are entitled, in the event of our liquidation, dissolution or winding-up, to share ratably in the distribution of assets remaining after
payment of debts and expenses.
Absence of Other Rights
Our Common Stock has no sinking fund or redemption provisions or preemptive, conversion or exchange rights.
Anti-Takeover Effects of Our Certificate of Incorporation and Bylaws
Our Certificate of Incorporation and Bylaws contain provisions that may delay, defer or discourage another party from
acquiring control of us. We expect that these provisions, some of which are summarized below, will discourage coercive takeover
practices or inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us
to first negotiate with the board of directors, which we believe may result in an improvement of the terms of any such acquisition
in favor of our shareholders. However, they also give the board of directors the power to discourage acquisitions that some
shareholders may favor.
Special Meetings of Shareholders
Our Bylaws provide that special meetings of shareholders may only be called by the board of directors, the chairman of
the board of directors, if any, or the president.
Advance Notice Requirements for Shareholder Proposals
Our Bylaws require advance notice procedures for shareholder proposals to be brought before an annual meeting of the
shareholders, including the nomination of directors.
Amendment to Certificate of Incorporation and Bylaws
New York law provides generally that a majority vote of all the outstanding shares entitled to vote thereon at a meeting
of shareholders is required to approve amendments to a corporation’s certificate of incorporation, unless a corporation’s certificate
of incorporation requires a greater percentage. New York law also provides generally that by-laws may be amended by a majority
of the votes cast by the shares at the time entitled to vote in the election of any directors. Under New York law, when so provided
in the certificate of incorporation or a by-law adopted by the shareholders, by-laws may also be amended by the vote specified in
the certificate of incorporation or by-law, but any by-law adopted by the board may be amended or repealed by the shareholders
entitled to vote thereon. Our Bylaws may be amended, altered, or repealed by a majority vote of our board of directors.
New York Anti-Takeover Statute
We are subject to Section 912 of the New York Business Combination Law. Accordingly, we may not engage in a business
combination, such as a merger, consolidation, recapitalization, asset sale or disposition of stock, with any “interested shareholder”
for a period of five years from the date that the interested shareholder first became an interested shareholder unless certain conditions
are met.
Indemnification of Officers and Directors
Our Bylaws provide that we indemnify our directors and officers to the fullest extent permitted by law and authorize the
Company to enter into agreements with any of our directors or officers to indemnify such person to the fullest extent permitted
by law.
Listing
The Company's Common Stock is listed on the New York Stock Exchange under the trading symbol "CNMD."
CONMED Corporation
Subsidiaries of the Registrant
EXHIBIT 21
Name
State or Country of Incorporation
Aspen Laboratories, Inc.
Buffalo Filter LLC
CONMED Andover Medical, Inc.
CONMED Austria GmbH
CONMED Denmark ApS
CONMED Deutschland GmbH
CONMED Endoscopic Technologies, Inc.
CONMED Finland Oy
CONMED France SAS
CONMED Iberia SL
CONMED Italia SrL
CONMED Japan K. K.
CONMED Linvatec Australia PTY Ltd
CONMED Linvatec (Beijing) Medical Appliances Co., Ltd
CONMED Linvatec Biomaterials Oy
CONMED U.K. Ltd.
Consolidated Medical Equipment Company S. de R.L. de C.V.
EndoDynamix, Inc.
GWH Limited Partnership
G.W. Comércio Importação e Exportação de Produtos Médicos Hospitalares Ltda.
Largo Lakes I Limited Partnership
Linvatec Corporation
Linvatec Belgium NV
Linvatec Canada ULC
Linvatec Europe SPRL
CONMED Korea Ltd.
Linvatec Nederland B.V.
Linvatec Polska Sp. z.o.o
Linvatec Conmed Sweden AB
Palmerton Holdings, Inc.
SurgiQuest, Inc.
Viking Systems, Inc.
Linvatec India Private Limited
Colorado
Delaware
New York
Austria
Denmark
Germany
Massachusetts
Finland
France
Spain
Italy
Japan
Australia
China
Finland
United Kingdom
Mexico
Delaware
Florida
Brazil
Delaware
Florida
Belgium
Canada
Belgium
Korea
Netherlands
Poland
Sweden
New York
Delaware
Delaware
India
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-78987, 333-90444,
333-124202, 333-136453, 333-145150, 333-162834, 333-168493, 333-182878, 333-207582, 333-214299, 333-223258 and
333-228171) of CONMED Corporation of our report dated February 24, 2020 relating to the consolidated financial statements,
financial statement schedule and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.
EXHIBIT 23
/s/ PricewaterhouseCoopers LLP
Rochester, New York
February 24, 2020
CERTIFICATION PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
Exhibit 31.1
I, Curt R. Hartman, certify that:
1.
I have reviewed this annual report on Form 10-K of CONMED Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material
fact necessary to make the statements made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present
in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the
periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and
procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as
defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in
which this report is being prepared;
b) designed such internal control over financial reporting, or caused such internal control over financial reporting
to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external purposes in accordance with generally accepted
accounting principles;
c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our
conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered
by this report based on such evaluation; and
d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during
the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over
financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over
financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons
performing the equivalent functions):
a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial
reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize
and report financial information; and
b) any fraud, whether or not material, that involves management or other employees who have a significant role
in the registrant's internal control over financial reporting.
February 24, 2020
/s/ Curt R. Hartman
Curt R. Hartman
President and
Chief Executive Officer
CERTIFICATION PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
Exhibit 31.2
I, Todd W. Garner, certify that:
1.
I have reviewed this annual report on Form 10-K of CONMED Corporation;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material
fact necessary to make the statements made, in light of the circumstances under which such statements were made, not
misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present
in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the
periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and
procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as
defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be
designed under our supervision, to ensure that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in
which this report is being prepared;
b) designed such internal control over financial reporting, or caused such internal control over financial reporting
to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial
reporting and the preparation of financial statements for external purposes in accordance with generally accepted
accounting principles;
c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our
conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered
by this report based on such evaluation; and
d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during
the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report)
that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over
financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over
financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons
performing the equivalent functions):
a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial
reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize
and report financial information; and
b) any fraud, whether or not material, that involves management or other employees who have a significant role
in the registrant's internal control over financial reporting.
February 24, 2020
/s/ Todd W. Garner
Todd W. Garner
Executive Vice President and
Chief Financial Officer
Exhibit 32.1
CERTIFICATIONS
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
(SUBSECTIONS (a) AND (b) OF SECTION 1350, CHAPTER 63 OF TITLE 18, UNITED STATES CODE)
Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title
18, United States Code), each of the undersigned officers of CONMED Corporation, a New York corporation (the “Corporation”),
does hereby certify that:
The Annual Report on Form 10-K for the year ended December 31, 2019 (the “Form 10-K”) of the Corporation fully
complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 and information contained in the
Form 10-K fairly presents, in all material respects, the financial condition and results of operations of the Corporation.
Date: February 24, 2020
Date: February 24, 2020
/s/ Curt R. Hartman
Curt R. Hartman
President and
Chief Executive Officer
/s/ Todd W. Garner
Todd W. Garner
Executive Vice President and
Chief Financial Officer
Company Notes
Company Notes
Company Notes
Company Notes
CONTINUING THE CLIMB
CONMED Corporation
525 French Road, Utica, NY 13502 | USA
©2020 CONMED Corporation. All Rights Reserved.